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Herpesviruses are enveloped viruses with a linear double-stranded DNA genome. Their 
genome sizes range from 125 to 230 kilobase pairs harboring at least 70 to 200 coding and 
up to 70 non-coding gene products [1]. These gene products give rise to viral proteins and 
several RNA species including mainly micro-RNAs and few non-coding RNAs. The virions of 
herpesviruses consist of an icosahedral capsid containing the densely packaged genome, the 
tegument surrounding the capsid, and the lipid envelope with several glycoproteins. 
To date, up to 200 distinct herpesvirus species have been identified in mainly vertebrates 
[1], of which 100 have been classified by the International Committee on Taxonomy of Viruses 
(ICTV).  As herpesviruses have generally a narrow host range, it is, therefore, likely that more 
than the 200 identified herpesviruses exist. The order of Herpesvirales consists of the families 
of Herpesviridae, Alloherpesviridae, and Malacoherpesviridae [2]. The hosts of Herpesviridae 
are mammals, birds and reptiles, while Alloherpesviridae and Malacoherpesviridae infect fish 
and amphibians, and bivalves, respectively. The family of Herpesviridae is divided into the 
three subfamilies α-, β-, and γ-Herpesvirinae. In humans, eight herpesvirus species have been 
identified. According to the guidelines of the ICTV, they are named human herpesvirus (HHV) 
1 through 8, but their traditional names are widely used. The human herpesvirus species are 
α-herpesviruses Herpes simplex virus (HSV)-1, -2 (HHV-1 and -2), Varizella Zoster virus 
(VZV, or HHV-3), the β-herpesviruses human cytomegalovirus (HCMV, or HHV-5), HHV-6 
and -7, as well as the two γ-herpesviruses Kaposi’s sarcoma-associated herpesvirus (KSHV 
or HHV-8), and Epstein-Barr virus (EBV or HHV-4) [3]. Human herpesviruses are typically 
highly prevalent. Epstein-Barr virus, for instance, is carried by about 90% of the adult world 
population [4]. KSHV is an exception with only very low prevalence in most Western societies 
(around 3%), while its prevalence is higher in areas such as the Mediterranean basin or sub-
Saharan Africa (15-25% and 50-60%, respectively) [5].
A hallmark of herpesvirus infection is the establishment of life-long latent infection. This 
is also reflected by the name of the virus family originating from the Greek word ‘herpein’ 
meaning ‘to creep’. Latency is characterized by limited viral gene expression without production 
of viral progeny. In contrast to other viruses establishing latent or chronic infection, such as 
human immunodeficiency virus (HIV), papillomaviruses (HPV), or hepatitis C virus (HCV), 
persistence of herpesviruses usually does not result in life-threating diseases. Primary infection 
with herpesviruses or reactivation from latency cause symptoms as seen for HSV-1 (cold sore) 
and VZV (chickenpox and shingles, respectively), but can also be asymptomatic as in many 
cases of EBV infection. The absence of severe symptoms may be interpreted as a delicate 
balance of immune control of herpesviruses and good adaptation of the virus to the host. Due 
to millions of years of co-evolution between herpesviruses and humans, herpesviruses have 
acquired successful strategies to evade innate and adaptive immune recognition including 
innate immune receptors (e.g TLRs) and downstream signalling [6,7,8], the complement 
system [9], and antigen presentation [10,11,12] without causing major damage of the human 
host. 




Life cycle of Epstein-Barr virus 
EBV is the prototypic human γ-herpesvirus belonging to the genus of Lymphocryptoviruses. 
In general, it is transmitted via saliva. Typically, EBV infects and replicates in epithelial cells 
and B lymphocytes. The entry mechanism of EBV into these cells is dependent on different 
cell surface molecules [13]. Interestingly, virions produced in epithelial cells appear to have an 
increased tropism for B cells and vice versa [14]. In a new host, EBV infects epithelial cells in 
the oropharynx, lytically replicates in these cells and disseminates to naïve B cells. According 
to the current model of the EBV life cycle [15], EBV infects naïve B cells, which then start to 
proliferate in response to the growth-transformation program of the nine latency-associated 
EBV proteins. During differentiation of EBV-infected B cells into memory B cells, the long-
term reservoir of EBV, expression of latent EBV proteins is continuously reduced. Finally, 
a quiescent stage is reached in which no EBV proteins are expressed (latency 0). Different 
stages of latency (latency I, II, and III) are characterized by expression of distinct sets of latent 
EBV proteins [16]. Besides latent proteins, EBV expresses the two non-coding EBV-encoded 
small RNAs (EBER) and about 40 miRNAs organized in two clusters, the BART and BHRF1 
miRNAs, during the latent stages [17]. The functions of these non-coding RNAs are now 
beginning to be elucidated and growth-transforming, anti-apoptotic, and immune evasive 
functions have been suggested [18]. Interestingly, miRNAs have been detected in EBV virions, 
allowing their release in newly infected cells [19]. Moreover, EBV miRNAs can be transferred 
via exosomes from EBV-infected cells to uninfected recipient cells in vitro, and may in this 
way regulate uninfected cells and cell types not typically infected by EBV [20,21]. 
Reactivation from latency and lytic replication of EBV in memory B cells is associated 
with terminal differentiation into plasma cells. The molecular mechanism and circumstances 
of reactivation are, however, ill-defined. Lytic replication is highly organized and consists 
of three distinct phases. During the immediate-early phase, the viral transactivators are 
expressed, which drive expression of the early phase proteins that are required for viral DNA 
replication and expression of the structural proteins during the late phase. New virions are 
assembled and infectious virus is released, which might be further amplified in epithelial 
cells shedding virus into saliva. Lytic replication does not remain unnoticed by the immune 
system as many immunogenic or immune-stimulatory viral molecules are generated. Finally, 
the host’s immune system controls and limits lytic replication of the virus. 
Clinical manifestation of Epstein-Barr virus infection 
EBV is the causative agent of infectious mononucleosis (IM), a disease characterized by 
sore throat, lymphoadenopathy, fever, and fatigue [13]. Onset of symptoms correlates with 
an exaggerated expansion of mononuclear cells, mainly EBV-specific CD8+ T cells [13,22]. 
This characteristic expansion is also reflected by the name of the disease. IM is a self-
limiting disease that mainly occurs in adolescents and adults upon primary EBV infection. A 
prospective study among EBV-naïve university students revealed that more than 75% of these 
students developed infectious mononucleosis upon primary EBV infection [23]. At young 
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age, EBV infection is asymptomatic in most cases, yet children might develop IM. In fact, IM 
has first been described by a pediatrician [24]. To date, it is unclear why IM is more common 
at adolescent or adult age. One hypothesis is that pre-existing immunity primes adults to 
respond stronger to EBV as they may have acquired more T cell clonotypes cross-reactive with 
EBV epitopes. However, only a minor fraction of CD8+ T cells from EBV-positive individuals 
show reactivity to both influenza and EBV peptides [25]. Another explanation is offered by a 
study showing that lytically EBV-infected B cells are preferably recognized by a specific NK 
cell subset, which is decreased in frequency in adults compared to children [26].  
EBV infection of primary B cells in vitro results in growth-transformation enabling 
prolonged culturing of these lymphoblastoid cell lines (LCL). Given the growth-transforming 
properties of EBV, it may not come as a surprise that various malignancies are associated 
with EBV, which are often of B lymphocyte or epithelial origin. Indeed, EBV was the first 
tumor virus described. EBV-associated malignancies were found to generate different sets of 
EBV latency proteins, thereby distinct latency stages were characterized. In 1964, EBV was 
first identified in Burkitt’s lymphoma (latency I), a B cell lymphoma [27]. Nowadays, EBV 
infection is also recognized to be associated with Hodgkin’s lymphoma, nasopharyngeal and 
gastric carcinoma (all latency II), lymphoproliferative disease in the immunocompromised 
(latency III)  and other malignancies (reviewed in [28]). 
Lessons from immune deficiencies
Inherited and acquired immune deficiencies as well as transplantation-related 
immunosuppression are pre-disposing conditions for life-threatening EBV-associated 
diseases [28,29,30]. These immunodeficiencies are characterized by defects in T and/or 
natural killer (NK) cell functions, thereby highlighting the importance of these cells in the 
control of EBV infection. 
Primary immunodeficiencies
Most of the primary (or inherited) immunodeficiencies predisposing for EBV-associated 
diseases are also linked to other pathogenic infections including viral, bacterial, and fungal 
infections. As an exception,  manifestation of the deficiencies X-linked lymphoproliferative 
disease (XLP) and X-linked inhibitor of apoptosis protein deficiency (XIAP) is mainly 
associated with primary EBV infection causing  severe and often fatal IM [31,32]. 
Moreover, life-threatening conditions as haemophagocytic lymphohistiocytosis (HLH) or 
dysgammaglobulinaemia might develop [29]. In case of XLP, lymphomas can arise as well, 
but those have not been observed in XIAP. 
Although XLP patients have normal NK and T cell numbers, these cells display a 
functional defect. In addition, XLP patients lack invariant NKT (iNKT) cells, a small subset 
of specialized T cells. Defects were attributed to mutations in the gene SH2D1A present on the 
X-chromosome. This gene encodes the signalling lymphocyte activation molecule (SLAM)-
associated protein SAP [33,34]. The adaptor protein SAP allows signalling of several members 




of SLAM receptors, which are required for interactions between B cells and NK or T cells [34]. 
SAP is required to transfer activating signals from SLAM receptors, while in its absence the 
signal is inhibitory. Since SAP is expressed in NK and T cells, these cells cannot be activated 
by (EBV-infected) B cells in XLP patients [35,36]. Moreover, SAP appears to be crucial for 
iNKT cell development explaining the absence of this cell type in XLP patients [37]. 
In females, one of the two X-chromosomes is randomly silenced in somatic cells. 
Interestingly, in females with heterozygous SAP expression, EBV-specific CD8+ T cells are 
exclusively SAP-positive [38] suggesting that SAP-negative T cells cannot contribute to 
control of the B lymphotropic virus EBV. In non-EBV-specific T cells, SAP-deficiency and 
expression is equally distributed. 
In conclusion, XLP patients are selectively prone to EBV-associated disease, since EBV-
infected B cell cannot be properly controlled by NK, T, and iNKT cells. 
XIAP patients display a similar phenotype upon infection with EBV, but the underlying 
molecular mechanism is different. These patients have decreased iNKT cell numbers, but 
normal T and NK cell numbers [32]. NK cells of XIAP patients appear to be functional, in 
contrast to those in XLP patients. In XIAP patients, the BIRC4 gene is mutated resulting in 
a defective XIAP protein. In healthy individuals, XIAP is present in lymphocytes, myeloid 
cells, and NK cells [32]. XIAP prevents cell death by inhibiting several caspases promoting 
apoptosis. Therefore, T cells in XIAP patients show increased sensitivity towards cell death-
inducing stimulation. How this excess of apoptosis in lymphocytes contributes to abnormal 
responses to EBV remains to be determined. As in XLP patients, heterozygous female 
carriers show a non-random X chromosome inactivation in leukocytes [32] supporting the 
importance of XIAP in cells controlling EBV infection.
Patients with primary immunodeficiencies are rare; therefore it may be challenging 
to picture the full phenotype and the consequences and contribution of the absent or 
dysfunctional molecule, which could also have an indirect, e.g. immunodevelopmental effect. 
Individuals with a secondary or acquired immunodeficiency are more abundant. Observed 
complications following EBV infection in these patients support the notion of T cell immunity 
being crucial in control of EBV. 
Secondary immunodeficiencies
A typical secondary immunodeficiency is progression to acquired immunodeficiency 
syndrome (AIDS) following upon HIV infection. In HIV-positive individuals, Burkitt’s 
lymphomas (BL) are more common than in the general population [28]. Another malignancy 
observed in AIDS patients is B cell lymphoproliferative disease during late AIDS progression. 
This malignancy may be associated with a decrease in T cell surveillance and is therefore, 
less often seen since introduction of highly active anti-retroviral therapy (HAART), which 
prevents progression to late stage AIDS.
Transplantation patients receiving an immunosuppressive therapy targeted to T cells 
to prevent graft rejection may also develop EBV-associated lymphoproliferative disease. It 
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has been demonstrated that this is due to diminished T cell control, as patients with post-
transplant lymphoproliferative disease (PTLD) can be effectively treated by adoptive transfer 
of EBV-reactive T cells [39]. 
In summary, EBV is the etiological agent of immunopathological diseases, such as IM, 
and several malignancies. Primary immunodeficiencies selectively affecting T and/or NK 
cell function, but also induced immunosuppression, contribute to our understanding of EBV 
control.
Immune responses to EBV
Control of EBV infection is achieved by the interplay of innate and adaptive immune 
responses. Innate immune responses precede adaptive immune responses. The innate immune 
system comprises different kind of cells like NK cells, macrophages, dendritic cells (DCs) 
and granulocytes; and soluble components such as the complement system. The composition 
of innate immune stimulation determines the ensuing adaptive immunity [40]. Various cell 
types, but especially innate immune cells, recognize foreign pathogen-associated molecular 
patterns (PAMPs) by their pattern recognition receptors (PRRs). Generally, viral infections 
are sensed by PRRs, such as Toll-like receptors (TLRs), cytosolic DNA and RNA sensors 
[41,42,43,44]. Especially viral nucleic acids are recognized by these receptors, but also other 
molecules such as viral glycoproteins might be sensed by PRRs. 
Innate immune recognition 
In contrast to the well-established role of T cell immunity for EBV control, the contribution 
of innate immune sensors to recognition of EBV infection in vivo is less clear, which might 
be due to the long incubation period of around 40 days after primary EBV infection before 
first symptoms arise and that virus reactivation is asymptomatic. A recent study could detect 
a transient type I interferon (IFN) signature in some individuals 3 to 15 days prior to onset of 
IM symptoms, possibly indicative of innate immune activation [22].  
Cells targeted by EBV express a variety of PRRs involved in initial sensing of viral infection. 
These receptors initiate signaling cascades that culminate in activation of the transcription 
factors interferon regulatory factors (IRF) 3 and 7 or NF-κB. Nuclear translocation of IRF3/7 
induces production of type I interferons (IFN I) and NF-κB-induced transcription activates 
anti-apoptotic and inflammatory processes, thereby creating an environment hostile to viral 
replication [42]. Various PRR signaling pathways are activated during EBV infection.
Toll-like and RIG-I-like receptors
The Toll-like receptors (TLRs) TLR2, TLR3, and TLR9 as well as the RNA sensor RIG-I 
have been implicated in the detection of EBV infection [45]. TLRs are membrane-bound 
receptors present on the cell surface or in the endosomal compartment, while RIG-I resides 
in the cytoplasm. 




TLR2 is present on the cell surface of monocytes. TLR2 typically senses lipopeptides, yet it 
has been suggested to sense EBV, possibly its glycoproteins present on the viral envelope [46]. 
The non-structural protein dUTPase of EBV has been shown to stimulate TLR2-mediated 
NF-κB activation and it has been suggested that this protein is present in exosomes released 
by infected cells [47,48]. RNA can be recognized by the ubiquitously expressed cytoplasmic 
RIG-I molecule and the endosomal TLR3 present in conventional DCs and other immune 
cells. TLR3 senses dsRNA, while RIG-I responds to ssRNA species. Yet, both sensors were 
shown to be stimulated by the single-stranded EBERs of EBV, which can form stem-loop 
structures [49,50,51]. The endosomal TLR9 present in B cells and plasmacytoid DCs (pDCs) 
responds to DNA. TLR9 has been shown to be stimulated by EBV DNA [52]. 
Nuclear and cytoplasmic DNA sensors 
Several cytosolic DNA sensors have been identified in recent years [53,54]. These DNA 
sensors can induce type I IFN responses by the STING-TBK1-IRF3 pathway or inflammasome 
activation resulting in caspase-1-mediated IL-1β/IL-18 maturation and pyroptosis [41,53,55]. 
ALR inflammasomes
The DNA-sensing AIM-like receptors (ALR) absent in melanoma 2 (AIM2) and IFN-
inducible protein 16 (IFI16) can form inflammasomes. Inflammasomes are associated with 
two different functions, namely cytokine processing and pyroptosis, which are both caspase-1 
dependent. In brief, pyroptosis is characterized as caspase-1 mediated cell death and differs 
to some extent morphologically from apoptosis [56]. Recently, gasdermin D was found to be 
a substrate for caspase-1 (and other caspases including the human caspase-4, and -5, as well 
as murine caspase-11). The N-terminal part of cleaved gasdermin D promotes pyroptosis 
[57,58]. Thus far, pyroptosis has been observed in macrophages, DCs, and neurons. The 
relevance of pyroptosis to viral infection is at current unclear. The best studied effector 
mechanism of inflammasomes is processing of the cytokines pro-IL1β and pro-IL-18 into 
mature and bioactive cytokines by caspase-1 [59]. These are then exported by an ill-defined 
and unconventional secretion pathway.
IL-1β has a potent pyrogenic effect. It activates immune cells and promotes upregulation 
of adhesion molecules on endothelial cells, thereby helping activated immune cells, such as 
neutrophils, to migrate to the site of infection. Mature IL1β signals through the IL1 receptor 
(IL-1R). IL1R is constitutively expressed on many cell types. In view of its strong effects, IL-1β 
release is tightly controlled at multiple levels, such as transcription, mRNA stability, protein 
cleavage by inflammasomes, and secretion [60]. Furthermore, downstream signalling of the 
cytokine is regulated by IL-1Rα, a soluble antagonist of IL1R. 
The importance of regulated IL-1β secretion is underscored by the severe clinical symptoms 
in patients with autoinflammatory disorders, which are characterized by uncontrolled IL1β 
release. Examples of these rare auto-inflammatory disorders include cryopyrin-associated 
periodic syndrome (CAPS), familial Mediterranean fever (FMF), and TNF receptor-associated 
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periodic syndrome (TRAPS), which are caused by mutations in NLRP3, pyrin (a regulator 
of ASC), and p55 TNF receptor, respectively [61]. Patients present symptoms ranging from 
fever, fatigue, and rash to joint, bone, and skin inflammation, serositis and deafness, and 
mental retardation in severe cases [62,63,64]. Patients can be treated effectively with either 
recombinant IL1Rα (anakinra), recombinant IL-1R-Fcγ1 fusion protein (rilonacept), or 
monoclonal antibodies neutralizing IL-1β (canakinumab) [61]. So far, knowledge is missing 
concerning susceptibility to infectious diseases in these patients.
IL-18 is the second cytokine being processed into its bioactive form by inflammasomes. 
In contrast to IL-1β, IL-18 has no pyrogenic activity; induction of de novo transcription of 
pro-IL-18 is not needed, as it is constitutively expressed in multiple cell types [65]. Similar 
to IL-1β, IL-18 signals through a heterodimeric IL-18 receptor (IL-18R) that contains a TIR 
domain activating NF-κB, p38, and JNK. Expression of IL-18R has been reported in TH1 cells, 
some myeloid cells, as well as intestinal epithelial cells [59,60]. IL-18, in conjunction with 
IL-12, is a potent inducer of the type II IFN response via activation of natural killer cells [66]. 
The sensor molecule AIM2 was identified by several groups and it was shown to form 
an ASC-dependent inflammasome [67,68,69,70]. AIM2 contains a HIN200 domain and a 
PYD domain, which interacts with ASC and thereby, recruits pro-caspase-1. The ligand of 
AIM2, dsDNA, has been identified and direct binding of DNA to the HIN200 domain was 
demonstrated [68]. 
Infections by the Orthopoxvirus vaccinia virus and by the beta-herpesvirus murine 
cytomegalovirus (mCMV) were found to be sensed by AIM2 in murine macrophages [68,71]. 
The contribution of the AIM2 inflammasome in vaccinia virus infections in vivo still needs 
to be assessed. In macrophages infected with mCMV in vitro AIM2 mediated both IL-1β 
processing and the expression of IFN-β, the latter occurring independently of inflammasome 
activation [71]. In vivo studies with mCMV infections revealed that serum IL-18 levels as well 
as splenic IFNγ+ natural killer cell numbers were reduced, while viral load in the spleen was 
increased in AIM2- or ASC-deficient mice compared to wild-type mice [71].
Interestingly, the AIM2 inflammasome did not recognize the alpha-herpesvirus HSV-
1, although this virus is known to trigger IL-1β release [72]. This suggests the existence of 
alternative, yet unidentified, inflammasome initiators. 
Like AIM2, IFI16 belongs to the ALR family, but its cellular localization is different: 
whereas AIM2 acts strictly cytosolically, IFI16 is mainly localized in the nucleus due to its 
nuclear localization sequence (NLS). IFI16 can relocalize to the cytoplasm in an acetylation-
dependent manner [73]. IFI16 was suggested to act as a nuclear dsDNA sensor in Kaposi’s 
sarcoma-associated herpesvirus (KSHV)-infected endothelial cells and in EBV-infected 
B-LCLs [74,75]. Subsequently, IFI16 assembles a functional inflammasome in the nucleus 
resulting in caspase-1 activation and processing of IL-1β in the cytoplasm, although IFI16-
dependent IL1β secretion was not studied. Formation of the nuclear inflammasomes was 
assessed by co-immunoprecipitation and colocalization studies of different inflammasome 
components such as ASC and caspase-1. Caspase-1 activation and cytosolic IL-1β processing 




were decreased upon IFI16 knockdown during KSHV infection. Assembly of the IFI16 
inflammasome in the nucleus is remarkable as all other known inflammasomes are activated 
and assembled in the cytoplasm. Activation of IFI16 and subsequent inflammasome formation 
might be restricted to DNA viruses, which replicate in the nucleus. Previous studies could not 
demonstrate the formation of an IFI16 inflammasome in 293T cells or THP-1 macrophages 
[67,68], thus formation of an IFI16 inflammasome might be restricted to certain cell types.
Type I IFN response
IFI16 is the only DNA sensor reported to form inflammasomes and induce IFN I 
responses. Initially IFI16 was shown to sense HSV-1, thereby leading to IFN-β induction via 
STING [76]. IFI16 is requires for DNA-induced type I IFN production via the STING-TBK1-
IRF3 axis in differentiated THP1 cells [77]. However, it is unclear how IFI16 contributes to 
STING activation. 
Most recently, the cytosolic DNA sensor cGAS has been identified and it seems that this 
sensor plays a major role in the induction of type I IFN responses during infection with DNA 
viruses [78], although several additional proteins were suggested to act as cytoplasmic DNA 
sensors [79]. Upon dsDNA binding, cGAS produces the second messenger molecule cyclic 
GMP-AMP (cGAMP) that binds to the adaptor protein STING resulting in its activation 
[80]. cGAMP can also be transferred to neighboring cells via gap junctions and even viral 
particles have been found to carry cGAMP, thereby possibly stimulating STING without 
the need of DNA sensing [81,82,83]. STING resides in the ER membrane, but translocates 
to the perinuclear region upon activation. Subsequently, TBK1 and IRF3 are recruited and 
phosphorylated. Consequently, dimerized pIRF3 is imported to the nucleus where type I IFN 
transcription is initiated. 
It is well known that incoming HSV-1 triggers this DNA sensing pathway in monocytes 
[78,80]. Also KSHV has been found to stimulate type I IFN responses in endothelial cells 
via this pathway [84]. Moreover, the first viral interference strategies of the cytosolic DNA 
sensing pathway have been identified suggesting that immune recognition via this pathway 
is relevant in vivo [84,85,86]. To date, it is not known whether EBV is sensed by the cGAS-
STING pathway. It is even unclear whether human B cells are equipped, except for IFI16, with 
the respective molecules.
In conclusion, several EBV-derived molecules trigger distinct PRRs resulting in activation 
of various pathways. These different innate immune signals aid in shaping the ensuing 
adaptive immune response via induction of pro-inflammatory cytokines and type I IFNs. 




Activation of the adaptive immune system largely depends on recognition of pathogen-
specific antigens. B cells secrete antibodies that help clearing extracellular virions, while 
pathogen-specific T cells help to eliminate virus-infected cells. To promote cellular anti-viral 
immunity, antigen presentation is required. Generally, viral peptide antigens are presented 
by two kinds of antigen-presenting molecules, major histocompatibility complex (MHC) 
class I (or HLA I in humans) and MHC class II (or HLA II in humans) to cytotoxic CD8+ 
or helper CD4+ T cells, respectively. Primary EBV infection induces strong, virus-specific 
T cell responses targeting both lytic and latent EBV-derived epitopes [30]. Analysis of EBV-
specific CD8+ T cells revealed that T cells with reactivity towards peptides derived from 
immediate-early and early EBV proteins were more frequent than those directed against 
late EBV peptides [87]. Immunodominance of immediate-early and early peptides has been 
attributed to immune evasion of HLA I-mediated antigen presentation during the early phase 
of lytic replication, thereby inhibiting presentation of late antigens. There is no evidence of 
immunodominance of certain HLA II-presented peptides reflected by an even distribution 
of peptide reactivity of all lytic phase antigens in CD4+ T cells. In contrast to CD8+ T cell 
responses, CD4+ T cells appear to be rather directed against latent peptides.
Peptide antigen presentation 
In general, all nucleated cells express HLA I on their cell surface and are therefore, 
equipped to present peptide epitopes derived from viral antigens to cytotoxic T lymphocytes 
(CTL). Presented epitopes are derived from endogenously synthesized proteins including 
viral proteins. Proteins are degraded by the proteasome into smaller peptide fragments that 
are transported by the transporter associated with antigen presentation (TAP) from the 
cytosol into the ER lumen. There antigenic peptides can be further processed before loaded 
into the groove of HLA I molecules, a heterodimer consisting of the HLA I heavy chain and 
β2-microglobulin (β2m). Peptide-loaded HLA I molecules are transported from the ER to the 
Golgi and finally to the cell surface by the secretory pathway. 
Surface expression of HLA II is far more restricted in comparison to HLA I. HLA II is 
primarily present on specialized antigen-presenting cells (APCs) such as DCs, monocytes, 
macrophages, and B cells. Peptides presented by HLA II are derived from exogenous proteins 
and pathogens taken up by APCs. Peptide processing and loading occurs in the so-called 
MHC II compartment (MIIC). HLA II is a heterodimer consisting of an α- and a β-chain. In 
the ER, newly synthesized HLA II associates with the invariant chain and is then transported 
to the late endocytic MIIC. The invariant chain is processed by cathepsins, which are proteases 
present in this compartment. Eventually CLIP, the part of the invariant chain residing in the 
binding groove of HLA II, is exchanged for the antigenic peptide. Peptide-loaded HLA II 
molecules are transported to the cell surface.  
In humans, three genes code for the classical HLA I molecules HLA-A, -B, and –C; and 
another three for the HLA II molecules HLA-DR, -DQ, and –DP [88]. Moreover, these 




genes exhibit allelic polymorphism; thereby each individual possesses an almost unique 
combination of HLA genes. The non-classical HLA I molecules HLA-E, -F, and –G as well as 
the HLA II molecules HLA-DM and –DO are monomorphic. Similarly, MHC-like molecules 
are non-polymorphic [89]. There are different families of MHC-like molecules, one of them 
being the CD1 family presenting lipid instead of peptide antigen to NKT cells (Fig.1 on page 
25). 
Lipid antigen presentation 
The human CD1 family consists of the five members CD1a-e. CD1 isoforms differ by 
intracellular trafficking pathways and antigen-binding specificities, thereby fulfilling distinct 
functions. CD1a-c and CD1d present lipid antigens to T cells, including natural killer T (NKT) 
cells and γδ T cells [90,91,92], whereas CD1e has been suggested to assist in lipid loading of 
the antigen-presenting CD1 molecules [93]. In mice, only two forms of CD1d (CD1d1 and 
CD1d2) are present. Most effector functions are CD1d1-dependent, also supported by the 
inability of CD1d2 to support NKT cell selection [94]. CD1d is reported to be expressed by 
various antigen-presenting cells including B cells, DCs, monocytes, and macrophages [95]. 
Moreover, certain epithelial cells and hepatocytes have this surface marker [96].
Invariant NKT cells and their role in anti-viral immunity
NKT cells recognize lipids presented by CD1d molecules and are divided into two subsets; 
invariant (type I) NKT (iNKT) cells and diverse (type II) NKT cells [97,98]. iNKT cells are of 
particular interest as their response bridges the innate and adaptive immune system by rapid 
secretion of vast amounts of polarizing cytokines. 
iNKT cells form an important subpopulation of CD1d-restricted T cells. The name iNKT 
cell originates from concurrent cellular expression of receptors that hallmark NK cells and 
a (semi-) invariant T cell receptor (TCR), which consists of an invariant α-chain (Vα24-
Jα18 in humans, Vα14-Jα18 in mice) paired with one of a limited set of β chains (Vβ11 in 
humans, Vβ2, Vβ7, or Vβ8 in mice). In mice, iNKT cells constitute a significant fraction of T 
cells, while in humans their representation is rather low, suggestive of a different role for the 
immune response in both species. 
iNKT cells are activated in multiple ways. Firstly, TCR engagement of CD1d complexes 
presenting pathogen-derived lipid antigens can lead to iNKT cell activation. Secondly, innate 
signals and cytokines such as IL-18 can activate iNKT cells independent of TCR signaling. 
The receptors NKG2D [99] and TIM-1 [100] can activate iNKT cells both independently and 
as co-stimulatory signals in concert with TCR triggering. Lastly, CD1d-mediated presentation 
of altered self-lipids in combination with cytokine signals can effectively activate iNKT cells. 
The mechanism of activation and the local polarizing cytokine environment dictate the 
subsequent iNKT cell response. 
Upon activation, iNKT cells rapidly produce large amounts of cytokines, including IFN-γ 
that has direct anti-viral effects and boosts NK cell activation. In addition, iNKT cells can 
160723 Proefschrift.indd   17 24.07.2016   21:49:42
Chapter 1
18
mediate cytolysis, as a consequence of granzyme B, perforin, TRAIL, and FasL expression. 
Thus, iNKT cells could directly eliminate pathogens and tumor cells, although the in vivo 
importance of iNKT cell-induced cytotoxicity in general remains to be assessed. It is, however, 
clear that iNKT cells can mediate direct immune defense in the course of microbial infection, 
as was shown in Salmonella typhimurium and Mycobacterium tuberculosis infection models in 
mice [101,102,103]. Through preferential secretion of TH1 or TH2 cytokines, iNKT cell skew 
CD4+ T cell responses and determine the quality of ensuing adaptive immunity. Interestingly, 
iNKT cells were suggested to limit EBV-mediated B cell transformation in vitro [104]. In 
recent years, evidence is accumulating that iNKT cells contribute significantly to anti-viral 
defense [96]. 
Susceptibility of iNKT cell-deficient humans so far appears restricted to herpesviral 
infections, especially EBV infection. In contrast, mice lacking expression of CD1d and/or 
iNKT cells were found to be vulnerable to a variety of viruses, including HSV-1 [105,106], 
HSV-2 [107], respiratory syncytial virus (RSV) [108], and influenza virus [109]. Furthermore, 
activation of iNKT cells by treatment with α-GalCer protected mice or decreased susceptibility 
in infection models studying diverse viruses, including murine cytomegalovirus (MCMV) 
[110], HSV-2 [111], RSV [108], influenza virus [109,112], HBV [113], and diabetogenic 
encephalomyocarditis virus (EMCV-D) [114]. This suggests that iNKT cells have a protective 
role in viral infections. However, pathogenic effects of iNKT cells have also been reported in 
dengue virus-infected mice [115]. In humans, iNKT cells might contribute to pathogenesis 
in DENV infection as activation of these cells was associated with disease severity during the 
febrile phase [116]. 
CD1d antigen presentation
CD1d molecules are composed of a heavy chain and β2-microglobulin (β2m). This 
structural homology with classical MHC class I molecules is reminiscent of the function 
shared by CD1d and MHC class I proteins, i.e. presenting antigens [117]. However, the diverse 
nature of antigens presented by either molecule is reflected in their antigen-binding grooves: 
whereas the grooves of highly polymorphic MHC class I are well-suited for binding defined 
peptides, lipid tails fit snugly into the hydrophobic pockets of CD1d, exposing the more polar 
moieties for TCR recognition. 
Before lipids can be inserted into the antigen-binding groove of CD1d, they must first be 
extracted from the hydrophobic lipid bilayer into aqueous solution, a process that is facilitated 
by lipid transfer proteins. Distinct lipid transfer proteins vary in their modes of action and 
lipid-binding specificities [118]. Thus, lipid transfer proteins may facilitate preferential 
binding of certain lipid species by CD1d, thereby conferring a level of antigen selectivity. 
In addition, the route of CD1d trafficking influences the lipid repertoire presented by 
CD1d molecules. After association of CD1d heavy chains with β2m in the endoplasmic 
reticulum (ER), CD1d molecules travel via the Golgi compartment to the plasma membrane. 
The majority of CD1d leaves the ER in association with β2m, yet this association is not an 




absolute requirement for ER exit. In fact, surface expressed murine CD1d heavy chains are still 
capable of eliciting an NKT cell response in the absence of β2m [119,120]. However, human 
cells expressing predominantly free CD1d heavy chains displayed a significantly reduced 
ability to activate iNKT cells, suggesting that CD1d/β2m complexes are the functional unit of 
lipid antigen presentation in humans [121]. Furthermore, association of CD1d heavy chains 
with β2m is required for resistance to lysosomal degradation [122]. In this way, β2m might 
influence the lipid repertoire presented by CD1d molecules. 
Similar to MHC class II, CD1d molecules survey endocytic compartments for the 
presence of antigens. Endosomal targeting signals in the cytoplasmic tail of the CD1d 
heavy chain regulate its trafficking. A threonine-based sequence targets the lipid-presenting 
molecules to the plasma membrane. Removal of this signal from the CD1d tail or mimicking 
phosphorylation of the threonine residue redirects CD1d molecules to endolysosomal 
compartments [121]. A tyrosine-based sorting motif (YXXZ; Y is tyrosine, X a random amino 
acid, and Z a bulky hydrophobic amino acid) is required for internalization of surface CD1d 
complexes [123]. In humans, this motif is recognized by adaptor protein (AP)-2, directing 
CD1d to early endosomes [124], while association of murine CD1d with AP-3 allows to gain 
access to late endosomes and lysosomes [125]. In humans, the cytoplasmic tail of CD1d lacks 
the consensus sequence required for association with AP-3 [126]. As a result, human CD1d 
mostly surveys early endocytic compartments. Still, a fraction of CD1d molecules (both 
human and mouse) gains access to the endolysosomal system via an alternative trafficking 
pathway, relying on binding of CD1d with invariant chains or MHC class II/invariant chain 
complexes. A dileucine motif in the cytoplasmic tail of the invariant chain directs associated 
CD1d and/or MHC class II molecules to the endolysosomal system, including the MHC class 
II-loading compartment (MIIC) [127,128,129]. Due to the restricted expression of MHC class 
II molecules, this alternative CD1d trafficking pathway is mostly constrained to professional 
APCs. Finally, the threonine-based targeting signal mediates re-expression of CD1d at the cell 
surface, where the CD1d molecules present their lipid cargo for surveillance by iNKT cells.
Lipid antigens presented by CD1d molecules
CD1d molecules present both pathogen-derived lipids and endogenous lipids. The 
first CD1d-restricted lipid antigen found to activate iNKT cells was α-galactosylceramide 
(α-GalCer), a glycosphingolipid compound derived from marine sponges [130]. Originally, 
this lipid was identified in a screen for compounds with anti-tumor activity [131]. For a long 
time, α-GalCer remained the only known CD1d-restricted antigen and it is still widely used in 
functional assays. The last decade has provided insights into the nature of other, biologically 
relevant, lipid antigens capable of activating iNKT cells. 
A large diversity of self-lipid species bound to human CD1d has been identified by elution 
studies. Among those were glycerophospholipids having a variety of polar head groups and 
containing either one, two, or four radyl chains. Furthermore, several sphingomyelins and 
glycosylated sphingolipids were also eluted from CD1d molecules [132]. 
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CD1d can present lipids from pathogenic bacteria including Sphingomonas [133,134,135], 
Borrelia burgdorferi  [136], and Streptococcus pneumonia [137]. The common feature of those 
lipids is the α-linked glycan headgroup, a feature shared with α-GalCer. For a long time, it 
was believed that mammalian cells cannot produce α-glycosylceramides, which were thought 
to represent a specific antigenic determinant of CD1d-presented, pathogen-derived lipids. 
However, it was recently shown that murine cells constitutively produce small amounts of 
α-glycosylceramides, although it remains to be determined how these lipids are synthesized 
in mammalian cells [138]. Another study provided evidence that a minor constituent of the 
endogenous glycosylceramide fraction was stimulatory for iNKT cells [139]. 
The identity of physiologically relevant, stimulatory lipid antigens presented by CD1d in 
the context of viral infection remains, at this time, incompletely understood. As opposed to 
microbial CD1d lipid antigens, virus-specific lipids do not exist. Therefore, the iNKT cell 
stimulatory lipids presented by CD1d during viral infection must be of host cell origin. This 
poses an intrinsic risk of undesired self-reactivity. To avoid this, self-lipids presented by 
CD1d should only be stimulatory towards iNKT cells during conditions of cellular stress, 
such as infection or carcinogenesis. Interestingly, the cellular lipid profile was found to be 
altered during hepatitis B virus (HBV) infection, leading to increased activation of NKT cells. 
Whereas diverse NKT cells were stimulated by HBV-induced lysophosphatidylethanolamine, 
different lipid(s) were responsible for the activation of iNKT cells, although their nature was 
not identified [140].
Alterations in CD1d lipid presentation induced by viral infection appear linked to activation 
of pattern-recognition receptors, such as Toll-like receptors (TLRs). TLR engagement could 
effectuate changes in CD1d antigen presentation in various ways such as increased synthesis 
or reduced degradation of antigenic self-lipids as well as different trafficking of CD1d or 
increased cell surface expression of this molecule. Stimulation of myeloid DCs with TLR 
ligands resulted in enhanced iNKT cell activation, which was dependent on both CD1d 
expression and cytokine secretion of IL-12 or type I IFN [141,142,143]. Stimulation of 
various TLRs, among which were the virus-sensing TLR3, 7, and 9, altered the expression of 
transcripts favoring β-glucopyranosylceramide synthesis. Yet the identity of the stimulatory 
lipids remains elusive at this point. 
Reduced degradation of antigenic self-lipids by the lysosome-resident enzyme 
α-galactosidase A (α-Gal-A) has been suggested to induce iNKT cell activity [144]. Moreover, 
TLR stimulation caused a temporary decrease in α-Gal-A activity. Thus, the TLR-dependent 
inhibition of α-Gal-A activity would provide a mechanistic link between TLR-mediated 
pathogen recognition and the generation, and subsequent presentation, of antigenic self-
lipids by CD1d [144].
The trafficking route of CD1d molecules affects lipid presentation. A subset (5-10%) of 
CD1d molecules associates with MHC class II complexes [129]. In TLR-stimulated mature 
DCs, MHC class II molecules are dramatically relocalized from intracellular endosomal 
compartments to the cell surface. As a consequence, the MHC class II-associated pool of 




CD1d molecules would not encounter certain lipid species along the endolysosomal route. In 
line with this, the presentation of exogenous lipid antigens by CD1d molecules is reduced for 
mature DCs [145]. In further support, mice that lack the MHC class II-associated invariant 
chain exhibit defects in the localization of MHC class II molecules to the endolysosomal route 
[146]. In these same invariant chain-deficient mice, CD1d-mediated lipid presentation of 
endosome-derived model antigen α-GalGalCer is also much reduced [103].
CD1d mRNA levels were found to be increased upon infection of DCs with herpes simplex 
virus type 1 (HSV-1) or human cytomegalovirus (HCMV). Stimulation of TLR7 also elevated 
CD1d mRNA expression levels. The increased CD1d mRNA levels were accompanied by 
enrichment of CD1d proteins at the cell surface and enhanced activation and proliferation of 
iNKT cells [147]. On monocytes, CD1d was upregulated upon dengue virus infection, which 
might contribute to iNKT cell activation [116]. 
In conclusion, TLR-mediated recognition of viral infection leads to altered lipid 
presentation by CD1d molecules, thereby affecting the activation of iNKT cells. However, it 
has been suggested recently that robust iNKT cell activation in response to bacterial or viral 
pathogens might also be achieved by TLR stimulation in the absence of antigenic stimulation 
[148]. 
Viral evasion of CD1d-restricted antigen presentation 
Considering the importance of iNKT cells in anti-viral defense, it may not come as a 
surprise that viruses have acquired strategies to modulate detection by iNKT cells. Viruses, 
and herpesviruses in particular, are well known to evade cytotoxic T lymphocyte (CTL) 
detection by reducing MHC class I surface display [149,150,151]. More recently, the first 
observations on virus-induced CD1d downregulation and iNKT cell evasion were reported. 
Human immunodeficiency virus (HIV) has been shown to escape iNKT cell recognition 
(reviewed in [152]). A marked depletion of iNKT cells is observed after HIV infection, most 
likely resulting from cytolytic infection combined with activation-induced cell death. HIV 
further escapes iNKT cell recognition by downregulating CD1d surface display. The three 
viral proteins Vpu, Nef, and gp120 were shown to be involved in this process. Incubation 
of cells with recombinant HIV gp120 protein resulted in downregulation of CD1d surface 
levels [153], although the mechanism of action remains to be elucidated. HIV Nef accelerates 
the internalization of CD1d from the plasma membrane, retaining these lipid-presenting 
molecules in the trans-Golgi network [154]. Nef-induced downregulation acts via the 
tyrosine-based targeting motif located in the cytoplasmic tail of CD1d [154,155]. Finally, HIV 
Vpu retains CD1d molecules in early endosomes, thereby impairing recycling of CD1d from 
endocytic compartments to the cell surface [156].
Infection with either vaccinia virus (VV) or vesicular stomatitis virus (VSV) resulted in 
reduced activation of iNKT cells, although CD1d surface levels remained unchanged. The two 
viruses modulated MAPK signaling and subsequent intracellular CD1d trafficking, thereby 
presumably altering the lipid repertoire presented by CD1d for iNKT cell recognition [157]. 
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The VV-encoded proteins B1R and H5R were found to be involved in evasion from CD1d-
restricted iNKT cells [158]. Yet, B1R is a viral kinase that phosphorylates H5R, a transcription 
factor involved in late viral protein expression, and thus the effects of B1R and H5R on iNKT 
cell evasion may be indirect.
Human papillomavirus (HPV) type 16 inhibits MHC class I- and class II-restricted 
peptide presentation through expression of the small hydrophobic E5 protein [159,160,161]. 
In addition, HPV interferes with CD1d-resticted lipid presentation. Expression of HPV E5 
protein caused a reduction in both cell surface and total CD1d protein levels. HPV E5 interacts 
with calnexin and prevents exit of CD1d molecules from the ER. Although mechanistic details 
are lacking, upon cellular expression of HPV E5, CD1d molecules end up in the cytosol, 
where they are degraded by the proteasome [162]. 
Products of herpesviruses HSV-1, KSHV, and EBV have been shown to interfere 
with trafficking of CD1d. In KSHV-mediated downregulation of surface CD1d, the viral 
proteins K3 and K5 have been implicated [163], which also are known to target HLA I for 
lysosomal degradation [164,165]. Although CD1d molecules enter the endocytic pathway 
as a consequence of K5-mediated ubiquitination of their cytoplasmic tails, the total cellular 
levels of CD1d remain virtually unchanged [163] suggesting that CD1d molecules appeared 
resistant to lysosomal degradation. 
HSV-1 downregulates CD1d surface display by inhibiting recycling of CD1d molecules 
from endosomal compartments to the cell surface, leading to redistribution of CD1d to the 
limiting membranes of lysosomes. This HSV-1 induced downregulation is independent of 
the cytoplasmic tail of CD1d [166]. A subsequent study found that phosphorylation of the 
kinesin KIF3A by the serine-threonine kinase US3 of HSV-1 inhibited exocytosis from late 
endosomes/lysosomes to the cell surface of CD1d molecules [167].
In addition, the glycoprotein gB and US3 appear to cooperatively hamper CD1d-
mediated antigen presentation to iNKT cells. gB was essential, but not sufficient, for CD1d 
downregulation during viral infection. Efficient CD1d downregulation required co-expression 
of an active US3 enzyme that modulates gB trafficking. CD1d trafficking is altered by the 
concerted action of gB and US3, redirecting CD1d to the trans-Golgi network [168]. 
Different B cell subsets like naïve, memory, and especially marginal zone-like B cells are 
CD1d-positive [169]. Ex vivo, cultured B cells show significantly decreased levels of CD1d 
molecules within several days. EBV infection of resting B cells even further decreased 
expression of CD1d in comparison to uninfected cells suggesting that EBV interferes with 
CD1d expression [104]. Transcription of CD1d molecules is regulated by retinoic acid 
receptor signalling in B cells [169]. Stimulation with retinoic acid rescued expression CD1d on 
cultured B cells as well as on EBV-infected B-LCLs. The observed increase of CD1d molecules 
resulted in enhanced iNKT cell stimulation in the presence of αGalCer. Interestingly, B-LCLs 
treated with retinoic acid, but not uninfected B cells, could stimulate iNKT cells even in the 
absence of αGalCer, pointing towards an endogenous ligand that is induced/upregulated by 
EBV infection of B cells [104]. The identity of this ligand remains elusive so far.




Immune evasion by Epstein-Barr virus 
Many viral gene products of EBV are dedicated to functions that modulate anti-viral 
responses of the host. Investigation of immune evasion mechanisms acquired by EBV and 
other herpesviruses might provide useful insights into viral-specific immune defense and the 
immune system in general.  
Evasion during the lytic cycle
About 80 proteins are expressed by EBV during its lytic cycle. Many of them interfere with 
molecules involved in immune responses of the innate and adaptive immune system. Some 
of them act highly specifically on certain host proteins, whereas others employ a mechanism 
of action with a broad target range. One of these broadly acting proteins is BGLF5, the EBV 
DNase (alkaline exonuclease) that is produced with early kinetics during the productive phase 
of infection [170] and is involved in a process termed shutoff. 
Shutoff by BGLF5
Like other γ-herpesviruses, EBV inhibits cellular protein synthesis in productively 
infected cells through global mRNA destabilization. This is mediated by BGLF5, the protein 
first identified as a DNase [171], later its involvement in shutoff has been recognized [172]. 
BGLF5’s additional RNase function utilizes the same catalytic site as its DNase activity, yet 
the substrate-binding site appears only partly shared by DNA and RNA substrates [173]. 
The promiscuous RNA degradation induced by EBV BGLF5 can affect immunologically 
relevant proteins. These include TLR2 and TLR9 that are capable of sensing EBV infection 
[46,52,174], but also the antigen-presenting molecules HLA I and HLA II [170,172] that 
present virus-derived peptides to CD8+ and CD4+ T cells, respectively. When BGLF5 was 
expressed in isolation, CD8+ T cell activation was decreased by 90%. During the lytic cycle, 
silencing of BGLF5 translation by 75% using shRNAs reduced, but not completely blocked, 
HLA I surface expression [174], indicating that other EBV gene products contribute to HLA 
I downregulation. It has been suggested that BGLF5 displays some selectivity, for example, 
TLR4 is not targeted by BGLF5 [46,174]. 
Evasion of antigen presentation
EBV compromises activation of both CD8+ and CD4+ T cells by interfering at various 
stages of the HLA class I and class II antigen presentation pathways, in particular during the 
productive phase of infection (Figure 1). During the early lytic cycle, BNLF2a and BILF1 
inhibit HLA I-mediated antigen presentation on the cell surface, while gp42/gH/gL directly 
act during the late productive phase on HLA II. 
BNLF2a is a gene product unique to lymphocryptoviruses of Old World primates. 
Expression of BNLF2a in isolation or in the context of EBV infection results in reduced CD8+ 
T cell recognition. BNLF2a appears to deplete peptides from the ER through inhibition of 
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peptide import by the transporter associated with antigen presentation (TAP) [175,176]. In 
vitro infection with BNLF2a-deleted recombinant EBV restores T cell recognition of peptides 
expressed by these cells early after viral reactivation [177]. The mechanism of action of BNLF2a 
is exceptional among viral TAP inhibitors known to date. BNLF2a corrupts the binding of 
both peptides and ATP to the TAP complex, thereby blocking its transporter function and, 
ultimately, surface display of peptide/HLA complexes. 
BILF1 encodes a constitutively active G-protein-coupled receptor (GPCR). The GPCR-
signaling function is not required for downregulation of HLA I [178]. The underlying 
mechanism involves reduced transport of HLA I from the trans-Golgi network, as well as 
an increased turnover from the cell surface and, subsequently, enhanced degradation via 
lysosomal proteases [178]. This molecular mechanism is distinct from the ones identified for 
other viruses that induce degradation of HLA I. The cytoplasmic C-termini of both BILF1 and 
its targets are critical for HLA I downregulation. Most HLA I haplotypes are downregulated 
by BILF1, yet HLA-C alleles appear resistant [179]; the latter could deviate NK cells.
The relative contribution of BGLF5, BNLF2, and BILF1 to HLA I downregulation differs 
during the IE, E, and L phases of the EBV lytic cycle [180]. Knockdown of BNLF2a in donor 
LCLs primarily results in reduced activation of CD8+ T cells specific for IE and E antigens, 
while BILF1 knockdown increases recognition of E and especially L antigens. Contrary to 
observations in overexpression studies, reducing BGLF5 expression displays limited effects 
on antigen recognition in any of the phases [180]. Timing of expression partially explains 
these differences, although some synergy between BNLF2a and BILF1 is also observed in 
reducing late antigen recognition.
Gp42 has initially been described as an entry receptor for EBV, binding to HLA class II 
molecules present on B cells. Additionally, gp42 acts as an immune evasion molecule. Its 
association with HLA class II / peptide complexes blocks T cell receptor (TCR) - class II 
interactions and precludes activation of CD4+ T cells [181]. Whereas downregulation of HLA 
II occurs during productive EBV infection, this effect is not observed upon expression of 
gp42 in isolation [182], indicating that EBV employs additional HLA II evasion strategies. 
The viral interaction partners of gp42, gH and gL, cooperate to increase HLA II evasion 
(unpublished observation). In line with this, T cell activation was further diminished by 
additional inclusion of gH and gL in the gp42-HLA II complexes. Mechanistically, the major 
effect of gH/gL appeared to be stabilization and increased expression of gp42 (unpublished 
observation).
In addition to these ORFs that directly impair HLA II recognition, other EBV gene 
products indirectly interfere with CD4+ T cell immunity. The immediate-early protein 
BZLF1 has been reported to impair IFNγ-signaling, thereby inhibiting CIITA promoter 
activity and, as a result, decreasing HLA II surface levels [183]. More recently, BZLF1 has 
been shown to impair HLA  II presentation post-transcriptionally by interfering with the 
function of the invariant chain [184]. In this study, expression of BZLF1 in isolation resulted 
in approximately 50% reduction in CD4+ T cell recognition. EBV also encodes a viral IL-10 




Figure 1 Antigen presentation pathways targeted by EBV. Multiple EBV-derived peptides are pre-
sented in the context of HLA I and II molecules to be scrutinized by specific T cells. Endogenous lipids 
are presented by CD1d to iNKT cells. Presentation to CD4+ T cells occurs by HLA II+ antigen-presenting 
cells, where EBV proteins are degraded in MHC class II-loading compartments (MIIC) and the result-
ing peptides are loaded onto HLA II molecules. For antigen presentation to CD8+ T cells, cytosolic EBV 
proteins, or fragments thereof, are degraded by the proteasome into peptides that are transported across 
the ER membrane by the transporter associated with antigen presentation (TAP) and are subsequently 
loaded onto newly synthesized HLA I molecules; mature HLA I/ peptide complexes travel through the 
Golgi compartments to the cell surface. Latent (green) and lytic (purple) EBV proteins interfere at vari-
ous steps with activation of the cellular immune response.
homologue (BCRF1) that may act, similarly to host IL-10, as an anti-inflammatory cytokine 
able to inhibit and modulate CD4+ T cell priming and effector functions [185]. Moreover, 
BCRF1 has been shown to inhibit co-stimulatory molecules on human monocytes, which 
potentially results in inefficient priming and expansion of CD4+ T cells [186]. 
In conclusion, EBV has evolved multiple layers of immune evasion that interfere with 
the recognition of infected cells by CD8+ and CD4+ T cells. This wide range of evasion 
mechanisms explains how EBV can replicate and establish a life-long infection of its host, 
despite the existence of strong CD8+ and CD4+ T cell immunity against a broad repertoire 
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of EBV antigens. Notably, the discovery of multiple EBV lytic cycle genes that co-operate 
to interfere with HLA class I and II antigen processing underscores the need for EBV to 
evade CD8+ and CD4+ T cell responses during replication, a time at which a large number of 
potential viral targets are expressed [187]. Together, these immune evasion strategies ensure a 
window for undetected replication of EBV. Additionally, these evasion mechanisms facilitate 
the establishment and maintenance of a life-long infection of the host.
Evasion of innate immunity
EBV interferes with innate immune responses at different levels. Modulation of the pro-
inflammatory NF-κB and the IFN-inducing IRF pathways, which have a major role in induction 
of anti-viral innate immunity, has been reported as well as direct or indirect inhibition of 
cytokines and IFNs or modulation of their downstream effects [7]. One major modulator of 
innate immunity in lytic EBV infection is the immediate-early EBV transactivator BZLF1, 
which interferes with the above mentioned pathways. 
BZLF1 interacts with the transcription factor IRF7 and inhibits its transcriptional activity 
on the IFNα4 and IFNβ promoters to prevent induction of an antiviral environment [188]. 
Productive EBV infection is associated with a reduction in NF-κB-dependent gene expression 
[189]. Viral BZLF1 and cellular NF-κB reciprocally inhibit each other’s expression and, as a 
consequence, higher levels of NF-κB in the absence of BZLF1 favor EBV latency, whereas 
increased expression of BZLF1 upon lytic cycle induction overwhelms the limiting amount 
of NF-κB [190,191,192]. While NF-κB is still translocated to the nucleus, its transcriptional 
activity is suppressed by BZLF1, preventing induction of anti-viral immune effector 
mechanisms [190]. Moreover, EBV BZLF1 counteracts innate effector molecules in several 
ways. It downregulates the receptors for TNFα and IFNγ to reduce cellular responsiveness 
to these cytokines [183,193,194]. In addition, BZLF1 induces the suppressor of cytokine 
signaling SOCS3, which inhibits JAK/STAT signaling and thereby favors a state of type I 
IFN-irresponsiveness [195]. Additionally, SOCS3 reduces IFNα production by monocytes. 
Moreover, BZLF1 causes expression of the immunosuppressive cytokine TGFβ [196] and 
disrupts the formation of PML-bodies [197], which can have antiviral activity [198].
Besides BZLF1, the EBV proteins BRLF1, LF2, and BGLF4 prevent transcription of IRF 
proteins or interfere with their activity, thereby resulting in reduced production of type I IFNs 
[199]. Recently, Dunmire et al. reported that a clear systemic IFN response is observed during 
acute EBV infection, but this response lacks some key components compared to observations 
for other viruses [200]. This may illustrate the successful actions of the immune evasion 
mechanisms employed by EBV to repress secretion of interferon responsive genes.
TLR signaling pathways leading to NF-κB activation are tightly controlled by post-
translational modifications, such as phosphorylation and ubiquitination [201,202]. EBV 
encodes the lytic proteins BGLF4 and BPLF1 that interfere with these modifications [203]. 
Being a component of the EBV tegument, BPLF1 could act both in productively as well as in 
newly infected cells [204,205].




EBV counteracts the pleiotropic host cytokine colony-stimulating factor 1 (CSF-1), 
which stimulates macrophage differentiation and IFNα secretion. To this end, EBV encodes a 
soluble form of the CSF-1 receptor, BARF1, that neutralizes the effects of host CSF-1 in vitro, 
leading to reduced IFNα secretion by EBV-infected mononuclear cells [206,207]. Mutating 
the BARF1 homologue in a related rhesus macaque lymphocryptovirus decreases viral load 
during primary infection and leads to a lower persistence setpoint in vivo [208]. 
The early-expressed EBV-encoded dUTPase (encoded by the BLLF3 gene) also modulates 
cytokine-induced responses. In a mouse model, dUTPase compromises lymphocyte 
responses, e.g. secretion of IFNγ [209]. In human cells, EBV dUTPase has seemingly opposing 
effects: it induces NF-κB activation in a TLR2/MyD88-dependent way [47,48,210], it inhibits 
lymphocyte proliferation, and it induces production of both proinflammatory cytokines as 
well as IL-10 [185,211]. Following this strategy, EBV appears to exploit the advantageous 
effects of NF-κB activation, while limiting ensuing anti-viral T cell responses.
Evasion during latent infection
Latent infection is characterized by limited EBV protein expression. In latency III cells, 
EBNA1-6 and LMP1 and 2 are expressed. During latency II, expression is restricted to EBNA1 
and LMP1 and 2. Latency I involves expression of EBNA1 only, and latency 0 exists without 
any EBV protein generation. Some latency-associated proteins have immune modulatory 
functions, thereby facilitating immune evasion. 
EBNA1
EBNA1, present during all latency stages, contains a long glycine-alanine repeat that 
inhibits translation as well as proteasomal degradation of EBNA1 through interference with 
processing by the 19S proteasomal subunit [212,213,214,215,216]. This strategy ensures 
sufficient EBNA1 levels to maintain the viral genome [217], while decreasing protein turnover 
to minimize viral antigen presentation to CD8+ T cells. Initially, EBNA1-specific CD8+ T cell 
responses were indeed not observed in vitro [213]. However, later studies did report EBNA1-
specific T cell responses initiated by endogenously presented EBNA1-derived antigens 
[218,219,220]. Potential sources of these antigens include defective ribosomal products that 
lack the glycine-alanine repeat, or cross-presented exogenous antigens released by EBV-
infected cells.
Other immune evasive actions of EBNA1 include inhibition of the canonical NF-κB 
pathway by interfering with phosphorylation of the IKK complex signaling intermediate 
[221] and modulation of the STAT1 and TGFβ signaling pathways [222].




EBNA2 applies a double-edged strategy by inducing low-level IFNβ production that 
leads to interferon-stimulated gene (ISG) production in BL cell lines [223], whereas anti-
proliferative effects are neutralized by EBNA2-mediated inhibition of selected ISGs [224,225] 
and enhanced transcriptional activity of STAT3 [226] following IFNα production. STAT3 
modulates IFN-induced immune responses through STAT1 and suppresses production of 
inflammatory mediators [227]. In addition, EBNA2 upregulates the IL-18 receptor on BL cells 
[228]. IL-18 plays a role in regulating innate and adaptive immune responses and is elevated 
in certain EBV-associated malignancies [229].
LMP1
LMP1 promotes B cell growth and survival by mimicking constitutive CD40 signaling 
to activate NF-κB, JNK, MAPK, JAK/STAT and PI3K signaling pathways [230]. These 
pathways affect many immunological processes and allow LMP1 to steer the host immune 
response (reviewed in [231]). LMP1-mediated NF-κB activation in EBV-immortalized 
B cells results in type I IFN production that stimulates STAT1 expression in autocrine 
and paracrine fashion [232,233,234]. STAT2 activity is inhibited by LMP1 [235]. LMP1-
mediated upregulation of IRF7 benefits EBV by promoting cell growth, while at the same 
time an inhibitory IRF7 splice variant is induced to repress the adverse effects of type I IFN-
production [236,237,238,239,240]. Furthermore, LMP1-mediated induction of JAK/STAT 
signaling pathways may be advantageous to EBV as the antiviral activities of ISGs prevent 
superinfection and facilitate establishment of latency [241,242]. Finally, LMP-1 mediated NF-
κB activation reduces TLR9 surface expression [243] and supplies growth benefits to infected 
cells [244,245].
LMP2a and LMP2b
LMP2a inhibits NF-κB activity, IL-6 production, and subsequent JAK/STAT signaling 
pathways in carcinoma cell lines [246]. In contrast LMP2a induces NF-κB activation in B 
cells and uses the subsequently increased levels of anti-apoptotic Bcl-2 to protect infected 
cells from apoptosis in a transgenic mouse model [247]. Furthermore, LMP2a and LMP2b 
accelerate turnover of IFN receptors, resulting in decreased responsiveness of epithelial cells 
to IFNα and IFNγ [248]. 
EBV miRNAs
Apart from growth-transforming and anti-apoptotic functions, EBV miRNAs target 
several host genes involved in anti-viral immunity. 
Among the first EBV miRNA targets identified was CXCL-11, a T cell attracting chemokine 
downregulated by EBV miRNAs BHRF1-3 [249]. Stress-induced NK cell ligands have been 
specifically investigated as potential viral miRNA targets. Initially, MICB was identified as a 
target of the HCMV encoded miR-UL112, and later it became apparent that also miRNAs 




encoded by KSHV and EBV downregulate MICB expression. Inhibiting EBV miRNA 
BART2-5p results in increased NK cell killing in vitro [250]. Inflammasomes are induced by 
various cytoplasmic and nuclear sensors (e.g. NLRP3 and IFI16) and lead to production of the 
inflammatory cytokines IL-1β and IL-18 [251]. Although EBV has so far only been observed 
to activate inflammasomes through IFI16 [75], EBV miRNA BART15 downregulates the 
alternative inflammasome-activating sensor NLRP3 [252]. Co-culture of monocytic recipient 
cells with EBV+ B cells secreting BART15-containing exosomes results in decreased IL-1β 
production. Additionally, EBV miRNAs regulate the IFNγ-STAT1 pathway in EBV+ NK cells 
by downregulating IFNγ transcriptional regulator T-bet (BART20-5p), IFNγ (BART20-5p), 
and STAT1 (BART8) [253,254]. Inhibition of BART6-3p in a BL cell line caused upregulation 
of the IL-6 receptor chains (p80 and gp130) at the mRNA and protein level, indicating that 
BART6-3p may affect IL-6 signaling [255].
Outline of this thesis
Viruses, especially those causing persistent infections such as EBV, have acquired 
strategies to counteract the host’s immune defense. During latency, viral protein production 
is limited or absent, thereby being virtually invisible to the immune system. Evasion strategies 
of EBV active during primary infection or upon reactivation are considered beneficial for 
establishment of latent infection or prolonged replication, respectively. Viral molecules 
interfering with antigen presentation by HLA I and HLA II have been identified previously. 
The aim of this thesis was to identify novel molecules directing immune evasion and investigate 
the respective underlying molecular mechanisms, thereby contributing to our understanding 
of EBV and the human immune system.
Chapter 2 describes an shRNA-based approach to silence translation of the shutoff protein 
BGLF5 in lytically EBV-infected B cells in order to unmask novel evasion targets of EBV. 
The non-classical lipid-presenting molecule CD1d was identified as a new target of BGLF5. 
Furthermore, the data suggested that likely additional mechanisms exist in EBV targeting 
CD1d. Identification of one of these molecules, EBV gp150, is described in Chapter 3. EBV 
gp150 appears to shield antigen-presenting molecules and other surface molecules on B cells 
by means of its abundant glycans. Thereby, EBV gp150 impairs T cell recognition of infected 
cells. In Chapter 4, allele specificity of the previously identified HLA I evasion molecule EBV 
BILF1 was investigated. Thereby, the molecular requirements in HLA I as well as in BILF1 
that are needed for immune evasion were identified. Recent advances in the field of DNA 
sensing led to the question whether B cells might sense foreign DNA by the cGAS-STING 
pathway. Chapter 5 describes that human B cells, the main target cells of EBV persistence, 
have the DNA sensors IFI16 and cGAS, but the majority of B cells tested lack STING protein. 
Irrespective of the presence of STING, human B cells were unresponsive to cytoplasmic DNA 
exposure. In Chapter 6 the results of this thesis are summarized, and implications and future 
directions of this research are discussed. 
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During productive infection with Epstein-Barr virus (EBV), a dramatic suppression of 
cellular protein expression is caused by the viral alkaline exonuclease BGLF5. Among the 
proteins downregulated by BGLF5 are multiple immune components. Here, we show that 
shutoff reduces expression of the innate EBV-sensing Toll-like receptor-2 and the lipid 
antigen-presenting CD1d molecule, thereby identifying these proteins as novel targets of 
BGLF5. 
To silence BGLF5 expression in B cells undergoing productive EBV infection, we employed 
an shRNA approach. Viral replication still occurred in these cells, albeit with reduced late 
gene expression. Surface levels of a group of proteins, including immunologically relevant 
molecules such as CD1d and HLA class I and class II, were only partly rescued by depletion 
of BGLF5, suggesting that additional viral gene products interfere with their expression. Our 
combined approach thus provides a means to unmask novel EBV (innate) immune evasion 
strategies that may operate in productively infected B cells.
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Herpesviruses are large enveloped DNA viruses that establish lifelong persistence in 
infected hosts. To achieve persistence, many herpesvirus gene products are dedicated to 
preventing elimination of virus-producing cells. For instance, members of all three herpesvirus 
subfamilies encode proteins that specifically interfere with antigen presentation to T cells 
(Griffin et al., 2010). Prior to adaptive immunity, innate responses are elicited upon sensing 
of infection through pattern-recognition receptors, such as the Toll-like receptors (TLRs) 
(Iwasaki & Medzhitov, 2010;Paludan et al., 2013). These innate antiviral responses are also 
subject to herpesvirus immune evasion (Feng et al., 2013;Ning, 2011;Paludan et al., 2013).
Productive infection by α- and γ-herpesviruses induces a global inhibition of protein 
synthesis resulting from enhanced mRNA degradation (Gaglia et al., 2012). For the 
γ-herpesviruses, this shutoff is mediated by the viral alkaline exonuclease (AE) (Covarrubias 
et al., 2009;Glaunsinger & Ganem, 2004;Rowe et al., 2007). AE proteins are conserved 
throughout the herpesvirus family, reflecting their critical DNase function in processing of 
newly synthesized viral genomes; their additional RNase-based shutoff function is unique 
to γ-herpesviruses (Glaunsinger & Ganem, 2004;Rowe et al., 2007). Shutoff appears broadly 
active and affects expression of most cellular proteins (Clyde & Glaunsinger, 2011). As 
such, herpesvirus-induced shutoff provides a general strategy to dampen anti-viral immune 
activation.
Additional, more specific, immune evasive mechanisms operating in herpesvirus-infected 
cells could be masked by the general effects of shutoff. Indeed, the first examples of T cell 
escape by dedicated herpesvirus immunoevasins were identified in the absence of shutoff: 
α-herpesvirus-encoded inhibitors of antigen presentation by HLA class I (HLA I) molecules 
were identified using shutoff-defective mutant viruses (Koppers-Lalic et al., 2003;York et al., 
1994), and multiple HLA I evasion strategies were identified for the β-herpesvirus human 
cytomegalovirus that lacks a virus-encoded shutoff function (Barnes & Grundy, 1992). 
Cooperative targeting of a single immune pathway by multiple viral gene products has emerged 
as a common theme (Jones et al., 1995;Ressing et al., 2008). Compared to α-herpesviruses, 
shutoff by γ-herpesviruses has been discovered more recently. Consequently, less is known 
about the role of AE-mediated shutoff in immune evasion during productive γ-herpesvirus 
infection.
The prototypic human γ-herpesvirus, Epstein-Barr virus (EBV), naturally infects B cells, 
which form the latent virus reservoir in vivo (Rickinson & Kieff, 2007). For production of 
new viral progeny, EBV reactivates from a small percentage of latently infected B cells. The 
AE protein of EBV, BGLF5, is expressed during this lytic phase of infection. Earlier, we have 
reported that cellular expression of BGLF5 downregulates immunologically relevant proteins, 
such as HLA molecules and TLR9 (Rowe et al., 2007;van Gent et al., 2011;Zuo et al., 2008), 
providing a means of general immune evasion. In this study, we aimed to evaluate BGLF5’s 
effects in the context of productive EBV infection in B cells.
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Figure 1 Silencing BGLF5 in productively EBV-infected B cells. AKBM B cells stably expressed 
no shRNA, a combination of two BGLF5-targeting shRNAs (shBGLF5), or an shRNA targeting Fas 
(shControl). By 20 hours of anti-human IgG treatment (+ anti-IgG), a population of cells had entered 
the EBV lytic cycle, with concomitant expression of the rCD2-GFP reporter. (a) Intracellular BGLF5 
levels were determined by flow cytometry, with percentages indicating BGLF5 levels compared to those 
in shControl cells. In over 10 experiments, around 15-40% BGLF5 protein expression remained in lytic 
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Several approaches have been used to eliminate expression of individual herpesvirus 
genes from infected cells, one of which is based on the use of bacterial artificial chromosomes 
(BACs) (Delecluse et al., 2008). Using this approach, deletion of BGLF5 was shown to perturb 
EBV replication in transfected 293T cells, resulting in reduced viral yields (Feederle et al., 
2009a). Studying EBV mutants during productive infection of B cells has been more difficult. 
Here, we have employed the EBV+ Akata B cell line AKBM, in which cross-linking of the B 
cell receptor with anti-human IgG reactivates EBV in 10-40% of cells. Productively infected 
B cells can be identified and sorted on the basis of induced expression of a reporter protein, 
ratCD2-GFP (rCD2-GFP) (Ressing et al., 2005). Using this system, we have elucidated several 
immune evasion mechanisms acting during the productive phase of EBV infection (Horst et 
al., 2009;Ressing et al., 2005;van Gent et al., 2011;van Gent et al., 2014). As our approach to 
suppress BGLF5-mediated shutoff during productive infection in B cells, lentivirus-delivered 
shRNAs were introduced into these EBV+ AKBM cells. 
Ten candidate shRNAs that target sites within the BGLF5 coding sequence were cloned 
into a lentiviral vector (Figure S1) (Lebbink et al., 2011). Two of these considerably reduced 
BGLF5 levels in EBV-producing B cells, whereas the expression of a control protein, 
transferrin receptor (CD71), was not substantially affected (Figure S2). Combining the two 
shRNAs (referred to as shBGLF5) reduced BGLF5 protein levels by 60-75% compared to 
lytically induced control AKBM cells (Figures 1a, S2). Also mRNA levels of BGLF5 were 
markedly reduced in productively infected AKBM-shBGLF5 cells, whereas levels of another 
EBV transcript, BNLF2a, remained unchanged (Figure 1b). Thus, stable expression of 
specific shRNAs through lentiviral transduction substantially reduced BGLF5 levels during 
productive EBV infection in B cells.
AE proteins, through their conserved DNase function, are required for processing of 
replicated herpesvirus genomes in infected cells. We examined whether silencing of BGLF5 
in B cells interfered with progression through the EBV replication cycle. Upon reactivation, 
immediate-early (IE), early, and late herpesvirus proteins are sequentially expressed (Table 
S1). Anti-IgG treatment of AKBM-shBGLF5 and control cells caused similar amounts of 
B cells to become positive for the IE transactivator BZLF1 and the early-expressed rCD2-
GFP reporter (Figures 1c, S3), both of which precede expression of the BGLF5 protein. In 
AKBM-shBGLF5 cells. See Figure S2 for further details. (b) Semi-quantitative RT-PCR analysis was 
performed to determine mRNA levels of BGLF5, an EBV control transcript (BNLF2a), or a cellular 
control RNA (18S ribosomal RNA). Almost pure populations of productively EBV-infected cells were 
obtained through magnetic sorting of lytically induced cells labeled with mouse-anti-rCD2 Ab and 
anti-mouse-magnetic beads (Miltenyi) (Ressing et al., 2005). (c) Effects of shRNAs on progression 
through the replicative cycle were monitored by flow cytometric analysis of several EBV antigens (Table 
S1, Figure S3). Percentages indicate viral antigen-negative (left) and -positive cells (right) within the 
productively infected population (lytic cells); solid lines, lytic AKBM cells gated on expression of the 
rCD2-GFP reporter protein (GFP+); dashed lines, latently EBV-infected cells (GFP-); grey lines, no 
primary Ab. 
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Figure 2 BGLF5 silencing rescues expression of surface proteins on EBV-producing B cells. EBV 
reactivation was induced in AKBM-shBGLF5 or -shControl cells. (a,b) Surface levels of the cellular 
antigens in Table S2, in (b) ordered by increasing downregulation from EBV-producing cells. (c) Surface 
levels of CD1d on AKBM cells that stably expressed human CD1d molecules after lentiviral transduction 
(AKBM-CD1d cells). The extent of BGLF5 silencing was visualized by intracellular staining. Solid lines, 
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contrast, the proportion of AKBM-shBGLF5 cells expressing late proteins gp350, gH, and gL 
was substantially reduced. Thus, silencing BGLF5 appears to hamper entry into the late phase 
of productive EBV infection in B cells.
To evaluate the effects of shutoff, relying on BGLF5’s RNase activity, in EBV-producing B 
cells, we examined the influence of BGLF5 silencing on the downregulation of various surface 
proteins. In control cells, EBV reactivation caused a minor reduction in CD71 surface levels, 
while HLA I and II were strongly downregulated (Figures 2a and S4a, upper panels), which is 
in line with earlier observations (Ressing et al., 2005). In lytic AKBM-shBGLF5 cells, surface 
display of HLA I and II was partly rescued (Figures 2a and S4a, lower panels), supporting a 
contribution of shutoff to evasion from T cell detection during EBV replication in B cells. Still, 
levels of these antigen presenting molecules remained markedly reduced on BGLF5-silenced 
cells, which could reflect the specific effects on HLA I expression mediated by two dedicated 
EBV lytic cycle proteins, BNLF2a and BILF1 (Ressing et al., 2008;Zuo et al., 2009). 
The analysis was extended to a panel of additional cellular proteins detectable at the surface 
of latently EBV-infected B cells (Table S2). Following viral reactivation, cellular display of the 
markers tested was reduced to varying degrees (Figures 2b,d, S4b). CD58, CD119, CD10, 
and CD45 were marginally affected and, therefore, the effect of BGLF5 silencing was difficult 
to evaluate (group I; Figures 2b,d, S4b), as was the case for CD71 (Figure 2a). Surface levels 
of another group of proteins, comprising CD38, CD47, CD19, and CD20, were strongly 
reduced during productive EBV infection of control cells and they remained downregulated 
in induced AKBM-shBGLF5 cells (group II, Figures 2b,d, S4b). The phenotype for this latter 
group of proteins resembles that of the peptide-presenting HLA I and II complexes. 
We also included the non-classical HLA molecule CD1d in this analysis. CD1d molecules 
present lipid antigens to invariant natural killer T (iNKT) cells that express a semi-invariant 
T cell receptor as well as NK cell markers. iNKT cells act at the interface of innate and 
adaptive immunity: they rapidly produce polarizing cytokines when activated, for instance 
in response to viral infection (Horst et al., 2012a;Kinjo et al., 2013). Induction of the EBV 
lytic cycle in AKBM-CD1d cells caused a dramatic decrease in surface appearance of human 
CD1d molecules (Figures 2c,d, S4c). Although CD1d expression was partly restored when 
BGLF5 was silenced, it remained far below the levels observed on latently infected cells. Thus, 
CD1d-restricted antigen presentation appears a novel target of EBV immune evasion, in part 
mediated by the shutoff protein BGLF5. 
The combined data imply that B cell proteins whose surface display remains markedly 
productively EBV-infected (GFP+) cells; dashed lines, latently infected (GFP-) cells; grey, no primary 
Ab (dot plots in Figure S4). (d) Relative protein levels on productively versus latently EBV- infected 
shControl cells (horizontal axis) were plotted against those in shBGLF5 cells (vertical axis). Values were 
obtained by dividing geometric mean fluorescence intensities by background signals (isotype control 
or without primary antibody) and denoted as percentages expression in lytically compared to latently 
infected cells, as determined in at least four independent experiments (average ± SD; values for CD58, 
CD45, and CD119 based on two replicates).
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reduced on BGLF5-silenced cells (Figure 2d, group II) are likely to be downregulated by 
additional EBV lytic phase proteins, for instance to effectuate reduced recognition of virus-
producing B cells by the immune system.
To complement the studies performed in naturally infected AKBM-CD1d-shBGLF5 cells, 
we investigated BGLF5’s effects on the non-classical antigen-presenting molecule CD1d in 
cells expressing BGLF5 in isolation. MJS-CD1d cells were transiently transfected with BGLF5 
and reduction of GFP and surface HLA I levels cells confirmed induction of shutoff. The 
BGLF5-transfected cells displayed reduced surface expression of CD1d (Figure 3a). This 
CD1d downregulation was, however, less pronounced than that on B cells expressing all EBV 
gene products (Figure 2c), reminiscent of the phenotype for HLA I (Figure 2a) (Rowe et al., 
2007). These results show that BGLF5 reduces CD1d levels and that other viral factors, absent 
from the transfected MJS cells, are likely to add to the robust CD1d downregulation observed 
during productive EBV infection of B cells.
Earlier, we have found that expression of innate sensors, namely several TLRs, is reduced 
upon EBV reactivation in AKBM cells and that BGLF5 contributes to the downregulation of 
TLR9 (van Gent et al., 2011). TLR2, 3, and 9 sense EBV particles (Gaudreault et al., 2007;Iwakiri 
et al., 2009;van Gent et al., 2011), yet no evidence for TLR4-mediated recognition of EBV has 
been reported (Gaudreault et al., 2007). Here, we monitored the influence of BGLF5 on TLR2 
and TLR4. 293-TLR2 and 293-TLR4 cells were transiently transfected with the empty IRES-
GFP vector, wild-type BGLF5, or a catalytically inactive mutant, BGLF5D203S. TLR2 levels 
were reduced on wild-type BGLF5-expressing cells, but not on control cells (Figure 3b). In 
contrast, TLR4 levels were not affected by any of the transfected gene products. Thus, BGLF5-
mediated shutoff appears to target TLR2, a pattern-recognition receptor sensing EBV.
To conclude, this study shows that lentivirus-delivered shRNAs can successfully be applied 
to our system for productive EBV infection of B cells to achieve stable silencing of BGLF5. 
A similar approach in EBV-transformed B-LCLs yielded around 75% knockdown of viral 
gene expression, which was sufficient to reveal a hierarchy in immune evasive properties of 
BNLF2a, BILF1, and BGLF5 (Quinn et al., 2014).
In our system of EBV-producing AKBM cells, a comparable reduction of BGLF5 protein 
levels interfered with viral replication (Figure 1). While confirming that knockdown in EBV-
producing B cells was sufficiently robust to observe a phenotype, this observation extends 
Figure 3 BGLF5 contributes to downregulation of CD1d and TLR2. (a) MelJuSo cells were lentivirally 
transduced to stably express human CD1d molecules (MJS-CD1d). MJS-CD1d cells (a) and 293-TLR2/
CD14 cells (Kurt-Jones et al., 2002) or 293-TLR4/CD14/MD2 cells (Invitrogen) (b) were transiently 
transfected with a pcDNA3-IRES-nlsGFP vector without insert or encoding BGLF5 or the catalytic 
mutant BGLF5D203S (Horst et al., 2012b). At 48 hours post-transfection, surface levels of HLA I, CD1d, 
TLR2, and TLR4 were determined by flow cytometry. Downregulation of GFP served as a measure for 
BGLF5’s shutoff function. Dashed lines, untransfected GFP- cells; solid lines, transfected GFP+ cells; 
grey lines, secondary Ab only. Data shown are from one experiment representative of three independent 
experiments.
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earlier studies in 293T cells transfected with a BGLF5 deletion mutant EBV BAC (Feederle et 
al., 2009a). Within the EBV genome, BGLF5 occurs in tandem with BGLF4, which codes for 
the EBV protein kinase that can regulate EBV late gene expression (El-Guindy et al., 2014). 
Since BGLF4 is translated from a transcript encoding both BGLF4 and BGLF5, expression 
of both proteins was lost from BGLF5-deleted virus-producing 293T cells (Feederle et al., 
2009b). Likewise, the use of RNA interference to silence BGLF5 expression in B cells will 
target both BGLF5 and BGLF5+BGLF4 transcripts. When applying this approach to AKBM 
B cells, we have focused on the shutoff effects that are selectively induced by BGLF5.
During productive EBV infection, a broad range of B cell surface proteins is downregulated 
in the presence of BGLF5, and this effect is partly reversed upon silencing of BGLF5 (Figure 
2). These findings are in agreement with promiscuous shutoff by γ-herpesvirus AE proteins, 
deduced from mRNA target analysis (Clyde & Glaunsinger, 2011) and metabolic labeling 
experiments (Rowe et al., 2007). Still, some gene products escape shutoff and TLR4 appears 
to be one of them (Figure 3). Based on our current data, two groups of host surface proteins 
can be discriminated. The first group comprises proteins that are downregulated to a limited 
extent during EBV replication; the costimulatory molecules CD80 and CD86 can be included 
in this group (Ressing et al., 2005). The second group is more strongly downregulated, likely 
by multiple EBV lytic proteins, and their surface levels remain substantially reduced when 
BGLF5 is silenced. For some proteins belonging to this latter group, a causative role for BGLF5 
in their downregulation has been confirmed through transient transfection experiments, i.e. 
for HLA I and II (Rowe et al., 2007), for TLR9 (van Gent et al., 2011), and for CD1d and TLR2 
(this study, Figure 3). These combined findings support the notion that BGLF5 contributes to 
EBV-induced immune evasion during productive infection of B cells.
A recent study in BGLF5-silenced B-LCLs revealed a minor role for BGLF5 in CD8+ T 
cell evasion when compared to BNLF2a and BILF1 (Quinn et al., 2014). Along the same line, 
we observed only partially rescued surface display of B cell proteins upon BGLF5 knockdown 
during productive EBV infection (Figure 2). Residual downregulation could result from the 
~25% BGLF5 protein expression that remained in induced AKBM-shBGLF5 cells and/or 
from additional EBV-encoded shutoff function(s), such as that recently reported to be exerted 
by BZLF1 (Park et al., 2014). In vivo studies on the α-herpesvirus HSV-1 and the murine 
γ-herpesvirus MHV68 suggest that the immune evasive functions of shutoff mainly affect 
newly synthesized proteins induced by type I interferons (Murphy et al., 2003;Pasieka et al., 
2008;Sheridan et al., 2014). The above observations, together with the absence of shutoff from 
β-herpesviruses, point to a relatively small contribution of shutoff to immune evasion. This 
would provide a rationale as to why herpesviruses have acquired additional, specific immune 
evasion mechanisms to synergistically achieve the proper timing and extent of immune 
interference. 
Analogous to all other herpesviruses studied, EBV encodes multiple gene products that 
act in concert to prevent T cell activation (Ressing et al., 2008). Additional EBV strategies 
interfering with innate immunity continue to be identified (Ning, 2011). Here, we have added 
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CD1d and TLR2 to the target list of EBV BGLF5. Furthermore, we have identified a group of 
B cell surface proteins including CD1d whose expression is likely downregulated by EBV lytic 
phase proteins besides BGLF5.
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Table S1. Viral antigens expressed during productive EBV infection
ORF Name Timing Function Ab clone
BZLF1 Z, Zta, ZEBRA IE Lytic cycle transactivator BZ.1
BNLF2a E HLA I downregulation N/A
BGLF5 EBV AE, DNase E Shutoff and exonuclease 311H
BLLF1 gp350 L Major envelope glyco-protein, 
attachment to CR2
72A1
BXLF1 gp85/gH L Viral membrane fusion/entry E1D1
BKRF2 gp25/gL L Chaperone of gH E1D1
rCD2-GFP rat CD2-GFP fusion 
protein
“E” Lytic reporter, magnetic sorting OX34 (α-ratCD2)
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Table S2. Expression of cellular surface proteins by AKBM cells
CD# Name Function Ab
Not expressed by latently EBV-infected AKBM cells
CD1d Non-classical HLA molecule, lipid presentation to iNKT cells 51.1.3
CD11b Integrin alpha M Complement receptor 3 subunit BD550019
CD11c Integrin alpha X Complement receptor 4 subunit BD559877
CD21 CR2 Complement receptor 2, B cell coreceptor component (with 
CD19), EBV B cell receptor
BC IM0473U
CD23 FcεRII IgE receptor BD347797
CD25 IL-2 receptor alpha-chain BD341011
CD32 B cell coreceptor RDI-CD32
abm-7PE
CD35 CR1 Complement receptor 1 BD559872
CD40 Costimulation SC65263
CD44 Variety of lymphocyte functions BD550989
CD54 ICAM-1 Intercellular adhesion molecule BD555511
CD132 Common gamma chain (γc) Common subunit of at least six interleukin receptors BD555898
CD162 P-selectin glycoprotein ligand-1 Neutrophil recruitment BD556055
CD181 CXCR1 IL-8 receptor R&D-FAB330P
CD191 CCR1 Chemokine receptor, inflammatory responses R&D-FAB145P
CD192 CCR2 Chemokine receptor, monocyte chemotaxis R&D-FAB151P
CD282 Toll-Like Receptor 2 Pattern-recognition receptor eBioscience 
12-9024-82
CD284 Toll-Like Receptor 4 Pattern-recognition receptor Biolegend 
312802
Marginally downregulated during productive EBV infection (group I)
CD10 Neprilysin Zinc-dependent metalloprotease BD340921
CD45 Leukocyte common antigen Protein tyrosine phosphatase BD555485
CD58 LFA-3 Adhesion molecule, antigen-presenting cell - T cell 
interaction
BD555921
CD71 Transferrin receptor Iron uptake BD555534
CD119 IFNγRα Ligand binding α chain of IFNγ receptor BD558934
Substantially downregulated during productive EBV infection (group II)
CD19 B cell coreceptor component, reduces activation threshold BD555415
CD20 Enables optimal B cell immune response BD345793
CD38 Cyclic ADP ribose hydrolase Multifunctional ectoenzyme, regulation of intracellular Ca2+ 
levels
BD347687
CD47 Integrin associated protein Range of cellular processes BD556047
HLA I Classical HLA molecule, peptide presentation to CD8+ T cells W6/32
HLA II Classical HLA molecule, peptide presentation to CD4+ T cells L243
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M  A  D  V  D  E  L  E  D  P  M  E  E  M  T  S  Y  T  F  A  R  F  L  R  S  P  E  T  E  A  F  V  R  N  L  D  R  P  P  Q  M  P   
ATGGCCGACGTGGATGAGCTCGAGGATCCCATGGAGGAGATGACCTCCTACACGTTTGCCCGCTTCCTCCGCAGTCCGGAGACTGAGGCCTTTGTCCGTAACCTTGACCGTCCACCTCAGATGCC 
ATGGCCGACGTGGATGAGCTCGAGGATCCCATGGAGGAGATGACCTCCTACACGTTTGCCCGCTTCCTCCGCAGTCCGGAGACTGAGGCCTTTGTCCGTAACCTTGACCGTCCGCCTCAGATGCC 
M  A  D  V  D  E  L  E  D  P  M  E  E  M  T  S  Y  T  F  A  R  F  L  R  S  P  E  T  E  A  F  V  R  N  L  D  R  P  P  Q  M  P 
 
 





 A  M  R  Y  V  Y  L  Y  C  L  C  K  Q  I  Q  E  F  S  G  E  T  G  F  C  D  F  V  S  S  L  V  Q  E  N  D  S  Q  D  G  P  S  L   
 
 
  K  S  I  Y  W  G  L  Q  E  A  T  D  E  Q  R  T  V  L  C  S  Y  V  E  S  M  T  R  G  Q  S  E  N  L  M  W  D  I  L  R  N  G   
TGAAATCCATTTACTGGGGGCTACAGGAGGCCACCGACGAGCAGAGGACTGTTCTCTGCTCGTACGTGGAGTCCATGACCAGGGGGCAGTCTGAGAACCTGATGTGGGACATATTGCGAAATGGC 
TGAAATCCATTTACTGGGGGCTACAGGCGGCCACCGACGAGCAGAGGACTGTTCTCTGCTCGTACGTGGAGTCCATGACCAGGGGGCAGTCTGAGAACCTGATGTGGGACATATTGCGAAATGGC 
  K  S  I  Y  W  G  L  Q  A  A  T  D  E  Q  R  T  V  L  C  S  Y  V  E  S  M  T   R  G  Q  S  E  N  L  M  W  D  I  L  R  N  G   
 
 
I  I  S  S  S  K  L  L  S  T  I  K  N  G  P  T  K  V  F  E  P  A  P  I  S  T  N  H  Y  F  G  G  P  V  A  F  G  L  R  C  E  D  
ATAATTTCCTCTTCCAAGCTGCTCTCCACCATTAAGAATGGACCCACCAAGGTGTTTGAGCCAGCTCCCATCTCCACAAATCACTACTTTGGGGGACCTGTGGCCTTTGGCCTGCGGTGTGAGGA
ATAATTTCCTCTTCCAAGCTGCTCTCCACCATTAAGAATGGACCCACCAAGGTGTTTGAGCCAGCTCCCATCTCCACAAATCACTACTTTGGGGGACCTGTGGCCTTTGGCCTGCGGTGTGAGGA





 T  V  K  D  I  V  C  K  L  I  C  G  D  A  S  A  N  R  Q  F  G  F  M  I  S  P  T  D  G  I  F  G  V  S  L  D  L  C  V  N  V  E 
CACGGTCAAGGACATTGTCTGTAAGCTCATCTGCGGGGACGCATCCGCCAACCGTCAATTTGGCTTTATGATTAGTCCCACGGATGGCATTTTTGGGGTGTCTCTGGATCTTTGCGTCAATGTGG 
CACGGTCAAGGACATTGTCTGTAAGCTCATCTGCGGGGACGCATCTGCCAACCGTCAATTTGGCTTTATGATTAGTCCCACGGATGGCATTTTTGGGGTGTCTCTGGATCTTTGCGTCAATGTGG 
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 N  L  K  D  V  R  K  R  K  L  G  P  G  H  D  L  V  A  D  S  L  A  A  N  R  G  V  E  S  M  L  Y  V  M  T  D  P  S   E  N  A  G  
 
 
  R  I  G  I  K  D  R  V  P  V  N  I  F  I  N  P  R  H  N  Y  F  Y  Q  V  L  L  Q  Y  K  I  V  G  D  Y  V  R  H  S  G  G  G   
GGCGCATTGGTATTAAAGACCGGGTCCCAGTCAACATCTTCATCAATCCACGGCACAACTACTTCTACCAGGTGCTCCTCCAATACAAAATTGTTGGAGACTACGTCCGCCACAGTGGGGGTGGC 
GGCGCATTGGTATTAAAGACCGGGTCCCAGTCAACATCTTCATCAATCCACGGCACAACTACTTCTACCAGGTGCTCCTCCAATACAAAATTGTTGGAGACTACGTCCGCCACAGTGGGGGTGGT 
  R  I  G  I  K  D  R  V  P  V  N  I  F  I  N  P  R  H  N  Y  F  Y  Q  V  L  L  Q  Y  K  I  V  G  D  Y  V  R  H  S  G  G  G  
 
 
K  P  G  R  D  C  S  P  R  V  N  I  V  T  A  F  F  R  K  R  S  P  L  D  P  A  T  C  T  L  G  S  D  L  L  L  D  A  S  V  E  I    
AAGCCCGGGAGAGACTGCTCACCCCGGGTGAACATTGTGACGGCCTTCTTTCGAAAACGGTCGCCTCTAGACCCGGCGACCTGCACGCTCGGCTCAGACCTGCTTCTGGACGCCTCGGTGGAGAT  
AAGCCCGGGAGAGACTGCTCACCCCGGGTGAACATTGTGACGGCCTTCTTTCGAAAACGGTCGCCTCTAGACCCGGCGACCTGCACGCTCGGCTCAGACCTGCTTCTGGACGCCTCGGTGGAGAT 
K  P  G  R  D  C  S  P  R  V  N  I  V  T  A  F  F  R  K  R  S  P  L  D  P  A  T  C  T  L  G  S  D  L  L  L  D  A  S  V  E  I     
 
 





 P  V  A  V  L  V  T  P  V  V  L  P  D  S  V  I  R  K  T  L  S  T  A  A  G  S  W  K  A  Y  A  D  N  T  F  D  T  A  P  W  V  P   
 
   
  S  G  L  F  A  D  D  E  S  T  P  . 
CCTCTGGTCTCTTTGCCGACGACGAGTCAACTCCATAG 
CCTCTGGTCTCTTTGCCGACGACGAGTCAACTCCATAG 
  S  G  L  F  A  D  D  E  S  T  P  . 
Figure S1 shRNA target sequences within EBV BGLF5. Nucleotide and amino acid alignments are 
depicted for the BGLF5 open reading frames from EBV strains B95.8 and Akata. Numbers indicate 
nucleotide positions and boxes show inter-strain differences. Ten candidate shRNA target sites within 
the BGLF5 coding sequence (in grey) were selected using a prediction algorithm (the Hannon lab 
website: http://cancan.cshl.edu/RNAi_central/main2.cgi) (Paddison et al., 2004). As a control shRNA, 
a target sequence (tatgcagaggatgaaagattaa) within the cellular gene encoding the Fas receptor was used. 
shRNAs were cloned into a lentiviral vector derived from pSicoR (Jacks Lab, MIT), in which the U6 
promoter was altered to allow for sticky cloning of shRNAs in between a BstXI and XhoI site, and in 
which an EF1α promoter was used to drive expression of a cassette encoding a puromycin resistance 
marker, the ribosome skipping peptide T2A, and mCherry. The resulting vectors were used for the 
generation of replication-deficient self-inactivating lentivirus stocks, as described (Lebbink et al., 2011).



























































































































































































































































































































































































































































































































































































































































































































































































































































160723 Proefschrift.indd   58 24.07.2016   21:50:07
Silencing BGLF5 expression in EBV-producing B cells
59
2
Figure S2 Experimental selection of shRNA target sequences that silence BGLF5 protein expression.
AKBM B cells were lentivirally transduced and puromycin selected (>95% mCherry-positive) to stably 
express single BGLF5-targeting shRNAs or a combination of two BGLF5 shRNAs (shRNAs #1 and #9, 
referred to as shBGLF5 in the remainder of the manuscript). Productive EBV infection was induced in 
these cells by treatment with anti-human IgG Abs (+ anti-IgG: 50 μg/mL; Cappel, MP Biochemicals) for 
20 hours (Ressing et al., 2005). Subsequently, cells were fixed, permeabilized, stained for intracellular 
expression of BGLF5 (Ab 311H; ‘intracellular’ staining; (Horst et al., 2012b)), and analyzed by flow 
cytometry. The transferrin receptor (CD71; Ab BD555534) was taken along as a control protein and 
was visualized at the surface of unfixed and non-permeabilized cells (‘surface’ staining). Results of a 
representative experiment with seven out of the ten shRNAs tested are depicted as dot plots (a) and as 
overlay histograms (b). Solid lines, lytically induced AKBM cells gated on expression of the rCD2-GFP 
reporter protein (GFP+); dashed lines, latently EBV-infected cells (GFP-); grey lines, no primary Ab. 
Percentages denote BGLF5 protein expression levels in productively infected AKBM cells with BGLF5-
targeting shRNAs compared to those of control cells without shRNA. Geometric mean fluorescence 
intensities of specifically stained cells (+ primary Ab + secondary APC-conjugated Ab) were divided by 
the background signal in the absence of primary Ab (second step only). The resulting fold inductions in 
lytic cells compared to latent cells were expressed as percentages with the expression in -shRNA control 
cells set at 100%. Over 10 such experiments have been performed with shBGLF5 (#1 + #9) yielding 60-
85% silencing of BGLF5 protein expression. Of note, screening of the shRNAs specific for B95.8 BGLF5 
by transient transfections in 293T cells (data not shown) had little predictive value for their efficacy 
during productive EBV infection in B cells, in our hands.
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Figure S3 Silencing BGLF5 expression in AKBM B cells affects progression through the EBV 
replicative cycle. AKBM B cells stably expressing no shRNAs (-shRNA), a control Fas-targeting shRNA 
(shControl), or a combination of two BGLF5-specific shRNAs (shBGLF5) were treated with anti-human 
IgG for 20 hours. Entry into the EBV replicative cycle was monitored by flow cytometry. Abs used 
for intracellular stainings were directed against the IE transactivator BZLF1 and early (E)-expressed 
BGLF5. Abs used for surface stainings vizualised the late (L) EBV glycoproteins gp350 and gHgL. Dot 
plots depict the, early-expressed, rCD2-GFP lytic cycle reporter (horizontal axis) and the indicated viral 
antigens (vertical axis). Histograms of this experiment are presented in Figure 1c.
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Figure S4 Silencing BGLF5 expression in AKBM B cells affects surface display of cellular antigens.
AKBM B cells (a,b) and AKBM-CD1d cells (c) stably expressing a control shRNA targeting Fas 
(shControl) or a combination of two shRNAs targeting BGLF5 (shBGLF5) were treated with anti-human 
IgG for 20 hours to induce productive EBV infection. Intracellular BGLF5 levels and downregulation of 
various B cell surface markers were analyzed by flow cytometry and depicted as dot plots. Histograms of 
this experiment are presented in Figure 2.
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Chapter 3
The Epstein-Barr Virus glycoprotein gp150 
forms an immune-evasive glycan 
shield at the surface of infected cells




Cell-mediated immunity plays a key role in host control of viral infection. This is 
exemplified by life-threatening reactivations of e.g. herpesviruses in individuals with impaired 
T- cell and/or iNKT cell responses. To allow lifelong persistence and virus production in the 
face of primed immunity, herpesviruses exploit immune evasion strategies. These include a 
reduction in viral antigen expression during latency and a number of escape mechanisms 
that target antigen presentation pathways. Given the plethora of foreign antigens expressed in 
virus-producing cells, herpesviruses are conceivably most vulnerable to elimination by cell-
mediated immunity during the replicative phase of infection.
Here, we show that a prototypic herpesvirus, Epstein-Barr virus (EBV), encodes a 
novel, broadly acting immunoevasin, gp150, that is expressed during the late phase of viral 
replication. In particular, EBV gp150 inhibits antigen presentation by HLA class I, HLA 
class II, and the non-classical, lipid-presenting CD1d molecules. The mechanism of gp150-
mediated T-cell escape does not depend on degradation of the antigen-presenting molecules 
nor does it require gp150’s cytoplasmic tail. Through its abundant glycosylation, gp150 creates 
a shield that impedes surface presentation of antigen. This is an unprecedented immune 
evasion mechanism for herpesviruses. In view of its likely broader target range, gp150 could 
additionally have an impact beyond escape of T cell activation.
Importantly, B cells infected with a gp150-null mutant EBV displayed rescued levels of 
surface antigen presentation by HLA class I, HLA class II, and CD1d, supporting an important 
role for iNKT cells next to classical T cells in fighting EBV infection. At the same time, our 
results indicate that EBV gp150 prolongs the timespan for producing viral offspring at the 
most vulnerable stage of the viral life cycle. 
Author summary 
The human herpesvirus Epstein-Barr virus (EBV) is an important human pathogen 
involved in infectious mononucleosis and several malignant tumors, including lymphomas 
in the immunosuppressed. Upon primary infection, a balance between virus and host is 
established, to which EBV’s capacity to dodge T cell-mediated attack contributes.
Here we identify the late protein EBV gp150 as a novel immunoevasin, frustrating antigen 
presentation by HLA class I, class II, and CD1d molecules. EBV gp150’s many sialoglycans 
create a shield impeding surface detection of presented antigen. Interestingly, exploiting 
glycan shielding as a mechanism to mask surface exposed proteins on infected cells could 
permit EBV to additionally modulate other aspects of host antiviral defense. B cells producing 
wild-type EBV escaped immune recognition more efficiently than those infected with a 
gp150-null virus, pointing towards a role for gp150 in natural infection. Our results reveal a 
novel, broadly active strategy by which a herpesvirus glycoprotein, EBV gp150, blocks antigen 
presentation to T cells through glycan shielding, a new paradigm in herpesvirus immune 
evasion.
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Viruses are exceptionally well equipped to adjust processes in infected host cells to 
support their own replication and survival. Especially in persistent infections, they must 
withstand many layers of anti-viral activities exerted by the host immune system. Cell-
mediated immunity, in particular that mediated by antigen (Ag)-specific T cells, is essential 
for elimination of virus-infected cells, reducing viral replication, and stimulating other 
immune effector functions. 
CD8+ and CD4+ T cells are activated by peptide Ags presented at the cell surface in the 
context of HLA class I and class II (HLA I and II) molecules, respectively. In contrast, invariant 
natural killer T (iNKT) cells, a subset of specialized T cells characterized by a semi-invariant 
T cell receptor (TCR) in combination with NK cell receptors, recognize lipid Ags presented 
by CD1d, a non-classical, non-polymorphic HLA molecule. Upon activation, iNKT cells 
secrete a vast array of polarizing cytokines and they can also directly exert cytotoxicity [1]. 
In addition to the anti-viral cytotoxic and helper T cells, a role for iNKT cells in providing 
protection against viral infection has more recently been appreciated [2].
Herpesviruses are widespread viruses that establish lifelong persistent infections in their 
host, even in the face of virus-specific immunity [3]. Within their large (125-230 kb) DNA 
genomes, herpesviruses encode functions essential for viral replication, yet many additional 
gene products are non-essential for propagation in vitro. Evidence is accumulating that the 
latter are required for establishment of the delicate balance between viral replication and host 
responses in vivo. Among these gene products are immune evasion molecules that frustrate 
the activation of cell-mediated immunity by thwarting Ag presentation. The fact that such 
gene products have been independently acquired and maintained by multiple members of the 
herpesvirus family throughout millions of years of coevolution with their host testifies to the 
importance of T cell activation in the control of herpesvirus infection [4].
In humans, the in vivo contribution of cell-mediated immunity to fighting viral infection 
is probably best demonstrated for Epstein-Barr virus (EBV). This γ-herpesvirus was the first 
human tumor virus discovered [5], being associated with malignancies such as Burkitt’s 
lymphoma and nasopharyngeal carcinoma. EBV is carried by more than 90% of adults 
worldwide, mostly asymptomatically. When primary EBV infection occurs during adolescence 
or adulthood, it presents in more than 50% of cases as self-limiting infectious mononucleosis 
[6], in which viral replication is eventually controlled by the EBV-specific immune response. 
This contrasts to patients with the primary immunodeficiency X-linked lymphoproliferative 
syndrome (XLP) who develop an often fatal mononucleosis when infected by EBV [6]. XLP 
patients have a genetic defect leading to nonfunctional T and NK cells and the absence of 
iNKT cells [7,8]. In addition, EBV can cause life-threatening lymphomas when cell-mediated 
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immunity is insufficient, for instance in transplantation or AIDS patients. Reconstitution of 
EBV-specific T cell immunity by adoptive transfer provides a cure for post-transplantation 
lymphoproliferative disease (PTLD) [9]. PTLD and XLP thus occur in two distinct patient 
groups having in common that they lack sufficient cell-mediated immunity to control EBV 
infection.
Like other herpesviruses, EBV has acquired ingenious strategies to escape elimination 
by cell-mediated immunity of the immunocompetent infected host. Among these, EBV 
downregulates its Ag expression in the latent stage of infection and exploits (viral) immune 
evasion gene products, in particular during its replicative phase, to interfere with immune 
activation [10]. In the early lytic phase, Ag presentation by HLA I is reduced by the concerted 
action of (at least) three EBV proteins: BNLF2a blocks antigenic peptide supply [11], BILF1 
diverts HLA I complexes away from the cell surface [12], and the shutoff protein BGLF5 
acts as an RNase that arrests synthesis of, for instance, HLA I, II, and CD1d [10]. Silencing 
expression of these early EBV proteins in B cells supporting productive infection yielded 
only partially rescued surface display of the Ag-presenting molecules [13,14]. This led to the 
hypothesis that EBV encodes additional immune evasion molecules targeting CD1d, HLA I, 
and HLA II, but their identity has remained elusive. In this study, we took a global look at Ag 
presentation by EBV-producing B cells with a focus on the late phase of infection, when most 
Ags are expressed that could activate T and iNKT cell immunity.
We identified the heavily glycosylated EBV protein gp150, encoded by the BDLF3 gene, 
as a new viral immune evasion molecule. BDLF3 is unique to EBV and the closely related 
Rhesus lymphocryptovirus (LCV). EBV gp150 interferes with immune recognition of HLA 
I, II, and CD1d/ Ag complexes at the cell surface. We provide evidence that gp150 shields the 
recognition of these surface molecules in a glycan-dependent manner. This represents a novel 
immune evasion mechanism in herpesviruses. 
Results
Identification of EBV BDLF3-encoded gp150 as a novel immune evasion 
molecule
To study alterations in surface display of Ag-presenting molecules in the course of 
productive EBV infection of B cells, we employed our previously described EBV+ AKBM 
Burkitt’s lymphoma system [15]. Following anti-human IgG treatment, cells supporting 
replication of EBV are identified in flow cytometry by expression of a lytic cycle reporter, 
rat CD2-GFP, and/or EBV lytic proteins, such as the gHgL complex (Figure 1A, upper row). 
Surface display of the Ag-presenting molecules HLA I, II, and the non-classical HLA molecule 
CD1d is markedly reduced on EBV-producing cells in comparison to latently infected control 
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cells (Figure 1A, left panels), in line with our earlier reports [13,15]. Downregulation of 
surface HLA I complexes commenced around 8-10 hours post induction of the lytic cycle [15], 
preceding that of HLA II and CD1d. Surface levels of the latter were progressively reduced 
on EBV-producing cells with a delay of about 4-6 hours compared to HLA I (S1A Figure and 
[15]). To distinguish the contributions of late versus (immediate-)early EBV proteins to the 
downregulation of surface Ag-presenting molecules, phosphonoacetic acid (PAA) was used 
to arrest viral replication at the early phase. Upon anti-human IgG treatment of AKBM cells 
in the presence of PAA, late EBV protein expression of, for instance, gHgL complexes was 
inhibited, while the early rat CD2GFP reporter was still expressed (Figure 1A, upper row). 
At the surface of PAA-treated cells, CD1d and HLA II levels were mostly retained (Figure 
1A, right panels), pointing towards involvement of late EBV protein(s) in T and iNKT cell 
immune evasion. HLA I downregulation was partly rescued upon PAA treatment indicating 
that, next to the early EBV proteins previously identified, also viral late proteins play a role in 
reducing the surface levels of HLA I (Figure 1A, right panels). In conclusion, one or several 
of the 30 late EBV proteins interfere with surface display of the CD1d, HLA I, and HLA II 
Ag-presenting molecules.
To identify the late EBV gene product(s) responsible for interference with Ag presentation 
observed during productive infection, we took the approach of expressing individual, or 
combinations of, late viral genes in 293T-CD1d cells through plasmid transfection (Figures 
1B and 1C) and/or in MJS-CD1d cells via lentiviral transduction (Figures 1D and S1). 
Screening of late EBV genes in 293T-CD1d cells revealed that most glycoproteins did not 
affect surface levels of CD1d (Figure 1B), HLA I, or the control protein transferrin receptor 
(TfR) to a major extent (S1B Figure). Also expression of EBV gB did not target CD1d, even 
though its homologue in herpes simplex virus type 1 (HSV-1) was found to act in concert with 
the viral kinase US3 to mediate intracellular retention of CD1d molecules observed during 
HSV-1 infection [16]. EBV gp350 caused some downregulation of CD1d, yet the strongest 
effect was observed for gp150, encoded by the BDLF3 gene (Figure 1B). Expression of EBV 
gp150 at levels comparable to those observed in virus-producing B cells (Figure 1C, left 
panels) resulted in marked downregulation of both Ag-presenting molecules tested (upper 
panels), which was not evident in control transfected cells. The dot plots show an apparent 
threshold to gp150 levels resulting in loss of HLA I and CD1d detection. These combined data 
demonstrate that expression of the BDLF3-encoded EBV gp150 reduces the detection of HLA 
I and CD1d at the cell surface. 
Finally, we determined whether the timing of gp150 expression during productive EBV 
infection of human B cells would match the observed downregulation of Ag-presenting 
molecules. To visualize total gp150 protein levels in the course of EBV reactivation in B cells, 
we used an antibody (Ab) directed against its intracellular cytoplasmic tail [19]. Whereas the 
early EBV protein BGLF5 was detectable from 4 hours post induction [15] onwards, no gp150 
protein was found before 8-10 hours into lytic infection with clear detection from 12 hours 
onwards (Figure 1D), leaving enough time to influence HLA I, II, and CD1d expression at 
160723 Proefschrift.indd   71 24.07.2016   21:50:10
Chapter 3
72
Figure 1 gp150 interferes with surface display of Ag-presenting molecules during productive 
EBV infection. A) EBV+ AKBM-CD1d BL cells were treated for 20 hours with anti-human IgG Ab to 
induce viral replication. EBV-producing cells were identified by induced expression of the lytic cycle 
reporter rat CD2-GFP. In the presence of PAA, productive infection is arrested before late protein 
expression. Surface levels of the EBV late complex gHgL and of the Ag-presenting molecules HLA I, 
II, and CD1d were determined by flow cytometry. Histograms depict overlays to allow comparison 
of latently (GFP-) and lytically (GFP+) infected B cells. B) 293T-CD1d cells were transfected with 
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late times. These combined data point to gp150 interfering with surface detection of Ag-
presenting molecules on EBV-producing B cells. Since no function had hitherto been ascribed 
to the EBV glycoprotein gp150, its role in immune evasion of Ag-presenting molecules was 
further investigated.
EBV gp150 causes expression level-dependent interference with different cell 
surface molecules 
To study gp150’s phenotype and mechanism of action in more detail, we expressed the 
EBV protein in MJS-CD1d cells via lentiviral transduction, together with GFP as a marker 
for successful transduction. This approach was validated with known EBV evasion molecules 
[11,17,18] that specifically reduced surface display of HLA I (BNLF2a and BILF1) or HLA 
II (gp42gHgL). At the same time, this experiment showed that the known EBV T cell 
immunoevasins did not interfere with CD1d expression (S2A Figure). 
HLA I and CD1d downregulation from the GFP+ MJS-CD1d-gp150 cells (Figs 2A and S2B) 
indicated that this immune evasive phenotype was not limited to transient overexpression 
in 293T cells (Figure 1). Furthermore, gp150 downregulated surface levels of HLA II and 
also affected other molecules such as CD10, CD54 (Figure 2A), and TfR (S2B Figure). To 
allow easier comparison of gp150’s effects on various cell surface markers, we calculated 
the difference in logarithmically transformed mean fluorescence intensities (ΔlogMFI) for 
each surface marker to serve as a measure for the extent of gp150-mediated downregulation, 
by subtracting the logMFI values for cells that were non- (GFP-) or successfully (GFP+) 
transduced with either gp150-IRES-GFP or a control GFP lentivirus (Figure 2B right panel; 
the left panels show examples of the logMFI for CD1d and CD54). This approach visualized 
that the antigen-presenting molecules HLA I, II and CD1d were more sensitive to EBV gp150 
downregulation than the CD10 and CD54 molecules (Figure 2B).
To investigate if gp150’s effects reflect level-dependency, we transduced MJS-CD1d cells 
with a range of lentivirus amounts to achieve decreasing levels of gp150 expression. This 
resulted in a concomitant reduction in surface downregulation of the cellular proteins tested 
(S2C Figure). When using the higher dose of gp150 lentiviruses in the adherent MJS-CD1d 
cells, we observed that a proportion of cells detached from the culture dish by 3 days after 
partner were transfected together (BMRF2/BDLF2 and gM/gN). EBV protein expression was deduced 
from coexpression of GFP (BMRF2/BDLF2) or on the basis of a C-terminal tag (gM/gN, gB, gp350, 
gp150). Cell surface CD1d was stained prior to an intracellular staining for the tagged EBV proteins. 
Surface levels were compared between non-transfected and transfected cells. C) 293T-CD1d cells were 
transfected with N-terminally HA-tagged gp150 or an empty IRES-GFP vector control. Total gp150 
expression was determined by intracellular staining and was compared to levels in EBV-producing B 
cells. The other histograms depict surface levels of HA (HA-gp150), HLA I, and CD1d staining for 
empty vector-transfected and gp150+GFPhigh 293T-CD1d cells; GFPhigh gating as indicated in the dot 
plots. D) Expression of gp150 was assessed at different time points during productive EBV infection of 
B cells; the early EBV antigen BGLF5 was taken along as a control (time points 6-10 hours and 12-20 
hours are from different experiments).
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Figure 2 EBV gp150 is broadly acting, but displays a degree of specificity for antigen-presenting 
molecules. Flow cytometric analyses of MJS-CD1d cells (adherent fraction) three days post transduction 
with gp150-IRES-GFP lentiviruses. A) Total EBV gp150 levels were determined by intracellular staining 
of permeabilized cells. Surface levels of HLA I, II, CD1d, CD10, and CD54 were determined using Ab 
staining on non-permeabilized cells. B) Surface levels of CD1d and CD54 are depicted as log MFI values 
with 95% confidence intervals, for GFP+ versus GFP- MJS-CD1d cells transduced with gp150 or a GFP 
control. The slopes of the connecting lines reflect the declines in fluorescence (Δlog MFI) and, thus, 
the downregulation of HLA I, II, CD1d, CD10, and CD54 induced by gp150 (for the GFP control, the 
Δlog MFI did not significantly differ from 0). C) Cell surface levels of HLA I, II, CD10, CD34, CD44, 
and CD54 were determined using surface Ab staining. EBV gp150-induced downregulation of these 














































































transduction. This detachment did not only occur as a consequence of lentiviral transduction 
or of gross gp150-induced cytotoxicity (see S3A Figure). Loss of attachment of the gp150high 
GFPhigh cells coincided with a further reduced surface detection of HLA I, II, and CD1d 
(compare Figs 2A and S3B). Very high levels of gp150 even downregulated the cell surface 
molecules CD10 and CD54, which were only marginally affected in the adherent cell fraction 
(Figs 2A and S3B). These results - together with the apparent threshold for gp150-induced 
downregulation (dot plots in Figs 1C and 2A) and the dose-dependent effect of gp150 
expression (S2C Figure) - demonstrate that higher levels of gp150 cause a stronger phenotype.
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Thus, EBV gp150 acts in an expression level-dependent manner to downregulate multiple 
cell surface molecules, to different extents. 
Finally, to obtain an impression of the target range of gp150, we looked for surface 
molecules on MJS-CD1d cells that were not downregulated by the EBV protein. We found 
that virtually equal levels of CD34, CD44, and CD55 were detected on cells that did or did 
not express gp150, even when gated on the GFPhigh fractions of cells (Figure 2C). From these 
data we conclude that various cell surface molecules display differential sensitivity to EBV 
gp150, with CD34, CD44, and CD55 as examples of proteins that are resistant (Figure 2). 
Since gp150 has a strong effect on the Ag-presenting molecules HLA I, II, and CD1d, this 
EBV glycoprotein appears to be a broadly acting immune evasion molecule.
EBV gp150-induced downregulation of Ag-presenting molecules impairs T cell 
activation
Next, we intended to determine the functional consequences of EBV gp150-induced 
immune evasion. Reduced surface HLA I, II, and CD1d levels were detected with Abs that 
are capable of blocking many TCR – HLA/Ag interactions (Figs. 1 and 2), pointing towards 
functional relevance of gp150’s blocking activity. 
To assess if EBV gp150 expression in Ag-presenting cells affects T cells activation, the 
capacity of HLA-A2+DR3+ MJS-A2 cells to induce interferon (IFN)-γ production was 
monitored with well-defined T cell clones with different specificities. Activation of CD8+ T 
cells specific for a human cytomegalovirus (HCMV) pp65 epitope presented in the context 
of HLA-A2 was analysed after stimulation with pp65-expressing MJS-A2 cells that did or did 
not co-express EBV gp150 (Figure 3A). Whereas GFP+ control cells efficiently activated the T 
cells, IFN-γ production was markedly reduced in T cells cultured with gp150-expressing Ag-
presenting cells (Figure 3A). The use of another T cell clone, a CD4+ T cell directed against 
a minor histocompatibility Ag (MiHa) endogenously expressed by MJS cells and presented 
in the context of HLA-DR3, allowed us to study inhibition of T cell responses restricted by 
HLA II. Diminished secretion of IFN-γ by the T-helper cells was observed in response to cells 
expressing gp150 compared to control cells (Figure 3B). These results show that not only 
detection of Ag-presenting molecules by Ab was blocked by gp150, but also T cell activation 
was hampered. 
T cell activation upon target cell engagement involves formation of multiple receptor-
ligand pairs, including TCR – HLA/Ag as well as costimulatory and adhesion molecule 
interactions. In view of the broader target range of EBV gp150, it could diminish multiple 
of these interactions. Here, we zoomed in on the effect of gp150 on MHC/peptide – TCR 
interactions. To this end, human 293T cells were used that express the mouse MHC molecule 
H-2Kb to present the ovalbumin-derived SIINFEKL epitope. Display of SIINFEKL-loaded 
Kb molecules at the cell surface was detected with the 25D1.16 Ab, thereby recapitulating 
TCR binding (Figure 3C). Upon introduction of EBV gp150 into these cells, a significant 
reduction in surface levels of epitope-loaded Kb molecules was observed (Figs. 3C and 3D). 
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This further supports the conclusion that T cell activation is diminished upon gp150-induced 
downregulation of surface Ag-presenting complexes. 
Our combined results indicate that EBV gp150 impairs Ag presentation to both HLA I- 
and II-restricted T cells.
Figure 3 Cellular expression of EBV gp150 limits CD8+ and CD4+ T cell activation by disrupting 
Ag presentation. A,B) MJS-A2-pp65 cells were lentivirally transduced to express gp150 or control GFP 
(vector). Ag-presenting cells expressing low or high levels of gp150 protein were obtained by harvesting 
the floating cells and by FACS-sorting the adherent GFP+ fraction into GFPint and GFPhigh cells. 
Following overnight co-culture of these cells with either A2/pp65-specific CD8+ (A) or DR3/MiHa-
specific CD4+ T cells (B), IFN-γ secretion into the culture supernatants was determined by ELISA. 
Relative T cell recognition is depicted with IFN-γ levels produced in response to stimulation with 
vector control cells set at 100%. C) 293T-Kb cells were transfected with an empty vector control or 
gp150. Cells were pulsed with SIINFEKL or a control peptide (SSIEFARL) and stained with Ab 25D1.16, 
which is specific for Kb/ SIINFEKL complexes. D) Statistical analysis of three independent experiments 
(performed as in C)) using the Student’s t-test (two-tailed).
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EBV gp150 does not induce the degradation of Ag-presenting molecules 
Having demonstrated the functional impact of gp150-induced T cell evasion, we wanted 
to unravel its mechanism of action. In the remainder of these studies, we focused on the 
adherent fraction of gp150-expressing cells, although the effects might even be stronger for 
floating cells. In addition, we made use of constructs that encode gp150 with an N-terminal 
HA-tag (Figure 4A) to allow visualisation of the proportion of this EBV molecule expressed 
at the cell surface. 
First, we investigated if reduced surface display of Ag-presenting molecules was due to 
gp150-induced protein degradation. Degradation of HLA molecules either by proteasomes 
residing in the cytoplasm or by endolysosomal proteases is an evasion strategy exploited 
by a number of herpesviruses, for instance by HCMV and by Kaposi’s sarcoma herpesvirus 
[4]. For EBV gp150-induced effects, however, no difference in surface levels was observed 
for HLA I or CD1d in the presence either of the proteasome inhibitor epoxomicin or of 
chloroquine, an inhibitor of the endolysosomal degradation pathway (Figure 4B). Of note, 
HA-gp150 molecules arrived at the cell surface, irrespective of treatment with these inhibitors. 
Additionally, intracellular staining with the D5 Ab, which detects free CD1d heavy chains 
(not associated with β2m) [20], revealed no reduction in this intracellular population of CD1d 
molecules in the presence of gp150 (Figure 4B, right panels), suggesting that gp150 does not 
induce degradation of newly synthesized CD1d molecules. 
In an alternative approach, we compared gp150’s effect on surface display directly to that 
on total cellular levels of HLA I in the form of an N-terminally eGFP-myc-tagged HLA-A2 
molecule [21], which was introduced into the HLA-A2- cell line MJS (MJS-GFPmycA2 cells). 
In the non-permeabilized cells, GFP fluorescence reflected total levels of this fusion protein 
and, at the same time, surface levels were visualized with Abs directed to the extracellular 
myc-tag or HLA-A2 epitope (BB7.2). High levels of BB7.2 and anti-myc Ab staining as well 
as GFP fluorescence were detected in MJS-GFPmycA2 cells by flow cytometry (Figure 4C, 
non-transduced cells), indicating that the HLA-A2 fusion protein was properly expressed and 
reached the cell surface. Upon subsequent introduction of HA-gp150, we observed a strong 
reduction in surface detection of the chimeric HLA-A2 molecule, whereas total GFP levels 
remained unaffected (Figure 4C, gp150+ cells). These data implicate that in gp150-expressing 
cells total levels of HLA molecules remain unaltered, yet their surface detection is reduced.
In the same experimental set-up, we studied which part(s) of gp150 are essential for 
immune evasion. EBV gp150 is a type I membrane protein with a short cytoplasmic tail 
(Figure 4A). Some herpesvirus proteins, such as EBV BILF1, depend on their cytoplasmic tail 
for interference with Ag presentation [22]. As deletion of 26 amino acids from the C-terminus 
of gp150 (HA-gp150ΔC) did not impair the apparent downregulation of HLA I (endogenous 
and A2-GFP; Figure 4C, lower panels) or of CD1d from the cell surface, we conclude that the 
immune evasion function of gp150 is independent of its cytoplasmic tail.
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Figure 4 Immune evasion by EBV gp150 does not depend on degradation of Ag-presenting molecules 
nor on gp150’s cytoplasmic tail. A) Schematic overview of the gp150 constructs and Abs used. Signal 
peptide, transmembrane domain, and cytoplasmic tail are abbreviated as signal pept, TM, and cytpl tail, 
respectively. B) Three days after lentiviral transduction, MJS-CD1d-gp150 cells were cultured overnight 
in the presence of an inhibitor of proteasomes (15nM epoxomicin) or of endolysosomal proteolysis 
(25µM chloroquine). Subsequently, flow cytometry was used to determine surface levels of HA-tagged 
gp150 (HA-gp150; detected with anti-HA Ab), HLA I, and mature CD1d (Ab #42) complexes on 
non-permeabilized cells and intracellular staining was performed to detect immature CD1d (Ab D5) 
molecules in permeabilized cells. C) MJS-GFPmycA2 cells were transduced with a lentivirus encoding 
HA-gp150 (upper) or HA-gp150ΔC (lower). Cell surface levels of CD1d, HLA I, and HLA-A2 (BB7.2 
and anti-myc tag) and total HLA-A2 (GFP) levels were compared for gp150- and gp150+ cells.
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The combined data obtained upon protease inhibitor treatment and with the GFPmycA2 
fusion protein demonstrate that gp150 does not promote degradation of Ag-presenting 
molecules as an immune evasive strategy.
EBV gp150 prevents detection of Ag-presenting molecules at the cell surface 
Although the Ag-presenting molecules were not degraded in gp150+ cells, they were not 
detectable at the cell surface either. Therefore, we probed the intracellular location of these 
molecules both in gp150-expressing cells and controls. 
As trafficking of newly synthesized glycoproteins from the ER onwards is reflected by the 
progressive maturation of their glycans, we compared the migration of the CD1d and HLA 
I heavy chains in Western blots using lysates of sorted populations of control and gp150-
transduced cells (non-transduced, vector, and gp150low/high, respectively; see S4 Figure). 
Differentially glycosylated maturation forms of these Ag-presenting molecules were identified 
upon glycosidase treatment. Endoglycosidase H (Endo H) removes high-mannose N-linked 
glycans, but not complex glycans that arise after the transport of glycoproteins beyond the cis-
Golgi compartment. Peptide N-glycosidase F (PNGase F) treatment reveals the deglycosylated 
protein backbone, as it removes all N-linked glycans regardless of their maturation. Mature 
CD1d heavy chains carry 4 N-linked glycans, three of which become Endo H-resistant and 
one of which remains Endo H-sensitive [23]. In untreated control cells, two CD1d bands 
were detected that probably reflect different glycosylation stages of CD1d (Figure 5A,+CHO, 
lanes 1 and 4). PNGase F treatment resulted in one dominant band and a very faint band, 
reflecting virtually complete deglycosylation of CD1d heavy chains (-CHO, lanes 3 and 6). 
Endo H treatment revealed the deglycosylated CD1d heavy chain (-CHO, lanes 2 and 5); 
the two additional bands represent Endo H-resistant heavy chains, showing that these CD1d 
molecules have travelled beyond the cis-Golgi.
The HLA I heavy chain carries a single N-linked glycan and only one band is observed 
in untreated control cell lysates (lanes 1 and 3), which is removed upon digestion with both 
PNGase F (lanes 3 and 6) and Endo H (lanes 2 and 5). Only a minor fraction of the HLA I 
molecules apparently becomes Endo H-resistant in these MJS cells.
The pattern of maturation forms of CD1d and HLA I in gp150+ cells was virtually identical 
to that observed in control cells (compare lanes 1-6 to 7-12). If anything, the mature, endo 
H-resistant heavy chains were more prominent in gp150+ cells. From these data, we conclude 
that the ER-to-Golgi trafficking of new HLA I and CD1d molecules is not inhibited in the 
presence of EBV gp150. Furthermore, the presence of the heavily glycosylated viral protein in 
the ER does not appear to act as a “glycosylation sink” preventing the exit of newly synthesized 
Ag-presenting molecules. 
Confocal microscopy allows the visualisation of Ag-presenting molecules within the 
cell as well as their potential colocalization with EBV gp150 [22]. For these experiments, 
we employed non-permeabilized, non-fixed MJS cells expressing a C-terminal GFP fusion 
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Figure 5 Immune evasion by EBV gp150 occurs at the cell surface. A) The glycosylation status of CD1d 
and HLA I molecules in lysates of MJS-CD1d-gp150 and control cells was analysed by Western blot. To 
this end, denatured post-nuclear lysates of different FACS sorted cell populations (see S4 Figure) were 
treated with Endo H or PNGase F to remove N-linked glycans. Endo H digestions served to examine 
protein transport beyond the cis-Golgi compartment; PNGase F digestions revealed the deglycosylated 
protein backbone (minus carbohydrates, -CHO). Actin was a loading control. B) Using the same 
experimental setup as in Figure 4C, MJS-A2-GFP cells were transduced with a lentivirus encoding 
HA-gp150ΔC. Cell surface levels of CD1d, HLA I, and HLA-A2 (BB7.2) and total levels of HLA-A2 
(GFP) were compared for (non-permeabilized) gp150- and gp150+ cells. C) Confocal microscopy of 
non-permeabilized MJS-A2GFP-HA-gp150ΔC cells. Cell surface stains were performed for HLA-A2 
(BB7.2) and gp150ΔC (HA). D) Quantification of surface expression of the indicated molecules based 
on multiple microscopy pictures.
B MJS-A2GFP-HA-gp150∆C cells
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molecule of HLA-A2 (A2GFP), which had been used before in microscopy studies on HLA 
I maturation and trafficking [24]. Flow cytometry analysis confirmed that this HLA-A2 
fusion protein behaved similarly to the other Ag-presenting molecules tested. Introduction 
of gp150 in MJS-A2GFP cells decreased surface detection by HLA I-specific Abs, while GFP 
fluorescence indicated that the total amount of cellular A2GFP molecules was not altered 
by gp150 (Figure 5B). In confocal microscopy, gp150+ MJS-A2-GFP cells were identified 
based on positive staining for the HA-tag attached to gp150 (in red; Figure 5C, lower left 
panel), which confirmed that HA-gp150 molecules arrived at the cell surface. Focusing on 
the non-transduced (HA-) control cells, the GFP signal shows localization of A2GFP fusion 
proteins at the plasma membrane (Figure 5C, upper right panel). Accordingly, the surface-
exposed A2GFP molecules were detectable with Ab BB7.2 (Figure 5C, upper left panel), yet 
only in the non-transduced fraction of cells. This costaining demonstrated the integrity of the 
chimeric HLA-A2 molecule. Using Ab-staining (BB7.2), surface A2GFP molecules were not 
detected on the gp150+ fraction of cells by confocal microscopy (Fig 5C, upper left panel), 
as may have been anticipated from the flow cytometry data described above (Figs 1,2 and 
4). However, GFP fluorescence revealed the presence of the A2GFP molecules also at the 
surface of gp150+ cells, where they colocalized with gp150 (Figure 5C, right panels). The 
arrival of HLA I molecules at the surface of both gp150+ and control cells, indicates that gp150 
does not alter the localization of these Ag-presenting molecules. Quantification of multiple 
microscopy pictures supports that the Ab-based detection of HLA-A2-GFP is significantly 
reduced for gp150-expressing cells compared to control cells and this was not due to reduced 
GFP fluorescence intensity at the cell surface (Figure 5D).
Together, these data indicate that cellular expression of EBV gp150 does not alter the total 
protein levels or localization of HLA molecules, but prevents their Ab-based detection on the 
cell surface. 
EBV gp150 shields surface molecules via sialoglycans on its ectodomain
Since the cytoplasmic tail of gp150 is not essential for immune modulation, it is likely that 
the extracellular domain of gp150 is mechanistically involved. The most peculiar characteristic 
of EBV gp150 is its highly abundant glycosylation, with about half of the amino acid residues 
in the N-terminal domain being potential substrates for N- or O-linked glycosylation (Figure 
4A). Its extensive glycosylation is reflected by the observation that in SDS-PAGE gels, gp150 
migrates as a diffuse band with a molecular weight of 100-150 kDa, whereas the unglycosylated 
protein backbone is around 30 kDa [25,26]. Although the exact glycan composition is not 
known, gp150 carries many negatively-charged sialic acid moieties [25,26]. To directly assess 
whether the glycan decoration on gp150 plays a role in the shielding of surface Ag-presenting 
molecules, flow cytometry analysis was performed on gp150 expressing cells from which 
sialic acids had been depleted using three different approaches.
First, we introduced human CD1d, HLA-A2, and β2m both into Lec2 cells, which are 
Chinese hamster ovary (CHO) cells with a mutated CMP-sialic acid Golgi transporter resulting 
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Figure 6 The mechanism of gp150-induced immune evasion relies on sialoglycans shielding 
surface-exposed Ag-presenting molecules. A-D) CHO and Lec2 cells expressing human β2m, HLA 
I, and CD1d were lentivirally transduced to co-express gp150 or HA-gp150ΔC and GFP (from EF1a 
and PGK promoters, respectively). A) Lectin (WGA-FITC) binding confirmed the glycosylation defect 
in Lec2 cells compared to parental CHO cells. B) Migration height of HA-gp150 was visualised by 
Western blot analysis. C-D) Levels of HLA I and CD1d at the surface of HA-gp150ΔC+GFP+ (gp150+) 
cells were compared to those on control, non-transduced GFP- (gp150-) cells. D) Surface levels of HLA 
I and CD1d are depicted as log MFI values with 95% confidence intervals, for gp150+ versus gp150- 
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in decreased sialylation of glycans [27], and into control CHO cells. Defective sialylation in 
the Lec2 cells was confirmed by decreased binding of wheat germ agglutinin (WGA), a lectin 
that binds sialic acid and N-acetylglucosamine structures (chitobiose) (Figure 6A). The 
effect of defective glycosylation on EBV gp150 expressed in Lec2 cells was visible by Western 
blot: compared to lysates from control CHO cells, gp150 from Lec2 cell lysates migrated at 
a higher apparent MW, likely due to the absence of negatively charged sialic acids (Figure 
6B). Staining for surface HLA I and CD1d on Lec2 cells was somewhat increased compared 
to parental CHO cells, probably reflecting a better accessibility of the Ab binding sites when 
the Ag-presenting molecules are less sialylated (Figure 6C,D). In the CHO cells, expression 
of EBV gp150 decreased HLA I and CD1d staining, which was partly reversed in Lec2 cells. 
This indicates that sialic acids contribute to the phenotype caused by gp150 (Figure 6C,D).
Second, to address the role of sialylation in protein downmodulation in human cells and, 
thereby, also to be able to test a broader panel of surface markers, sialylation was inhibited by 
pretreating MJS-CD1d cells with the fluorinated sialic acid analogue P-3Fax-Neu5Ac [28]. This 
analogue blocks sialyltransferases, enzymes that transfer sialic acids onto glycans. Inhibition 
of sialylation was detected by the reduced binding of the sialic acid-binding lectins SNAI and 
MALII to treated cells (Figure 6E). Strongly enhanced binding of PNA, a lectin that binds 
to glycan structures that become accessible upon desialylation, further confirmed successful 
inhibition of sialyltransferases following cell culture in the presence of this competitive 
inhibitor (Figure 6E). Similar to the sialylation-defective hamster cells, sialyltransferase 
inhibitor treatment of MJS-CD1d cells expressing gp150 was sufficient to cause the viral 
protein to migrate differently in SDS-PAGE (Figure 6F). Cells transduced to express gp150 
that were pre-incubated with P-3Fax-Neu5Ac showed increased surface staining for HLA I, 
II, and CD1d compared to control cells (Figure 6G,H), consistent with a crucial role for 
sialylation in the shielding of Ab binding sites by gp150.
the downregulation induced by gp150. Statistical analysis was performed using two-way ANOVAs and 
significance of the interaction term was assessed, as described in the Material and Methods section. 
One representative experiment of at least six is depicted. * p<0.01. E-L) MJS-CD1d-gp150 cells were 
generated by transduction with a lentivirus encoding both gp150 and GFP (from a CMV promoter 
and an IRES sequence, respectively) and were analysed 3 days post-transduction by Western blot and 
by flow cytometry, as for A-D with the modifications indicated below. E-H) To prevent sialylation, cells 
were treated with the sialic acid transferase inhibitor (500 μM inhibitor) fluorinated P-3Fax-Neu5Ac. 
As a control, cells were treated with the non-fluorinated compound (500 µM, ctrl) for 4 days, starting 1 
day prior to transduction. This control treatment was comparable to when cells were left untreated. E) 
Lectins SNAI, MALII, or PNA were used to detect sialoglycans or desialylated glycans, respectively. G) 
gp150+GFPhigh cells were compared to non-transduced cells. H) One representative experiment of two 
is depicted. * p<0.01. I-L) To remove surface sialylation, intact cells were treated with neuraminidase 
(1U/μl, 60 min, 37°C) prior to cell lysis or lectin/Ab staining. L) One representative experiment of three 
is depicted. * p<0.01.
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Figure 7 Glycan shielding of surface Ag-presenting molecules by gp150 occurs in human B cells and 
is reversed during productive EBV infection when gp150 is deleted. A-B) Latent AkataΔgp150 cells 
were lentivirally transduced to co-express either HA-gp150 or HA-gp150ΔC and GFP (from EF1a and 
PGK promoters, respectively) and were puromycin-selected to obtain pure populations of gp150+ cells. 
B cells already grow in suspension and gp150-positive B cells were maintained in culture for several 
weeks, indicating that gp150 expression was not toxic to the cells. A) Flow cytometry was used to assess 
total (intracellular staining with anti-gp150 Ab on permeabilized cells) and surface (anti-HA Ab on non-
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Third, to selectively cleave off cell surface sialic acids, we treated cells with neuraminidase. 
Enzymatic desialylation occurred in a dose-dependent fashion, as witnessed by progressive 
loss of WGA lectin binding at the cell surface (Figs 6I and S5). Selectivity of this neuraminidase 
treatment for surface-exposed glycans was supported by Western blot analysis, in which 
a proportion of gp150 molecules from treated cells displayed reduced mobility, whereas 
the remaining, likely intracellular, EBV proteins had an apparent MW comparable to that 
in untreated cells (Figure 6J). At the surface of gp150-transduced MJS-CD1d cells, CD1d 
detection improved with increasing doses of neuraminidase (Figs 6K and S5), pointing to 
a direct involvement of sialic acid-modified glycans in interference with CD1d detection. 
Likewise, surface display of the host cell molecules HLA I and HLA II was improved by 
neuraminidase treatment (Figure 6K,L) to the same range as observed for the inhibitor 
treatment (Figure 6G,H), suggesting that primarily sialic acids at the cell surface played a 
role.
In the three settings above (Figure 6), a rescue of 15-25% in the surface detection of 
Ag-presenting molecules was observed in the presence of desialylated versus fully sialylated 
gp150. This rescue being modest is perhaps due to the remaining glycan structures on gp150. 
Still, a highly significant increase in display was detected in all abovementioned experimental 
approaches. Therefore, these combined results provide evidence that surface sialic acid-
carrying N- and O-linked glycans contribute to EBV gp150’s ability to hide certain host 
cell surface molecules, including those involved in Ag presentation, thereby providing a 
mechanistic basis for T and iNKT cell evasion.
EBV gp150 mediates glycan shielding of Ag-presenting molecules on human B 
cells 
Natural EBV infection in vivo targets human B cells and epithelial cells and the main 
reservoir of persistent infection is the memory B cell. To produce new offspring, EBV 
reactivates from latently infected B cells carrying the viral genome. Whereas the 293T and 
MJS cells could reflect epithelial infection, we specifically addressed the question if gp150-
mediated immune evasion was also operative in human B cells.
As relevant human B cells for this study, we chose Akata BL cells in latency, which upon 
induction are capable of supporting productive EBV infection, implying that all host cell factors 
permeabilized cells) levels of EBVgp150. Expression levels of gp150 were compared to lytically induced 
AKBM cells (20 hours anti-human IgG treatment, rat CD2GFP+ cells). B) Akata+gp150 and non-
transduced control cells were left untreated or were treated with neuraminidase (1U/μl, 60 min, 37°C). 
Surface levels of Ag-presenting molecules and cellular CD10 as a control were compared to gp150- non-
transduced cells. One representative experiment of three is depicted. C) Viral reactivation was induced 
in Akata wt and Δgp150 B cells by overnight culture with anti-human IgG and EBV-producing cells 
were identified by staining for the late viral protein gp350. Surface levels of Ag-presenting molecules and 
CD10 on lytic (gp350+) and latent (gp350-) cells are depicted in overlay histograms. One representative 
experiment of at least four is depicted. Statistical analysis was performed for B and C) as described for 
Figure 6. * p<0.05, ** p<0.01. 
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essential for EBV replication are present. These Akata BL cells are the parental equivalent 
of the AKBM cells described above (without the rat CD2GFP lytic cycle reporter). In the 
Akata BL background, Borza and Hutt-Fletcher [19] had previously generated a knockout 
mutant EBV that lacks the BDLF3 open-reading frame coding for gp150 (AkataΔgp150 cells, 
see below). For immune evasion studies, we introduced a constitutively expressed EBV gp150 
gene into these latent AkataΔgp150 B cells, thereby avoiding potential interference by any 
endogenous gp150 expression (referred to as Akata+gp150 cells).
To achieve gp150 expression at levels similar to those occurring in EBV-producing B 
cells, we compared gp150 protein levels in Akata cells transduced with HA-gp150 or HA-
gp150ΔC lentiviruses to those in lytically induced AKBM cells. In flow cytometry using an 
Ab against the gp150 C-terminus, levels of gp150 in productively infected B cells appeared 
to exceed those in cells transduced to express full-length gp150 in isolation (Figure 7A, left 
panel). The C-terminally truncated gp150 lacks the epitope recognized by the anti-gp150 Ab. 
Therefore, we next compared full-length and truncated gp150 expression levels in transduced 
B cells by means of their HA-tag and found that levels of the cytoplasmic tailless gp150 were 
slightly higher than those of the full-length protein (Figure 7A, right panel). Based on this, 
we reasoned that B cells expressing gp150ΔC in isolation likely reflect the levels occurring in 
the context of natural EBV-infection of B cells and we have, therefore, studied these cells in 
more detail.
Detection of HA-tag on non-permeabilized HA-gp150 Akata cells (Figure 7B) also 
shows that the gp150 protein arrives at the surface of B cells as it did on 293T (Figure 1C) 
and MJS (Figs 2A, 4B and C, 5B and C) cells. At the surface of HA-gp150ΔC-transduced 
Akata B cells, detection of HLA I, II, CD1d, and to a lesser extent CD10 was reduced in 
comparison to untransduced control cells (Figure 7B, upper panels). This shows that gp150 
induces an immune evasive phenotype in human B cells as it did in the other cell types 
studied. Neuraminidase treatment of Akata+gp150 cells increased surface binding of Abs 
specific for the three Ag-presenting molecules and CD10 (Figure 7B, lower panels and bar 
graphs), pointing towards direct involvement of sialic acids in gp150-induced shielding of B 
cell surface markers. 
These data combined with those in Figure 6 of gp150 masking surface HLA I, II, and 
CD1d via a glycan shield indicate that the same mechanism of action can operate both in 
epithelium-like cells and in B cells, the natural targets for EBV infection in vivo.
EBV gp150 contributes to evasion of Ag presentation during productive 
infection
To assess the contribution of gp150-mediated interference with Ag presentation in the 
full viral context, we studied the productive phase of infection in B cells that harbour either 
wildtype EBV (Akata wt) or the BDLF3 deletion mutant AkataΔgp150. Based on the use of 
these cells, gp150 was earlier reported not to be essential for EBV replication in vitro, as the 
recombinant virus had no defects in binding, infectivity, assembly, or egress [19]. In line with 
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this, we found no apparent differences in progression through the replicative cycle between 
lytically induced Akata wt and Δgp150 cells: both expressed the EBV immediate-early BZLF1, 
early BGLF5, and late gp350 proteins, but only Akata wt cells produced gp150, as did control 
induced AKBM cells (S6A Figure). 
To determine surface levels of the host cell molecules HLA I, II, CD1d, and CD10 by flow 
cytometry, both types of induced Akata cells were counter-stained for gp350, to identify the 
EBV-producing B cells. As observed for AKBM cells (Figure 1A), induction of the lytic cycle 
caused a downregulation of surface display of the Ag-presenting molecules HLA I, II, and 
CD1d in (gp350+) Akata wt cells, when compared to the latently infected cells (Figure 7C). In 
the absence of gp150, however, HLA I, II, and CD1d surface levels were significantly higher 
during productive infection, as visible when comparing gp350+ AkataΔgp150 to Akata wt 
cells (Figure 7C, compare tinted with non-filled grey histograms). Likewise, downregulation 
of the B cell surface markers CD10 and CD86 was less pronounced in lytic cells devoid of 
gp150 (Figure 7C and S6B Figure). These results indicate that gp150 contributes to the 
apparent downregulation of Ag-presenting molecules and – to a lesser extent- other surface 
markers in a model for natural EBV infection of human B cells.
Our combined data support a model in which surface molecules, including Ag-presenting 
molecules, are shielded from recognition by the extensive glycosylation of gp150, pointing 
towards a contribution of this novel EBV evasion molecule to interference with cell-mediated 
immunity against EBV (Figure 8). 
CD8+ T cell
TCR
CD4+ T cell iNKT cell
HLA class I HLA class II CD1d
EBV gp150
Figure 8 Schematic model of a glycan shielding mechanism for T and iNKT cell immune evasion 
mediated by EBV gp150.




Cell-mediated immunity by HLA I and II-restricted cytotoxic and helper T cells as well as 
by CD1d-restricted iNKT cells is critical in the defence against many viruses [1]. Especially 
persistent viruses, such as herpesviruses, have acquired strategies to permit their escape from 
elimination by these immune cells. In this study, we report that EBV infection, even in its 
late productive phase, substantially reduced display of CD1d, HLA I, and HLA II complexes 
at the surface of human B cells. Reduced detection of these antigen-presenting molecules 
was observed with Abs that can block TCR binding. This effect is functionally important, 
because HLA downregulation results in reduced T cell activation. For transmission to other 
target cells or hosts, new viral particles need to be produced through EBV reactivation from 
latently infected B cells, the primary natural targets for EBV infection. At the late stage of 
viral replication, up to 100 EBV genes are expressed, thus resulting in a wide array of Ags 
presented at the surface of infected cells to T cells. EBV-specific T cells are generated upon 
primary infection [6]. Therefore, immune escape strategies targeting Ag-presenting molecules 
including HLA I, II, and CD1d might allow EBV-producing B cells to effectively evade T and 
iNKT cell surveillance in vivo, prolonging the timespan for the production of viral offspring. 
Indeed, patients with reduced functional T and iNKT cell numbers are known to have life-
threatening complications upon encountering EBV [6].
Our finding that gp150 acts as a novel EBV-encoded immune evasion molecule causing 
reduced detection of surface CD1d, HLA I, and HLA II complexes is intriguing as it is not 
only the first function ascribed to this viral glycoprotein, it also reveals a novel mechanism 
employed by herpesviruses to dodge immune recognition. In contrast to most herpesvirus 
structural glycoproteins, EBV gp150 was found to be non-essential for viral entry, assembly, 
or egress [19] and the function of this late viral protein has remained enigmatic until now. 
Here, we provide evidence in support of a model in which gp150 is able to shield surface 
HLA molecules, through its abundantly sialylated glycans, in order to escape T cell activation 
(Figure 8). Cellular expression of gp150 in isolation was sufficient to reduce detection of 
multiple cellular surface molecules, for example interfering with binding of an Ab detecting 
the H-2 Kb/SIINFEKL antigenic complex. Moreover, we show that B cells producing a gp150-
deleted mutant virus display more Ag-presenting molecules as compared to wild-type EBV, 
indicating that gp150 contributes to immune evasion in the full viral context. EBV gp150 
did not appear to promote degradation, retention, internalization, or altered glycosylation of 
HLA molecules. Rather, HLA molecules arrived at the cell surface, yet failed to be recognized, 
a defect which was restored in part by preventing sialylation. 
To date, only the Ebola virus glycoprotein (EBOV GP) has been described to shield host cell 
surface molecules, namely HLA I and β1 integrin molecules, via its extensively glycosylated 
mucin-like domain [29]. This suggests that similar mechanisms have evolved independently 
in different viruses belonging to different families. Both EBOV GP’s mucin-like domain and 
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the ectodomain of EBV gp150 contain around 10 potential N-glycosylation and more than 70 
potential O-glycosylation sites. The mucin-like domain of EBOV GP consists of mainly core 
2 O-linked glycans [30]. The ‘core’ type of O-linked glycans on gp150 is, at present, unknown, 
but could also consist of core 2 glycans in view of its resistance to O-glycanase that removes 
core 1 and core 3 O-glycans [25]. Thus, it remains to be investigated whether the glycans of 
EBV gp150 and EBOV GP share key features or whether they evolved similarly to shield host 
surface molecules. Detailed characterization of the glycans of EBOV GP and EBV gp150 is 
likely required to fully comprehend the molecular necessities of viral glycoproteins to shield 
cell surface molecules and thereby facilitate further identification of such proteins. 
It would be interesting to know whether other (herpes)viruses have incorporated similar 
strategies to escape from immune recognition, as this would provide further insight into the 
significance and requirements of this mechanism. The BDLF3 ORF is also present in Rhesus 
LCV. Rhesus LCV BDLF3 protein displays only 46% amino acid homology to EBV gp150, 
but shares the feature of the serine/threonine-rich ectodomain indicating that it too might be 
heavily glycosylated. In view of the low sequence homology between the BDLF3 proteins of 
these closely related γ-herpesviruses, glycosylation potential rather than amino acid sequence 
might provide immune evasive properties. It will be interesting to analyse the immune evasive 
properties of MHV-68 ORF28, the positional homologue of EBV BDLF3. MHV-68 ORF28 
also appears to be non-essential for viral replication in vitro and in vivo [31]. Compared 
to gp150, the ectodomain of ORF28 is reduced in size, yet highly glycosylated and could 
therefore provide insights into the structural requirements for glycan shielding. It is tempting 
to speculate that other proteins or different (herpes)viruses present functional homologues of 
EBV gp150 and EBOV GP that do not share amino acid similarity, yet retain the feature of a 
heavily glycosylated extracellular domain. Intriguingly, we observed that the major envelope 
glycoprotein of EBV, gp350, also interfered with surface detection of CD1d (Figure 1B) and 
TfR (S2B Figure). 
Interestingly, not only do viruses appear to exploit a glycan shielding strategy, but also 
cancer cells show aberrant expression of sialic acid-modified glycans that are thought to play 
a role in tumor immune evasion [32], which may in part be due to the reported sialylation-
dependent inhibition of NK cells by masking ligands of activating NK cell receptors [33]. 
Relevance of sialylation-dependent immune interference by tumors is demonstrated by 
the fact that hypersialylation of tumor cells is associated with poor prognosis for patients 
[34]. Interestingly, when sialic acid decoration on tumor cells was inhibited with the same 
compound as we have used (Figure 6E-H), it resulted in reduced metastases in an in vivo 
mouse model [35].
 
Our results show a direct effect of gp150 on the presentation of antigenic peptides to T 
cells. In addition to Ag-presenting molecules, EBV gp150 could also affect the function of 
various other cell surface molecules. Potential targets include receptor-ligand pairs involved 
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in formation of the immunological synapse. An immunological synapse is formed at the 
interface of the T cell and the virus-infected cell through interactions of several receptor-
ligand pairs [36]. In the centre of this synapse, HLA/Ag complexes reside, engaged by specific 
TCRs. Costimulatory molecules locate in proximity of the Ag-presenting molecules, and 
are surrounded by a ring of adhesion molecules. We have observed that cellular expression 
of gp150 also appears to mask the adhesion molecule CD54/ICAM1 (Figure 2A), the 
costimulatory molecule CD86 (S6B Figure), as well as TfR (S2B Figure), and CD10 (Figure 
2A). Of note, shielding of these molecules appears to require higher levels of gp150 expression 
than was sufficient for shielding of these Ag-presenting molecules (S2C Figure, and Figure 
2 & S3B Figure). In contrast, CD33, CD44, and CD55 were not sensitive to downregulation 
by gp150, even when expressed at high levels (Figure 2C), showing that gp150 does not mask 
all cell surface molecules. The broad target range of gp150 suggests that other receptor-ligand 
interactions, such as receptor-induced apoptosis by FasL-Fas interactions, or other (non)-
immune cell-cell contacts could be disturbed by gp150. Intriguingly, cell adherence and cell-
cell contact were lost in floating MJS cells expressing high levels of gp150 (S3A Figure), as 
was also observed for EBOV GP [29], suggesting that gp150 can uncouple, at least partially, 
actively EBV-producing B cells from environmental cues. One could speculate that the EBV-
producing B cell could thus become mobile by interfering with signals that restrain B cells at 
a particular site in the body, allowing them to localize for instance to tonsils, facilitating viral 
shedding in saliva. 
Besides the host cell molecules described above, expression of the heavily glycosylated 
gp150 protein could also shield the recognition of viral membrane-expressed proteins 
that could otherwise by recognized by EBV-specific Abs. EBV exploits the endogenous 
glycosylation machinery of the infected cell to form glycan structures, which are, by nature, 
not foreign to the immune system. When these “self-structures” are placed on a - foreign - 
viral protein, it could be shielded from recognition by Ab-producing B cells. In line with this, 
no good Abs against the extracellular part of gp150 are available. Furthermore, when the 
glycosylation is abundant as is the case for gp150, it could also lead to the masking of other 
viral proteins that are expressed at the cell/ virus surface. So far, we have not observed strongly 
reduced detection of gHgL, gp350, or gB on wild-type versus gp150-null EBV-producing B 
cells, and it would not be advantageous to viral entry if these receptors were fully shielded. Yet, 
both for EBOV GP [37] as well as for some herpesviruses, glycosylation-mediated evasion 
of Ab neutralization has been reported, for example for the proteins gN of HCMV and the 
bovine herpesvirus 4 (BoHV-4) gp180, which is the functional homologue of EBV gp350. 
Truncated HCMV gN lacking part of its glycosylated ectodomain as well as absence of BoHV-
4 gp180 renders viral particles more sensitive to Ab neutralization [38,39]. In addition, cells 
infected with BoHV-4 lacking gp180 show increased Ab binding to viral proteins, pointing to 
the role of glycans in shielding viral proteins from immune recognition. 
Persistent viruses dedicate a large part of their genome to modulating host antiviral 
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activities. Among these, herpesviruses have acquired a very diverse set of strategies to 
downregulate Ag-presenting molecules and, thereby, T cell activation in a temporal 
fashion. Viral strategies include blocking protein synthesis, depletion of antigenic peptides, 
dislocalization to the cytoplasm followed by proteasomal degradation, re-routing and/or 
accelerated internalization, or steric hindrance of TCR binding [4]. In this study, we report 
on a novel EBV strategy: by expressing the heavily glycosylated, late EBV protein gp150, 
Ag-presenting molecules on productively infected cells are shielded from interaction with 
TCRs, thereby allowing replication and production of viral particles that would otherwise by 
interrupted by a cellular immune response. This mechanism is novel in herpesvirus biology, 
and further supports the notion that herpesviruses use very diverse ways to achieve escape 
not only from T cells, but also from iNKT cell immunity. Evasion from CD1d-mediated Ag 
presentation supports an essential role for iNKT cells in anti-EBV immunity, which was 
already inferred from the devastating effects of EBV infection in XLP patients. Combining 
multiple strategies allows them to escape various layers of immune elimination during various 
stages of infection. This underscores the notion that EBV, as other herpesviruses, is extremely 
well adapted to persist in the face of functional immunity. 
Material and Methods
Ethics Statement
For T-helper cell assays, peripheral blood samples from patients and healthy individuals 
were obtained after approval by the LUMC institutional review board and written informed 
consent according to the Declaration of Helsinki.
Cells 
All media were supplemented with 10% FCS, 100 U/ml penicillin, and 100μg/ml 
streptomycin. The EBV+ BL cell lines AKBM [15], Akata wt, and Akata Δgp150 [19] were 
cultured in supplemented RPMI medium. Productive EBV infection and inhibition of late 
protein expression by phosphonoacetic acid were performed as previously described [22]. 
Human embryonic kidney (HEK) 293T, HEK 293H-2Kb, and the human melanoma cell 
line MelJuSo (MJS, HLA typing A*01, B*08, DR3) and MJS-derived cell lines were cultured 
in supplemented DMEM medium. MJS-A2-GFP cells were obtained from Dr. E Reits [24]. 
Chinese hamster ovary (CHO) and Lec2 cells [40] were cultured in supplemented MEM-α 
medium. 
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Antibodies and streptavidin conjugates
Primary antibodies used in this study were mouse α-CD1d (CD1d42, CD1d51, CD1d55, 
D5; a kind gift by S. Porcelli, NY, USA), mouse α-CD1d-PE (clone CD1d42, BD Pharmingen), 
mouse α-HLA-ABC (W6/32), mouse α-HLA-ABC-PE (W6/32, Serotec), mouse α-HLA-A2 
(BB7.2), mouse α-HLA-DR (L243), mouse α-HLA-DR-PE (L243, BD Biosciences), mouse 
α-TfR (CD71, clone M-A721, BD Pharmingen), mouse α-CD10-PE (clone Hl10a, BD 
Pharmingen), mouse α-CD34-PE (clone 8G12, BD Biosciences), rat α-CD44-PE (clone 
IM7, BD Pharmingen), mouse α-CD54-PE (ICAM-1, clone HA58, BD Pharmingen), mouse 
α-CD55-PE (clone IA10, BD Pharmingen), mouse α-BZLF1 (clone BZ.1, kindly provided 
by Dr. M. Rowe, Birmingham, UK), mouse α-BGLF5 (clone 311H, kindly provided by Dr. 
J. Chen, Taipei, Taiwan), mouse α-gHgL (E1D1), rabbit α-gp150 (V8), biotinylated mouse 
α-gp350 (72A1), rat α-HA-tag (3F10, Roche), rat α-EBNA1-tag (1H4, kindly provided by Dr. 
J. Mautner), mouse α-myc-tag (9E10). Secondary antibodies used in flow cytometry were 
goat α-mouse-PE (eBioscience), donkey α-rat-APC or –FITC (Jackson Immunoresearch), 
and goat α-rabbit-PE (Jackson Immunoresearch). To detect biotinylated antibodies or lectins, 
streptavidin-BV421 or streptavidin-PE (both BioLegend) were used, respectively. For Western 
blot analysis, an HRP-conjugated goat α-rabbit (Southern Biotech) antibody was used. For 
confocal microscopy, goat α-mouse-Atto647 (Sigma) and goat α-rat-Alexa594 (Invitrogen) 
antibodies were used.
Plasmids
Plasmids encoding His- and EBNA1 (aa435-445, recognized by 1H4 Ab)-tagged EBV 
glycoproteins (gM, gN, gp78, gp350, and gp150) were a generous gift from Dr J. Mautner and 
were described previously [41]. 
In this study, different lentiviral vectors were used to create third generation replication-
deficient lentiviruses. Expression of the human CD1d or HLA-A2 gene fused to a zeocin 
resistance gene by means of the ribosomal skipping peptide P2A was driven by an EF1a 
promoter [22]. C-terminally Flag (DYKDDDDK)-tagged BMRF2, N-terminally Flag-tagged 
BDLF2, and BDLF3 EBV genes were PCR-amplified from EBV B95.8 genome. PCR products 
were cloned into the lentiviral vector pLV-CMV-IRES-GFP. We generated an in-frame 
N-terminal HA-tagged (YPYDVPDYA) gp150 full-length variant and a mutant lacking the 
last 26 aa (209-234) of the cytoplasmic tail (HA-gp150ΔC). The PCR products were cloned 
behind an EF1a promoter into the dual promotor lentiviral vector EF1a-/pGK-GFP-T2A-
puro, described elsewhere [21], and into the lentiviral vectors pLV-CMV-IRES-GFP and pLV-
CMV-IRES-puroR. The lentiviral vector encoding eGFP-myc-HLA-A2 has been described 
elsewhere [21]. 
Codon-optimized human β2m was encoded in a variant of the abovementioned dual 
promoter lentiviral vector containing a zeocin resistance gene and mAmetrine fluorescence 
gene fused by means of the ribosomal skipping peptide T2A. 
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Replication-deficient retroviruses and retroviral transductions
Third generation replication-deficient SIN recombinant lentiviruses were generated 
by PEI transfection of 293T cells with pCMV-VSVG, pMDLg-RRE, and pRSV-REV and a 
lentiviral vector coding for the genes of interest. Target cells were transduced with lentivirus 
supernatant in the presence of 4 μg/ml polybrene by spin infection (1000xg, 2h, 33°C). AKBM 
and Akata B cells, MJS, and 293T cells were transduced with human CD1d and selected using 
zeocin (200-500 μg/ml). 
MJS cells were retrovirally transduced in the presence of 12μg/ml retronectin with the 
pLZRS-HCMV pp65-IRES-trNGFR vector to generate MJS-pp65 cells. Cells were FACS 
sorted for surface trNGFR expression. MJS or MJS-pp65 cells were transduced with eGFP-
myc-tagged HLA-A2 or HLA-A2 to generate MJS-GFPmycA2 and MJS-A2/pp65 cells, 
respectively.
To generate CHO-A2-CD1d and Lec2-A2-CD1d cells, CHO and Lec2 cells were first 
transduced with human codon-optimized β2m and selected with zeocin (500 μg/ml). 
Subsequently, cells were transduced to express HLA-A2 and human CD1d. HLA-A2+CD1d+ 
cells were FACS sorted using a FACS Aria III (BD). 
To study gp150 in MJS cell lines, gp150 or the variants HA-gp150 or HA-gp150ΔC were 
expressed from a lentiviral pCMV-IRES-GFP or pCMV-IRES-puroR vector. The empty pCMV-
IRES-GFP vector served as a control. MJS cell lines were transduced and analysed 3 to 5 days 
post transduction. Floating MJS cells were harvested and analysed 3-4 days post transduction. 
CHO and AkataΔgp150 cell lines were transduced, as indicated, with gp150, HA-gp150, or 
HA-gp150ΔC, which were expressed from the dual promotor lentiviral vector pEF1a-/pGK-
GFP-T2A-puroR. CHO cells were analysed up to 10 days post transduction. AkataΔgp150 
cells were selected using puromycin and analysed up to 4 weeks post transduction.
Transient transfection
For transient transfections, 293T cells were seeded in 12w plates one day prior to 
transfection. Cells were transfected with 1 μg plasmid DNA coding for EBV proteins using 
Lipofectamine2000 (Invitrogen) according to the manufacturer’s protocol. Cells were analysed 
by flow cytometry two days post transfection. 
Flow cytometry, cell sorting, and cell viability assay
To assess cell surface levels of indicated molecules, cells were stained with antibodies 
of indicated specificity in PBS supplemented with 0,5% BSA and 0,02% sodium azide. For 
intracellular stains (ICS), cells were fixed in 2% PFA and permeabilized in ICS-FACS buffer 
(PBS, 2% FCS, 0,5% saponine). Subsequent staining and washing steps were performed in 
ICS-FACS buffer. All stainings were performed at 4°C. Cells were fixed prior to analysis in 
FACS buffer containing 2% PFA. Samples were subjected to flow cytometry using a LSR II 
or Canto II (BD Biosciences). Flow cytometry data were analysed using FlowJo (Tree star) 




For cell sorting, cells were stained with indicated antibodies in PBS supplemented with 
0,5% BSA for 1 hour on ice. Cells were washed in supplemented PBS and subjected to sorting 
by flow cytometry using an Aria III (BD Biosciences). Sorted cells were washed and prepared 
for use in T cell assays or Western blot analysis. 
To determine cell viability by flow cytometry, unfixed cells were incubated with 7-AAD 
for 5 min at RT and subjected to flow cytometry. Live cells excluded the dye, whereas dead 
cells become 7-AAD positive. 
Functional assays
MJS-HLA-A2/pp65 cells were transduced with two different doses of lentivirus for gp150 
expression or an empty vector control. Three days post-transduction, floating and adherent 
cells were harvested and adherent cells were FACS sorted for GFPhigh and GFPint cells. In 
96w U-bottom plates, triplicates of 5000 cells were incubated with equal numbers of A2/pp65-
specific CD8+ T cells or DR3/MiHa-specific CD4+ T cells overnight. Culture supernatants were 
collected to determine IFN-γ secretion by ELISA (Affymetrix) according to manufacturer’s 
protocol. Standard deviation was determined over biological triplicates. 
For MHC/peptide-TCR interactions, 293Kb cells were transfected with gp150 or an empty 
vector control. One day post-transfection, cells were peptide-pulsed for 2h with either 1 μM 
ovalbumin-derived SIINFEKL peptide or the control peptide SSIEFARL. Cells were harvested 
and cell surface-stained using the 25D1.16 Ab, which is specific for Kb/SIINFEKL complexes. 
Samples were subjected to flow cytometry. Mean fluorescence intensity was determined 
for triplicates in each experiment. Statistical analysis was performed on three independent 
experiments using Student’s t-test (two-tailed).
Confocal microscopy
The localization of C-terminally GFP-tagged HLA-A2 expressed in MJS cells was 
determined by confocal microscopy. HA-gp150ΔC-transduced cells were harvested 
and cell surface stained for HLA-A2 (BB7.2) and gp150 (anti-HA) as performed for flow 
cytometry. Cell suspension was applied on a glass coverslip. Cells were analysed using a 
Leica TCS SP5 confocal microscope. Microscopy images were adjusted in levels in a linear 
fashion. For quantification, around 30 single cells were analysed using a composite colour 
image of the three different channels. Images of single-stained cells (BB7.2 or anti-HA) were 
used to define the amount of fluorescence leakage into the regarding other channel. Prior 
to image quantification of double-stained cells, measured pixel intensity was corrected for 
the determined leakage. Pixel intensity was determined for the outer 8 pixels of the selected 
objects. Statistical analysis was performed using an unpaired t-test (two-tailed).
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Post-nuclear cell lysates were prepared using NP40 lysis buffer (50 mM Tris HCl (pH 7.5), 
150 mM NaCl, 0.5% Igepal-CA630) containing protease inhibitors (Roche, Protease cocktail), 
as described previously [15]. For treatment with glycosidases, lysates were denatured at 95°C 
for 5 min prior to incubation with Endo H or PNGase F (both NEB) at 37°C for 1h. Proteins 
were separated by SDS-PAGE and blotted onto PVDF membranes. Membranes were blocked 
using 5% milk in PBS. The indicated primary antibodies were used to probe membranes 
overnight at 4°C in 1% milk in PBST (PBS, 0,1% Tween 20). Incubation with secondary 
antibody was performed for 2 hours at RT. Antibody-reactive bands were detected by ECL 
and signal was captured by film.
Protease inhibitor treatment
Cells were cultured overnight in the presence of 25 µM chloroquine (provided by Dr. 
A de Wilde) or 15 nM epoxomicin (provided by Dr. H Overkleeft) to inhibit proteolysis by 
endolysosomal proteases or cytoplasmic proteasomes, respecitively.
Inhibition of sialylation
Optimal concentration of the fluorinated P-3Fax-Neu5Ac inhibitor was determined 
and effectiveness of treatment was monitored by binding of the biotinylated lectins SNAI 
(Sambucus nigra), MALII (Maackia amurensis), and PNA (Ara chishypogaea, all purchased 
by EY Laboratories). Lectin stains were performed in carbo-free blocking solution (Vector 
Laboratories) as described previously [42]. Cells were treated with 500 μM fluorinated 
P-3Fax-Neu5Ac inhibitor or with the control compound P-Neu5Ac 1 day prior to lentiviral 
transduction. Cells were cultured in presence of inhibitor for additional four days and 
analysed by flow cytometry. 
Neuraminidase treatment
Neuraminidase treatment was performed in FACS buffer containing 1U/μl neuraminidase 
(NEB), at 37°C for 45-60 min. Subsequently, cells were washed and stained in cold FACS 
buffer. Neuraminidase treatment was monitored by loss of binding of the biotinylated or FITC-
conjugated lectin WGA (Triticum vulgaris). Stained cells were subjected to flow cytometry. 
Statistical analysis
Fluorescence intensity signals of each analysed cell were logarithmically transformed 
and 1000 cells per parameter (Figure 6 and 7B, gp150-/gp150+, Figure 7C, latent/lytic) were 
randomly picked. For each parameter, two “treatments” were compared (Figure 6D, CHO vs 
Lec2, 6H, control vs inhibitor, 6L and 7B, untreated vs neuraminidase, 7C, WT vs Δgp150). 
Whether treatment differences vary over gp150 expression has been explored by means of 
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A) EBV+ AKBM-CD1d BL cells were treated for 
indicated periods with anti-human IgG Ab to induce 
viral replication. EBV-producing cells were identified 
by induced expression of the lytic cycle reporter rat 
CD2-GFP. Surface levels of the Ag-presenting molecules HLA I, II, and CD1d were determined by flow 
cytometry. Histograms depict overlays to allow comparison of latently (rat CD2-GFP-) and lytically (rat 
CD2-GFP+) infected B cells. B) 293T-CD1d cells were transfected with expression vectors encoding 
late EBV glycoproteins. Glycoproteins known to require a viral interaction partner were transfected 
together (BMRF2/BDLF2 and gM/gN). EBV protein expression was deduced from coexpression of GFP 
(BMRF2/BDLF2) or on the basis of a C-terminal tag (gM/gN, gB, gp350, gp150). Cell surface HLA I 
or TfR was stained prior to an intracellular staining for the tagged EBV proteins. Surface levels were 
compared between non-transfected and transfected cells.
evaluating a statistical interaction between these factors in an analysis of variance model. 
Statistical analysis was performed using two-way ANOVAs and significance of the interaction 
terms (ctrl/gp150*untreated/treated) was assessed using SPSS (version 20.0.0.2). p-values < 
0.05 were considered statistically significant. 
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MJS-CD1d cells were transduced with 
lentiviruses encoding (A) the indicated EBV 
immune evasion gene products (BNLF2a, 
BILF1, gp42+gH+gL) or only IRES-GFP 
(vector) and (B,C) gp150-IRES-GFP. 
Surface levels of HLA I, HLA II, and CD1d 
(A) as well as TfR (B) or CD10 and CD54 
(C) were determined by flow cytometry 
on non-permeabilized cells. Histograms 
depict a comparison of GFP- control 
(non-transduced) and GFP+ EBV protein-
expressing (transduced) cells. C) A dose 
range of pCMV-gp150-IRES-GFP lentivirus 
was used for transduction. Total gp150 
expression levels in permeabilized cells were 
determined by intracellular staining with an 
Ab specific for gp150’s cytoplasmic tail.




A) The adherent MJS cell line was transduced either with the gp150-IRES-GFP lentivirus or an IRES-
GFP control. Three days post transduction, both the floating and adherent fractions of transduced cells 
were subjected to flow cytometry. The proportion of floating cells was larger for gp150-transduced cells 
than for control cells and, additionally, the gp150+ floating cells were enriched for gp150 expression 
(reflected by higher GFP levels compared to the adherent cells). These observations suggested that high 
levels of gp150 expression induce loss of cell adherence. To exclude that the higher gp150 levels were 
cytotoxic, the viability of floating and adherent fractions of transduced cells from the same culture dish 
was determined by incubation with the live exclusion dye 7-aminoactinomycin D (7AAD) followed by 
flow cytometry analysis. As controls served the adherent fraction of untreated MJS-CD1d cells (control) 
and the adherent and floating fractions of cells treated with toxic concentrations of the proteasome 
inhibitor epoxomicin (epox; 200 nM) for 24h. In the FSCxSSC dot plots, the live gates are depicted for 
the cell populations analyzed for GFP levels (transduction efficiencies) and 7AAD exclusion (viability). 
An additional gate on population 1 in the floating epoxomicin-treated cells shows that the 7AAD was 
effective in penetrating dead cells. 
Among both the adherent and the floating cells transduced with either control or gp150 lentivirus, only 
very few 7AAD+ (dead) cells were present, indicating that gp150 does not cause gross cytotoxicity. 
B) The floating cell fraction from the experiment depicted in Figure 2A was analyzed by flow cytometry, 
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Three days after lentiviral transduction, four different 
populations were FACS sorted from MJS-CD1d cells 
that were transduced with gp150-IRES-GFP or control 
IRES-GFP viruses: GFP- (1, non-transduced) and GFP+ 
(2, vector) cells were isolated from control cells and the 
GFP+ cells from the gp150-transduction were further 
separated into gp150low (3, HLA Ihigh) cells and 
gp150high (4, HLA Ilow) cells on the basis of the extent 
of HLA I downregulation. The sorted cell populations 
were lysed for analysis by immunoblot (see Figure 4B). 
S5 Figure
Intact MJS-CD1d-gp150 and control-IRES-GFP cells were treated with decreasing amounts of 
neuraminidase (5-0,008U/ml) for 60 min at 37°C and compared to untreated cells. Effectiveness of 
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A) EBV+ AKBM, Akata wt and Δgp150 BL cells were treated with anti-human IgG to induce the viral 
lytic cycle. Twenty hours later, expression of several EBV proteins - BZLF1 (immediate-early), BGLF5 
(early), and gp150 and surface gp350 (both late) - was determined using flow cytometry. B) Akata wt 
and Δgp150 BL cells were treated with anti-human IgG for 20 hours. Surface expression of the cellular 






























Lytically induced Akata-CD1d B cells harbouring EBV wt or ∆gp150
CD1dHLA I CD86
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Chapter 4
Epstein-Barr virus BILF1 evolved to 
downregulate cell surface display of a 
wide range of HLA class I molecules 
through their cytoplasmic tail




Co-evolution of herpesviruses and their hosts has driven the development of both host 
antiviral mechanisms to detect and eliminate infected cells, and viral ploys to escape immune 
surveillance. Among the immune evasion strategies employed by the lymphocryptovirus (g1-
herpesvirus) EBV is the downregulation of surface HLA class I expression by the virally-
encoded G-protein coupled receptor BILF1, thereby impeding presentation of viral antigens 
and cytotoxic T cell recognition of the infected cell. Here, we show EBV BILF1 to be expressed 
early in the viral lytic cycle. BILF1 targets a broad range of HLA class I molecules, including 
multiple HLA-A and -B types, and HLA-E. In contrast, HLA-C was only marginally affected. 
We advance the mechanistic understanding of the process by showing the cytoplasmic 
C-terminal tail of EBV BILF1 to be required for reducing surface HLA class I expression. 
Susceptibility to BILF1-mediated downregulation is in turn conferred by specific residues 
in the intracellular tail of the HLA class I heavy chain. Finally, we explore the evolution 
of BILF1 within the lymphocryptovirus genus. While the homolog of BILF1 encoded by 
the lymphocryptovirus infecting Old World rhesus primates shares the ability of EBV to 
downregulate cell surface HLA class I expression, this function is not possessed by New 
World marmoset lymphocryptovirus BILF1. This study therefore furthers our knowledge on 
the evolution of immunoevasive functions by the lymphocryptovirus genus of herpesviruses.
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Lymphocryptoviruses (LCVs) comprise a genus of the γ-herpesvirus subfamily whose 
members are only found in primates [1]. The LCV targeting humans, Epstein-Barr virus 
(EBV), is carried by more than 90% of adults worldwide [2, 3]. While infection is usually 
asymptomatic, primary encounter with the virus can present as infectious mononucleosis. 
EBV infection is also strongly associated with tumours of lymphoid and epithelial origin, 
reflecting the tropism of the virus for B cells and epithelial cells, and its potential for oncogenic 
transformation [4]. 
Despite the activation of a robust host T cell response upon primary infection, and 
the capacity for a memory T cell response thereafter, the virus persists for life even 
in immunocompetent individuals [5]. This is partly due to the ability of EBV, like all 
herpesviruses, to enter a state of latency in which protein expression is minimized, thereby 
limiting viral antigen display by the infected cell. Yet in order for EBV to spread to a new 
host, it must produce infectious virions by entering the replicative, or lytic, phase of its life 
cycle. In this phase, over 80 EBV-encoded proteins are expressed in a temporal cascade, 
with initial production of immediate early (IE) transactivators triggering induction of early 
genes, including enzymes required for viral replication [2]. This is followed by expression of 
late genes encoding virion structural components. The lytic phase thus creates ample viral 
antigens for proteasomal processing and HLA class I cell surface presentation, which can then 
recruit memory CD8+ T cells capable of eliminating the infected cell. However, millions of 
years of co-evolution with their hosts have seen herpesviruses acquire active immune evasion 
mechanisms to thwart this host response and permit sufficient time for the lytically infected 
cell to generate new virus particles [6-8].  
In the case of EBV, several such immune evasion strategies target the HLA class I antigen 
processing and presentation pathways [9]. The EBV host shutoff protein BGLF5 degrades 
mRNA, thus obstructing synthesis of new HLA class I molecules [10, 11]. Meanwhile, BNLF2a 
blocks entry of proteasome-generated peptides into the ER and subsequent loading onto 
HLA class I molecules by inhibiting the heterodimeric TAP complex [12, 13]. TAP transport 
is also hindered by the viral chemokine homolog, vIL-10, which reduces expression of the 
TAP1 subunit [14]. Another manner in which EBV can downregulate cell surface HLA class I 
expression and inhibit T cell recognition of infected cells is through BILF1, a viral G-protein 
coupled receptor (vGPCR) [15, 16].
  Several poxviruses and herpesviruses encode GPCRs that were most likely pirated 
from their host by retrotransposition [17-19]. vGPCRs serve many functions, including the 
scavenging of host chemokines [20], cell-to-cell-adhesion [21] and the re-programming of 
intracellular signalling networks to promote efficient viral replication [22]. BILF1 is expressed 
during the EBV lytic cycle and was first identified as a potential vGPCR due to the presence of 
seven membrane-spanning domains and (limited) homology with known herpesviral GPCRs 
[23-25]. While it displays both structural and functional similarities to chemokine receptors, 
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EBV BILF1 modulates intracellular signalling pathways constitutively as an orphan receptor 
[24, 25]. 
Initial immune evasion ability was ascribed to EBV BILF1 as it reduced phosphorylation 
of the dsRNA-dependent protein kinase R [24]. It has also been found to heterodimerize 
with human chemokine receptors [26]. In the case of CXCR4 this results in impairment of 
ligand-induced receptor signalling [27]. Finally, EBV BILF1 decreases cell-surface levels 
of HLA class I [15]. This can be achieved by BILF1-mediated acceleration of endocytosis 
and subsequent lysosomal degradation of HLA class I molecules from the cell surface, or 
by diversion of newly synthesized HLA class I molecules from the normal exocytic pathway 
that allows proteins to travel from the ER to the cell surface ([16]). In turn, this leads to the 
inhibition of CD8+ T cell recognition of infected cells.
Here, we further investigate the ability of EBV BILF1 to subvert the antigen presentation 
pathway. We assess the ability of BILF1 to target a range of specific HLA class I alleles and 
identify the protein domain present in BILF1 and specific amino acid residues in the HLA 
class I heavy chain (HC) that are required to facilitate downregulation of HLA class I from 
the cell surface. Finally, we examine the evolution of BILF1 by comparing the immunoevasive 
ability of EBV BILF1 with that of homologs expressed by LCVs infecting Old World rhesus 
and New World marmoset primates.  
Results
EBV BILF1 is an early lytic cycle gene
Previous reports present conflicting information on the expression of BILF1 during the 
productive phase of EBV infection [24, 25, 35].  As the absence of a working anti-BILF1 
antibody precluded the detection of BILF1 protein, we monitored the appearance of BILF1 
mRNA in an EBV+ Akata-derived B cell line following induction of the viral lytic cycle by 
cross-linking of the B cell receptor. BILF1 expression was strongly induced by 4 h and remained 
elevated up to 16 h post-induction (Figure 1A). The faint band observed for uninduced cells 
may indicate a low level of BILF1 expression, as has been described for other EBV+ B cell 
lines under strict latency [24]. PAA inhibits the viral DNA polymerase and transcription of 
late lytic genes, and can thus be used to dissect the temporal profile of lytic gene expression. 
While expression of the gp42-encoding late gene BZLF2 was detectable after overnight lytic 
cycle induction, it was completely blocked by prior addition of PAA (Figure 1B upper panel). 
In contrast, BILF1 mRNA was still induced in the presence of PAA (middle panel). Together, 
these data show EBV BILF1 to be an early lytic cycle gene. 
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EBV BILF1 can selectively modulate cell surface expression of HLA class I alleles
To examine its effect on individual HLA class I alleles, cells with different HLA haplotypes 
were transduced to express EBV BILF1. In a lentiviral vector, the EBV BILF1 gene was cloned 
upstream of an internal ribosomal entry site that is followed by the gene encoding enhanced 
GFP. Transduced cells could thus be identified easily as a GFP+ population. In addition, a 
FLAG-tag added to the BILF1 N-terminus made it possible to confirm surface expression 
of the viral protein. Cells were transduced with control GFP or EBV BILF1/GFP-encoding 
lentivirus and the presence of surface markers was analysed by flow cytometry after 7 days. 
Prior to staining, transduced and untransduced cells were mixed to allow comparison in a 
single assay. 
Melanoma-derived Mel JuSo (MJS) cells [30], widely used in antigen presentation studies 
due to the expression of both HLA class I and II, displayed strong cell surface BILF1 expression 
after transduction with BILF1/GFP lentivirus (Figure 2A, upper row). Total surface HLA class 
I expression was reduced in BILF1/GFP-expressing cells compared to untransduced cells and 
cells expressing GFP alone (second row). However, BILF1 did not decrease cell surface HLA 
class II expression (third row). Through the use of alloantigen-specific antibodies, the effect 
of BILF1 on individual HLA class I types expressed by MJS cells was then evaluated. BILF1 
reduced expression of HLA-A1 (fourth row) and mediated a particularly strong decrease in 
surface HLA-B8 expression (bottom row). 
HeLa cells expressing EBV BILF1 after lentiviral transduction also displayed reduced 
surface levels of W6/32-reactive HLA class I (Figure 2B). Specific staining of both HLA-A68 
and HLA-B15 showed that expression of both was decreased in BILF1+ HeLa cells. Similarly, 
surface HLA class I levels in BILF1+ HEK 293T cells were reduced compared to control 
cells (Figure 2C). Downregulation of HLA-B7 and a moderate decrease in HLA-A2 levels 
contributed to this effect (Figure 2C). Taking these data together, EBV BILF1 can thus target 
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Figure 1 The BILF1 gene is expressed 
early in the EBV lytic cycle. EBV lytic 
cycle gene expression was induced 
in AKBM cells by cross-linking of 
the B cell receptor with α-IgG for the 
indicated time periods (hours) (A), 
or for 16 h in the presence or absence 
of PAA (B). RNA was isolated, cDNA 
generated, and expression levels of the 
indicated gene products determined by 
PCR and EtBr gel electrophoresis. 
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Figure 2 EBV BILF1 reduces surface expression of a broad range of HLA class I alleles. A, MJS 
cells were transduced with GFP-encoding (control) or EBV BILF1/GFP-encoding (BILF1) replication-
deficient lentivirus. After 7 days, surface expression of FLAG-tagged EBV BILF1, total HLA class I, 
HLA class II, HLA-A1 and HLA-B8 was determined by flow cytometry. Transduced and untransduced 
MJS cells were mixed before antibody staining to allow comparison in a single assay (left and middle 
columns). Surface levels of the indicated proteins were also compared between GFP+ control cells and 
BILF1/GFP+ cells (histograms, right column). B, HeLa; C, 293T and D, U373 cells were transduced 
with GFP-encoding (control) or EBV BILF1/GFP-encoding (BILF1) lentivirus. Surface expression of 
FLAG-tagged EBV BILF1, total HLA class I or of the indicated HLA class I alleles was examined by flow 
cytometry after 7 days.
HLA-A and -B gene products, giving a reduction in expression of W6/32-reactive HLA class 
I molecules at the cell surface. 
We next examined whether expression of the non-classical HLA-E is also affected by 
BILF1. U373 cells expressing endogenous HLA-E were lentivirally transduced to achieve 
BILF1 expression. BILF1 caused a decrease in cell surface levels of W6/32-reactive HLA class 
I, molecules (Figure 2D). Interestingly, BILF1+ cells also displayed reduced levels of HLA-E, 
demonstrating that EBV BILF1 can target a wide range of HLA class I molecules to bring 
about a reduction in cell surface HLA class I expression.
Finally, we assessed whether EBV BILF1 can also downregulate cell surface levels of 
HLA-C.  Although poorly expressed by many cell types, HLA-C is expressed at the surface of 
U937 myeloid cells and can be specifically detected using the human antibody WK4C11 [36]. 
N-terminally HA-tagged BILF1 was efficiently expressed in U937 cells following retroviral 
transduction (Figure 3, upper row), which led to a reduction in total surface HLA class I 
expression (second row). While surface expression of HLA-A3 (third row) and HLA-B18 
(fourth row) was strongly reduced by BILF1, HLA-C was only marginally downregulated 
(bottom row). EBV BILF1 can therefore selectively decrease cell surface levels of HLA-A, -B 
and -E alleles, while only slightly affecting HLA-C.
The C-terminal tail of EBV BILF1 is required for downregulation of surface 
HLA class I
The C-terminal domain of GPCRs is known to interact with intracellular proteins 
including endocytic adaptors [37]. To assess whether the C-terminal domain of EBV BILF1 
is involved in downregulation of surface HLA class I molecules, we generated a C-terminal 
deletion mutant, BILF1-∆C19, which lacks the 19 most C-terminally-located amino acid 
residues (Figure 4A). This C-terminal deletion mutant retained some of the characteristics 
of its wt counterpart. EBV BILF1wt activates the transcription factor NFκB in a manner 
dependent on the integrity of the EKT motif in its third transmembrane domain [15]. BILF-
∆C19 expression also activated NFκB in HEK 293-kB luc cells following transient transfection 
(Figure 4B). 
BILF1-∆C19, containing an N-terminal FLAG-tag, was cloned into a lentiviral expression 
vector. MJS cells were then transduced with control, BILF1wt, or BILF1-∆C19 lentivirus. 
Anti-FLAG staining showed that similar levels of BILF1wt and BILF1-∆C19 were expressed at 
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the surface of transduced cells (Figure 4C). However, whereas MJS cells expressing BILF1 wt 
displayed a concomitant decrease in surface HLA-B8 expression, BILF1-∆C19 was severely 
diminished in its ability to downregulate HLA-B8. Meanwhile, neither BILF1 wt nor BILF1-
∆C19 significantly altered the surface levels of HLA class II. This indicates that the C-terminal 
domain of EBV BILF1, specifically the 19 last C-terminal residues, is required to bring about 
the downregulation of HLA class I from the cell surface. 
Inspection of the sequence of the BILF1 C-terminus identified two potential internalization 
motifs (highlighted in dashed-line boxes in Figure 4A). The first was QVTV, a putative Type II 
PDZ ligand sequence, conforming to the consensus sequence X-Φ-X-Φ, where X is any amino 
acid and Φ is a bulky hydrophobic residue [37, 38]. The second was a potential non–classical 
tyrosine-based motif, YFRRV, conforming to the consensus sequence Y-X-X-X-Φ [39, 40]. 
We thus generated two independent BILF1 point mutant proteins, substituting an alanine 
residue for either V299 of the putative Type II PDZ ligand sequence or Y303 of the proposed 
tyrosine based motif. The resulting point mutants were both expressed at the cell surface. 
However, the ability to downregulate HLA class I was retained in both cases, demonstrating 
that neither putative motif contributes to EBV BILF1-mediated downregulation of surface 
























































Figure 3 EBV BILF1 only 
marginally downregulates cell 
surface HLA-C expression. 
U937 cells were transduced with 
GFP-encoding (control) or EBV 
BILF1/GFP-encoding (BILF1) 
replication-deficient retrovirus. 
Surface expression of HA-
tagged EBV BILF1, total HLA 
class I, HLA-A3 and HLA-B18 
and HLA-C was determined by 
flow cytometry. Surface levels 
of the indicated proteins were 
compared between BILF1-/GFP- 
cells and BILF1+/GFP+ cells 
(histograms, right column).
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Figure 4 The EBV BILF1 C-terminal tail is required for HLA class I downregulation. A, Schematic 
representation of the 7-transmembrane EBV BILF1 vGPCR with the sequence of the 26 most C-terminally 
located amino acid residues described. The arrow indicates the point of truncation used to generate 
EBV BILF1-∆C19. Dashed-line boxes indicate putative endocytosis/sorting motifs. B, EBV BILF1-∆C19 
activates intracellular signalling pathways. 293-NFκB-luciferase cells were co-transfected with control 
expression vector or constructs encoding EBV BILF1wt, EBV BILF1-K122A or EBV BILF1-∆C19, and 
pGL3-Renilla (for normalizing transfection efficiency) luciferase. At 24 h post-transfection, cell lysates 
were assayed for firefly and Renilla luciferase activity. Data are presented as fold NFκB induction relative 
to cells transfected with vector alone. Results represent mean +/- SEM of a representative experiment 
performed in triplicate. C, MJS cells were transduced with GFP-encoding (control), EBV BILF1wt/GFP-
encoding (BILF1wt) or EBV BILF1-∆C19/GFP-encoding (∆C19) replication-deficient lentivirus. After 
7 days, surface expression of FLAG-tagged EBV BILF1, HLA-B8 and HLA class II was determined by 
flow cytometry. 
The intracellular region of the HLA class I HC is required for downregulation by 
BILF1
Given the requirement for the C-terminal domain of BILF1 in bringing about a reduction 
of surface HLA class I, we further hypothesized that the intracellular region of the HLA class 
I HC might also be necessary. We therefore generated a form of the HLA-B8 HC from which 
the 24 most C-terminal amino acid residues were deleted, leaving only 6 intracellular residues 
(HLA-B8 short; Figure 5A). Full-length HLA-B8 and HLA-B8 short were cloned into a 
lentiviral expression vector that co-expressed the control protein truncated nerve growth 
factor receptor (trNGFR). The U373 cell line, which is susceptible to the effects of BILF1 on 
HLA class I (Figure 2D) and does not express endogenous HLA-B8 (Figure 5B), was then 
transduced with either HLA-B8 wt/trNGFR or HLA-B8 short/trNGFR lentivirus. Equivalent 
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surface levels of trNGFR and of wt and short HLA-B8 were observed in the respective U373 
transductants (Figure 5B).  
The U373-HLA-B8wt and U373-HLA-B8 short cell lines were next transduced with 
either control or BILF1 lentivirus. BILF1 functionality in both cell lines was confirmed by its 
ability to downregulate surface expression of the endogenously expressed HLA-B18 allele to 
a similar extent (Figure 5C). 
Interestingly, BILF1 caused a decrease in HLA-B8wt levels in U373 cells, but failed to 
reduce surface levels of HLA-B8 short. Surface levels of trNGFR were not affected by BILF1, 
while surface expression of BILF1 itself was equivalent in U373-HLA-B8wt and U373-
HLA-B8 short cells (Supplementary Figure II). These data therefore show that in addition to 
the C-terminal domain of BILF1, the intracellular region of the HLA class I HC is required for 
BILF1-mediated downregulation of HLA class I surface expression.
Having assessed the effect of BILF1 on a wide range of HLA class I alleles (Figures 2 and 
3), we next examined whether the selective targeting of surface HLA-A, -B and -E, but not 
HLA-C, molecules could help pinpoint key residues in the HLA class I HC tail that facilitate 
BILF1-mediated downregulation (Figure 6A). Comparing the amino acid sequence of the 
BILF1-sensitive HLA-B intracellular tails with those of BILF1-resistant HLA-C showed that 
discriminating differences exist at positions 344, 351, 358 and 361 of the HLA-B alleles as 
indicated in Figure 6A. We therefore generated point mutations in HLA-B8 to examine 
whether the replacement of HLA-B8 residues with those found in the corresponding positions 
of the HLA-C intracellular tail would render the mutant HLA protein resistant to the effects 
of BILF1. The C-tail sequence of the HLA-B8 point mutants used is indicated in Figure 6A, 
lower panel.
U937 cells, which do not express endogenous HLA-B8 (data not shown), were transduced 
to express HLA-B8 wt or HLA-B8 point mutant proteins. Surface levels of endogenously 
expressed HLA-B18 were reduced by BILF1 to a similar extent in U937-HLA-B8 wt and 
U937-HLA-B8 point mutant cell lines (Figure 6B). However, while BILF1 downregulated 
cell surface HLA-B8 wt, it did not decrease cell surface HLA-B8 Y344C/D351N/V358E/T361I 
expression (Figure 6B). This strongly indicated that one, some, or all of the HLA-B8 residues 
mutated in HLA-B8 Y344C/D351N/V358E/T361I are required to facilitate targeting by BILF1.
In further analysis of HLA-B8 point mutants, surface expression of HLA-B8 T361I was 
efficiently decreased by BILF1, demonstrating that residue T361 is not essential for BILF1-
mediated HLA-B8 downregulation. Indeed, as with HLA-B8 Y344C/D351N/V358E/T361I, surface 
levels of HLA-B8 Y344C/D351N/V358E remained unaffected by BILF1. Individual mutation of 
residues Y344, D351 and V358 has not allowed a single amino acid to be identified as being 
essential to targeting of HLA-B8 by BILF1 (data not shown). Rather, the possibility exists that 
each could play a contributory role.  
In conclusion, the BILF1-mediated downregulation of HLA class I molecules requires 
their cytoplasmic domains; the amino acid residues at position 344, 351 and 358 appear to 
contribute essentially to the observed phenotype in the case of HLA-B8. 
160723 Proefschrift.indd   114 24.07.2016   21:50:23
Lymphocryptovirus BILF1 downregulation of  MHC class I
115
4
Figure 5 The cytoplasmic region of HLA class I HC is required for BILF1-mediated cell surface 
downregulation. A, Sequence of the HLA-B8 C-terminus. The arrow denotes the point of truncation 
used to generate HLA-B8 short. B, U373 cells were transduced with HLA-B8wt/trNGFR-encoding or 
HLA-B8 short/trNGFR-encoding replication-deficient lentivirus. Surface expression of HLA-B8 and 
trNGFR on transduced and untransduced cells was determined by flow cytometry. C, U373-HLA-B8wt 
and U373-HLA-B8 short cells were further transduced with GFP-encoding (control) or EBV BILF1/
GFP-encoding (BILF1) replication-deficient lentivirus. After 7 days, surface expression of HLA-B8 and 
the endogenous HLA-B18 allele was measured by flow cytometry. 
Marmoset LCV BILF1 fails to downregulate cell surface MHC class I
BILF1 homologs are encoded by rhesus LCV (80.4% amino acid identity to EBV BILF1 
in an NCBI blastp two-sequence comparison) and marmoset LCV (41% identity to EBV 
BILF1) (Figure 7A). Rhesus LCV BILF1 has previously been shown to mediate MHC class I 
downregulation [15], but the functionality of marmoset LCV BILF1 in this regard is unknown. 
Cloning the rhesus and marmoset LCV BILF1 genes into a lentiviral expression vector allowed 
us to directly compare the ability of the three LCV BILF1 homologs to downregulate surface 
HLA class I in MJS cells. Both EBV BILF1 and rhesus LCV BILF1 strongly decreased surface 
HLA-B8 in lentivirally transduced MJS cells, but marmoset LCV BILF1 failed to do so (Figure 
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                              RRKSSGGKGGSYSQAACSDSAQGSDVSLTA
                              RRKSSGGKGGSCSQAASSNSAQGSDESLIACKA 
RRKSSGGKGGSCSQAACSNSAQGSDESLIA 
                              RRKSSGGKGGSCSQAACSNSAQGSDESLTA 
                              RRKSSGGKGGSYSQAACSDSAQGSDVSLIA 
HLA-B7                         RRKSSGGKGGSYSQAACSDSAQGSD-VSLTA--- 
HLA-B8                         RRKSSGGKGGSYSQAACSDSAQGSD-VSLTA--- 
HLA-A1                         RRKSSDRKGGSYTQAASSDSAQGSD-VSLTACKV 
HLA-A3                         RRKSSDRKGGSYTQAASSDSAQGSD-VSLTACKV 
HLA-A2                         RRKSSDRKGGSYSQAASSDSAQGSD-VSLTACKV 
HLA-A68                        RRKSSDRKGGSYSQAASSDSAQGSD-VSLTACKV 
HLA-B15                        RRKSSGGKGGSYSQAASSDSAQGSD-VSLTA--- 
HLA-B18                        RRKSSGGKGGSYSQAASSDSAQGSD-VSLTA--- 
HLA-C                          RRKSSGGKGGSCSQAASSNSAQGSD-ESLIACKA 
HLA-E                          RKKSSGGKGGSYSKAEWSDSAQGSESHSL----- 
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All three BILF1 homologs contained N-terminal FLAG tags, allowing their surface expression 
to be assessed (Figure 7B). Marmoset LCV BILF1 was efficiently expressed at the cell surface, 
albeit to a lesser extent than its EBV and rhesus LCV counterparts. Further analysis showed 
HLA-B8 levels to be reduced in the population of MJS cells expressing EBV or rhesus LCV 
BILF1 at an equivalent level to that obtained with marmoset LCV BILF1 (Figure 7C).
Although marmoset LCV BILF1 failed to reduce surface expression of MHC class I in 
human cells, it remained possible that the viral protein could be functional in this respect in 
marmoset cells. We thus transiently transfected primary marmoset fibroblasts with a vector 
offering co-expression of FLAG-tagged marmoset LCV BILF1 and GFP. Marmoset MHC 
class I on these cells was detectable using the W6/32 mAb. At 48 hours post-transfection, 
transfected cells were identified by GFP expression. No decrease in surface MHC class I was 
evident in cells transfected with the marmoset LCV BILF1-IRES-GFP vector (Figure 7D; left, 
upper panel). As a population of GFP+ cells failed to express detectable levels of marmoset 
LCV BILF1 at the surface (middle, upper panel), a double-staining procedure was performed 
to more precisely assess MHC class I levels in cells clearly expressing marmoset LCV BILF1. 
This confirmed that GFP+ marmoset cells containing high surface levels of FLAG-tagged 
marmoset LCV BILF1 did not undergo a downregulation of MHC class I (right, upper 
panel). EBV BILF1 also failed to reduce surface expression of marmoset MHC class I (Figure 
7D, lower panels). This indicates that a species restriction exists with regard to EBV BILF1 
function, and suggests that a sufficient level of homology with the host protein(s) required 
for EBV BILF1-mediated MHC class I downregulation may not be present in marmoset cells.
Given the importance of the C-terminal domain of EBV BILF1 in mediating its effect 
towards HLA class I, we examined finally whether this domain was itself sufficient to confer 
the ability to downregulate HLA class I to a heterotypic protein. We therefore generated a 
chimeric BILF1 protein in which the 19 most C-terminal amino acids of marmoset LCV BILF1 
were removed and replaced by those of EBV BILF1 (marmoset LCV-EBV C-tail swap BILF1). 
Figure 6 EBV BILF1-mediated HLA-B8 downregulation requires amino acid residues in the 
cytoplasmic region of the HLA-B8 molecule. A, upper panel, Amino acid sequence alignment of 
selected HLA class I heavy chain C-terminal tails. Alignments were generated using ClustalW2. 
An asterisk (*) indicates positions that have a single, fully conserved residue. A colon (:) indicates 
conservation between groups of strongly similar properties. A full stop (.) indicates conservation 
between groups of weakly similar properties. Sequences of the following subtypes were selected from the 
IMGT/HLA Database: A*01:01:01:01 (HLA-A1), A*02:01:01:01 (HLA-A2), A*03:01:01:01 (HLA-A3), 
A*68:01:01:01 (HLA-A68), B*07:02:01 (HLA-B7), B*08:01:01 (HLA-B8), B*15:03:01 (HLA-B15), 
B*18:01:01:01 (HLA-B18), C*01:02:01 (HLA-C), E*01:01:01:01 (HLA-E). The dashed box indicates a 
putative YXXA internalization motif present in HLA-A, -B and -E alleles but not HLA-C. A, lower panel, 
C-terminal tail amino acid sequences of HLA-B8 point mutants. Amino acids in the dashed boxes were 
subject to substitution. The numbers above the dashed boxes indicate the position of the residue in the 
HLA-B8 protein. B, U937 cells transduced to express HLA-B8 wild type, HLA-B8 Y344C/D351N/V358E/
T361I, HLA-B8 T361I, or HLA-B8 Y344C/D351N/V358E were transduced with GFP-encoding (control) or 
EBV BILF1/GFP-encoding (BILF1) replication-deficient retrovirus. Surface expression of HLA-B8 and 
HLA-B18 was determined by flow cytometry. Surface levels of the indicated proteins were compared 
between BILF1-/GFP- cells and BILF1+/GFP+ cells (histograms).
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EBV BILF1             1 MLSTMAPGSTVGTLVANMTSVNATED-ACTKSYSAFLSGMTSLLLVLLILLTLAGILFII
Rhesus LCV BILF1      1 MLSTLAPGSTVVTQVANMTFVNATDD-ACTRSYSAFLSGMTSLLLILLILLTVVGLLFIA
Marmoset LCV BILF1    1 --------MDETTQIMGSPTVELPEGPGCNSSYNTGLSIFTGVTMVTEILILIILLLFLL
EBV BILF1            60 FVRKLVHRMDVWLIALLIELLLWVLGKMIQEFSSTGLCLLTQNMMFLGLMCSVWTHLGMA
Rhesus LCV BILF1     60 LVRKFAHRMDVWLSALLLELLFWVLGKMIQEFSTTGLCILTQNLMFLGLMCSVWTHVGMA
Marmoset LCV BILF1   53 LIRKLKDSIDWWLAVMFMDTLLWLLGKLIQEFSNTGLCMLTQHMMLMSLLLSGFHHSGMA
EBV BILF1           120 LEKTLALFSRTPKRTSHRNVCLYLMGVFCLVLLLIIILLITMGPDANLNRGPNMCREGPT
Rhesus LCV BILF1    120 VEKTRALTSTKPMRHSNRTVYLYLGGVFALVLLLIIILLIIMGPNADLNRGPNMCREGPT
Marmoset LCV BILF1  113 AHRALMVSAKTIKPVSNRCIIMYLLLTLITVFILVLASVFEAGISSNLNRGPNLCREGAT
EBV BILF1           180 KGMHTAVQGLKAGCYLLAAVLIVLLTVIIIWKLLRTKFGRKPRLICNVTFTGLICAFSWF
Rhesus LCV BILF1    180 RAMHTTIQGMKAGCYLLAGILIVILTLIIIWKLLHTKFGRKWRLICNVAFTGLICAFSWF
Marmoset LCV BILF1  173 QAGHAIRQAAKGFFFLCCCVATIIATCYITYKIWHTRLSTRMRIICNVMFTGIIGATCWL
EBV BILF1           240 MLSLPLLFLGEAGSLGFDCTESLVARYYPGPAACLALLLIILYAWSFSHFMDSLKNQVTV
Rhesus LCV BILF1    240 MLSLPLLFLGEAGSLGFACTESLAARYYPGPAAFLALLLILLYAWSFNHFMDSLKNKVSV
Marmoset LCV BILF1  233 LLAAPLVFRPEPGNLGFFCPSSLMTRYYHAFGSLLILLLLLLYIWAHRQFIDDLKNILES
EBV BILF1           300 TARYFRRVPSQST
Rhesus LCV BILF1    300 TAKFFRGTSTQST
Marmoset LCV BILF1  293 TLVSFRRASNPNS
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This LCV BILF1 fusion gene was cloned into a lentiviral expression vector and human cells 
were transduced with control, EBV BILF1wt, marmoset LCV BILF1wt, or C-tail swap BILF1 
lentivirus. C-tail swap BILF1 was expressed at the cell surface at a similar level to marmoset 
LCV BILF1wt in MJS cells but did not mediate downregulation of HLA class I (Figure 7E). 
This indicates that the intracellular C-terminal domain of EBV BILF1 is necessary but not 
alone sufficient for bringing about a reduction in surface HLA class I levels.
 
Discussion
Central to the execution of host anti-viral immunity is the action of CD8+ T lymphocytes 
in detecting and eliminating virally infected cells. Herpesviruses have counter-evolved several 
strategies to thwart this system of immune surveillance by inhibiting the display of MHC class 
I:viral peptide complexes at the cell surface [7-9]. EBV inhibition of the HLA class I antigen 
presentation pathway during the viral lytic cycle is mediated through the concerted action 
of BGLF5 [10, 11], BNLF2a [12, 13], BILF1 [15, 16] and vIL-10 [14].  In understanding the 
dynamic process of multigenic immune evasion during the productive phase of the EBV life 
cycle, it is important to ascertain the temporal profile of individual gene expression. Previous 
studies have shown both BNLF2a and BGLF5 protein to be detectable approximately 3 h after 
lytic cycle induction [11, 41]. The vIL-10-encoding BCRF1 gene, in contrast, is expressed late 
in the lytic cycle [14]. Conflicting reports exist on the temporal expression of EBV BILF1 
[24, 25, 35]. Here, we show BILF1 to be an early EBV lytic cycle gene, with transcripts first 
detectable by 4 h post induction. While this suggests that BILF1 protein is first expressed in 
conditions where BGLF5-mediated host-shutoff and BNLF2a-mediated TAP inhibition have 
Figure 7 MHC class I is not downregulated by the marmoset LCV BILF1 homolog. A, Amino 
acid sequence alignment of the BILF1 homologs encoded by EBV, rhesus LCV and marmoset LCV. 
Alignments were constructed using ClustalW2 and displayed using BOXSHADE version 3.21. B, 
MJS cells were transduced with GFP- (control), EBV BILF1/GFP- (EBV), rhesus LCV BILF1/GFP- 
(Rhe) or marmoset LCV BILF1 (Mar)-encoding replication-deficient lentivirus. After 7 days, surface 
expression of FLAG-tagged EBV BILF1 and HLA-B8 was determined by flow cytometry. Transduced 
and untransduced MJS cells were mixed before antibody staining to allow comparison in a single assay. 
C, Populations of transduced MJS cells expressing equivalent surface levels of FLAG-tagged EBV, rhesus 
LCV and marmoset LCV BILF1 were further analysed to examine their HLA-B8 surface expression 
levels. D, Marmoset primary fibroblasts were transfected with EBV or marmoset LCV FLAG-BILF1 
genes in the pLV-IRES-GFP bicistronic vector. 48 h post-transfection, cells were stained with PE-
conjugated W6/32 mAb, or with anti-FLAG and APC-conjugated anti-mouse antibody. Double staining 
of samples was performed to determine surface MHC class I expression on cells displaying cell surface 
FLAG-BILF1. E, MJS cells were transduced with GFP- (control), EBV BILF1wt/GFP- (EBV), marmoset 
LCV BILF1wt- (Mar), or marmoset LCV-EBV C-tail swap (C-tail swap)-encoding replication-deficient 
lentivirus. After 7 days, surface expression of FLAG-tagged EBV BILF1 and HLA class I was determined 
by flow cytometry. Transduced and untransduced MJS cells were mixed before antibody staining to 
allow comparison in a single assay.
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already been established, BILF1 may function to remove pre-existing HLA class I molecules 
from the cell surface. Furthermore, BNLF2a protein expression is transient, whereas the 
detection of BILF1 transcripts 16 h post-induction suggests that BILF1 is able to target HLA 
class I molecules presenting viral antigens late in the lytic cycle. 
Although we have previously shown EBV BILF1 to downregulate HLA class I in human 
cells [15], the use of the pan-HLA class I-reactive mAb W6/32 could have masked selective 
targeting of specific HLA class I molecules. Other herpesvirus proteins targeting HLA class 
I for degradation have been found to demonstrate HLA class I type specificity. The Kaposi’s 
sarcoma-associated herpesvirus (KSHV) E3 ligases K3 and K5 mediate ubiquitination of cell-
surface HLA class I molecules, which are subsequently endocytosed and degraded by the 
lysosome [42-45]. While K3 is broadly reactive towards HLA-A, -B, -C and -E, K5 is selective 
for HLA-A and -B [45]. Meanwhile, HCMV US2 induces dislocation of newly synthesized 
HLA class I molecules from the ER to the cytosol for proteasomal degradation [46]. US2 
targets HLA-A and certain HLA-B types, while surface expression of HLA-C, HLA-E and 
other HLA-B alleles is not affected [47].
Here, we employed a panel of alloantigen-specific mAbs to examine for the first time the 
effect of BILF1 on expression of individual HLA class I alleles in different cell types.  Most cells 
express HLA-A, -B alleles, along with low levels of HLA-E, and in some cases HLA-C. HLA-A 
and -B molecules are most important for the presentation of viral peptides, a fact reflected in 
their high level of polymorphism. Surface expression of all HLA-A and -B alleles tested, was 
reduced by BILF1. Interestingly, the HLA-A2, -B7 and -B8 molecules shown here to undergo 
BILF1-mediated surface downregulation have been found to present epitopes derived from 
lytic cycle proteins, expressed by vaccinia virus infection of B cells, to EBV-specific CD8+ T 
cells [48].  As some of the epitopes were from IE antigens, this provides further support to the 
idea that EBV BILF1 may target pre-existing HLA class I molecules for endocytosis upon its 
synthesis approximately 4 h after lytic cycle induction.  
Additionally, it has been proposed that the repertoire of peptides bound by HLA-A2, 
-B7 and -B8 include those that do not require TAP for transport into the ER [49]. The EBV 
transmembrane protein LMP2 contains HLA-A2-restricted TAP-independent CD8+ T cell 
epitopes [50], while a HLA-B7-restricted T cell clone specific for the EBV lytic cycle protein 
BMRF1 has been isolated from a TAP-deficient individual [51]. It is therefore possible 
that HLA class I molecules loaded with peptide in the presence of BNLF2a-mediated TAP 
inhibition during the lytic cycle may still be targeted by BILF1. 
Different HLA class I molecules possess distinct peptide-binding specificity and will thus 
present a unique spectrum of viral peptides to CD8+ T cells. A mechanism of immune escape 
confined to a narrow subset of HLA-A and -B alleles would not provide a selective advantage 
to the virus in transmission to a wide range of hosts. BILF1 likely mediates a broad-spectrum 
inhibition of HLA-A and -B surface expression that is particularly useful in a virus targeting 
a population with such high HLA-A and -B polymorphism.
HLA-C molecules are predominantly involved in regulating natural killer (NK) cell 
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function. HLA-C interacts with NK cell inhibitory receptors to prevent NK cell-mediated 
lysis. Interestingly, whereas a range of HLA-A and -B alleles were downregulated from the 
cell surface by EBV BILF1, HLA-C was only slightly affected. Through selective modulation 
of classical HLA class I molecules, BILF1 could target HLA-A and -B alleles presenting 
viral peptides to CD8+ T lymphocytes, while allowing the virally-infected cell to retain the 
inhibitory effect of HLA-C on NK cells. In this way, BILF1 could assist EBV evasion of both 
adaptive and innate immune mechanisms.
HLA-E is also best known for its role in regulating NK cell function. By presenting 
peptides derived from the HLA-A, -B and -C signal sequences and acting as a ligand for 
the CD94/NKG2A NK cell inhibitory receptor complex, HLA-E prevents killing by NK cells. 
EBV BILF1 did however decrease surface expression of HLA-E. Reducing surface HLA-E 
expression and removal of this inhibitory signal from the virally infected cell may therefore 
appear detrimental to virus survival. However, HLA-E has also been shown to bind viral 
antigens, including a BZLF1-derived peptide [52]. HLA-E:viral peptide complexes can then 
be recognized by CD8+ T cells [53]. It may thus be advantageous for EBV to target HLA-E 
through BILF1, with the increased risk of NK cell attack being offset by other NK cell immune 
evasion tactics, such as the retention of HLA-C expression, and the action of miRNA BART-2 
in reducing expression of the NK cell activating ligand MICB [54]. 
Previous studies have shown BILF1 to accelerate internalisation of HLA class I molecules, 
which are subsequently targeted for lysosomal degradation [15]. In an effort to gain further 
mechanistic insight into EBV BILF1-mediated HLA class I downregulation, we focussed on 
the role of BILF1 C-terminal tail, as this region of GPCRs is often involved in intracellular 
sorting and interaction with endocytic adaptor proteins [55]. While the C-tail is required 
for cell surface expression in the case of some GPCRs [56], our EBV BILF1 truncation 
mutant lacking the 19 most C-terminal residues was still detectable at the plasma membrane. 
The BILF1 deletion mutant was still functional with respect to modulation of intracellular 
signalling, as it retained the capacity to activate NFκB. However, BILF1-∆C19 displayed a 
substantially abrogated ability to downregulate HLA class I surface expression relative to 
BILF1wt. Using a BILF1 deletion mutant lacking the 21 most C-terminal amino acid residues, 
a study by Zuo et al. indicated that the BILF1 C-tail is required for directing endocytosed 
HLA class I molecules to lysosomes [16]. The results of the present study are therefore in 
agreement with those of Zuo et al. in identifying a critical role for the BILF1 C-tail in reducing 
HLA class I levels. 
As the C-tail of EBV BILF1 therefore likely contains motifs involved in the targeting 
of HLA class I to lysosomes, we scanned this domain for the short, linear amino acid 
sequences that typically mediate trafficking from the cell surface and sorting to lysosomes. 
Two candidate putative motifs related to protein endocytosis and intracellular sorting were 
identified. One, a type II PDZ ligand sequence, can be involved in regulating endocytosis, in 
addition to protein recycling [37]. The second, a non-classical tyrosine-based signal differs 
from the more common consensus motif by containing an extra residue between the tyrosine 
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and hydrophobic residue [37, 40]. Tyrosine-based motifs are recognized by clathrin adaptor 
proteins and can direct both protein endocytosis and lysosomal targeting [39]. In the case of 
both motifs, substitution of a key amino acid residue by alanine has been previously shown 
to functionally inactivate the signal [40, 57]. However, the failure of such point mutations to 
block the effect of BILF1 on HLA class I surface expression indicates that other structural 
determinants with the vGPCR C-tail are involved. 
In addition to demonstrating the importance of the BILF1 C-tail, we found the intracellular 
portion of the HLA class I HC to be essential for BILF1-mediated downregulation. Other viral 
immunoevasins targeting the class I HC display a similar requirement. For instance, KSHV 
K3 catalyzes ubiquitination of lysine residues in the HC C-tail, thereby tagging the protein for 
internalisation and degradation [58]. However, the fact that BILF1 expression does not trigger 
ubiquitination of class I HC [15] points towards another basis for this dependence in the case 
of the EBV immunoevasin. 
We identified three amino acid residues in the HLA-B8 intracellular tail that may 
be essential for BILF1-mediated downregulation. One of these, Y344, forms part of the 
tyrosine-based YXXA internalisation motif, which is conserved and required for constitutive 
endocytosis in the case of HLA-B27 [59]. This motif is present in all alleles tested in this study 
that were downregulated by BILF1, but absent from HLA-C (Figure 6A) and the HLA-B8 
short mutant (Figure 5A). As it is reminiscent of the YXXΦ signal, the YXXA motif may also 
interact with clathrin adaptor proteins. However, the observation that the AP-2 is not required 
for BILF1-mediated HLA class I downregulation [16] would argue against the interaction of 
clathrin adaptor proteins with the HLA class I YXXA motif in facilitating the accelerated 
endocytosis or intracellular sorting directed by BILF1. 
Thus, while the specific EBV BILF1 internalisation and sorting motifs and the intracellular 
adaptor protein(s) facilitating BILF1-mediated surface downregulation of HLA class I 
remain to be identified, our findings advance the molecular understanding of the process by 
identifying a critical domain in the viral effector protein and key amino acid residues in the 
host target proteins. 
Besides EBV, other members of the LCV genus include Callithricine herpesvirus 3 
(marmoset LCV) and Macacine herpesvirus 4 (rhesus LCV) [1]. These LCVs are prototypes 
for the New World and Old World primate LCVs, respectively, and display broadly similar 
biological properties to EBV. They can induce B cell growth transformation in vitro, possess 
inherent oncogenic potential in vivo and persistently infect their hosts. Rhesus LCV has a 
genetic repertoire that is identical to EBV, even though they are separated by an evolutionary 
distance of approximately 25 million years [60]. All EBV ORFs are accounted for in rhesus 
LCV and vice versa, with a similar relative genomic position. In contrast, marmoset LCV, 
which is estimated to have evolved 35 million years before EBV, has a similar, but less complete, 
genetic repertoire to EBV and rhesus LCV, suggesting a different evolutionary path [61, 62]. 
Notably, marmoset LCV lacks 14 genes encoded by the LCVs infecting higher-order 
primates [60-62]. None of these 14 genes are known to be essential for viral replication or B 
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cell immortalization, but they do include the immunomodulatory genes BNLF2a, vIL-10, the 
CSF receptor homolog BARF1 [63] and the EBERs [64]. Thus, the viral genes acquired during 
LCV evolution from New World hosts to Old World and human hosts may be less involved 
with intrinsic viral replication pathways during latent or lytic LCV infection, and may have 
evolved in order to survive in hosts with increasingly sophisticated host immunity, e.g. a more 
diverse MHC in humans and Old World versus New World hosts. While a BILF1 homolog 
is encoded by marmoset LCV, our results suggest the ability to downregulate cell surface 
MHC class I expression functionally evolved within the same related gene present in all LCV. 
Thus, LCV have made a concerted effort to target the host antigen presentation pathway and 
downregulate MHC by multiple evolutionary mechanisms, including (i) creation of novel 
immunomodulatory proteins (BNLF2a), (ii) acquisition of cellular homologs (vIL-10), and 
(iii) adaptation of novel functions into existing gene products (BILF1).
Materials and Methods 
DNA Constructs
BILF1 wild type (wt) and mutant coding sequences were subcloned into the PstI/XhoI 
sites upstream of the internal ribosomal entry site (IRES) in the lentiviral expression vector 
pLV-IRES-GFP [28]. All were engineered to contain an N-terminal FLAG-tag. The EBV 
BILF1 wt sequence was subcloned from pcDNA5-FLAG-BILF1 and the EBV BILF1-K122A 
sequence from pcDNA3.1/TOPO-FLAG EBV BILF1 K122A (both gifts from H. Vischer, M. 
Smit, VU, Amsterdam, The Netherlands). The coding sequence of rhesus LCV BILF1 was 
amplified by PCR from pcDNA-Rhe LCV BILF1-IRES-GFP (a gift from M. Rowe, University 
of Birmingham, UK). The EBV BILF1 C-terminal truncation mutant ∆C19 was generated by 
PCR amplification of the wt sequence with the introduction of an early stop codon. To derive 
the EBV BILF1 point mutants, EBV BILF1-V299A and EBV BILF1-Y303A, the QuickChange site-
directed mutagenesis kit (Stratagene) was used according to the manufacturer’s instructions. 
The chimeric gene encoding a protein with amino acid residues 1-285 of marmoset LCV 
BILF1 fused to residues 293-312 of EBV BILF1 (BILF1 C-tail swap) was generated by PCR 
amplification using a reverse primer that encoded the 19 most C-terminal residues of the 
EBV BILF1 C-tail and annealed to nucleotides 830-855 of the marmoset LCV BILF1 coding 
sequence template. 
The construct containing the N-terminally HA-tagged EBV BILF1 wt coding sequence in 
the retroviral expression vector pLZRS-IRES-GFP was a kind gift from J. Zuo and M. Rowe, 
University of Birmingham, UK.
The HLA-B8 wt sequence was PCR-amplified from pLZRS-HLA-B8-GFP (a gift from M. 
Heemskerk, LUMC, Leiden, the Netherlands) and subcloned into a lentiviral bidirectional 
vector, pCCLsin.PPT.pA.CTE.eGFP.mCMV.hPGK.NGFR.pre (kindly provided by L. Naldini, 
Milano, Italy), in which the human EF1A promoter replaced the minimal CMV-eGFP 
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cassette. The HLA-B8 short truncation mutant was generated by PCR amplification of the wt 
sequence with the introduction of an early stop codon. 
To express HLA-B8 wt and C-tail mutants in U937 cells, cells were transduced with 
replication-deficient lentiviruses generated from the following lentiviral vector pSicoR-
EF1a-Zeo-P2A (kindly provided by R.J. Lebbink, Utrecht, The Netherlands). The pSicoR-
EGFP backbone vector (Addgene) was altered by removing the U6 promoter and replacing 
the CMV-EGFP cassette with the human EF1A promoter driving expression of the Zeocin 
resistance gene and the gene of interest.  Zeocin and HLA-B8 genes were fused together by 
a self-cleaving 2A peptide derived from the porcine teschovirus-1 (P2A). The P2A peptide 
allows expression of both proteins from a single transcript. HLA-B8 wt was PCR-amplified 
from the bidirectional lentiviral vector mentioned above; the cytoplasmic tail mutants were 
generated by using reverse primers that encoded the mutations. 
Restriction digests and sequence analysis verified the integrity of all gene sequences.
Cell Lines
The AKBM cell line is an EBV+ Burkitt’s lymphoma B cell line (Akata) stably transfected 
with the pHEBO-BMRF1p-rCD2-GFP reporter plasmid [29]. AKBM cells were maintained in 
RPMI 1640 medium (Invitrogen) supplemented with 10% FBS (PAA Laboratories, Pasching, 
Austria), 2 mM L-glutamine, 100 U/ml penicillin, and 100 μg/ml streptomycin and 0.3 mg/
ml hygromycin B. The MJS (Mel JuSo; HLA typing A*01, B*08) melanoma-derived cell line 
[30], the monocytic U937 cell line (A*03, B*18, Cw*01), and primary fibroblasts obtained 
from a common marmoset (Callithrix jacchus) (kindly provided by G. Koopman, BPRC, 
Rijswijk) were both maintained in RPMI (Invitrogen, Carlsbad, CA) supplemented with 10% 
FBS (European Union approved; Invitrogen), 2 mM L-glutamine, 100 U/ml penicillin, and 
100 mg/ml streptomycin. 293T (A*02, B*07), 293-kB-luc ([31] ; a gift from G. B. Lipford, 
Coley Pharmaceutical Group), U373 (A*0201, B*18) and HeLa (A*68, B*15) cells were 
maintained in DMEM (Invitrogen, Carlsbad, CA) supplemented with 10% FBS (Invitrogen), 
2 mM L-glutamine, 100 U/ml penicillin, and 100 mg/ml streptomycin. 293-kB-luc cells were 
cultured in the presence of 0.7 mg/ml geneticin. 
Replication-deficient lentiviruses and retroviruses
Replication-deficient recombinant lentiviruses were generated by calcium phosphate co-
transfection of HEK 293T cells with a pLV-CMV-IRES-eGFP, pCCLsin.PPT.pA.CTE.EF1A.
hPGK.NGFR.pre or pSicoR-EF1a-zeocin-P2A lentiviral vector encoding the gene of interest, 
and pCMV-VSVG, pMDLg-RRE and pRSV-REV (kindly provided by R. Hoeben, LUMC, 
Leiden, the Netherlands) [32]. Replication-deficient recombinant retroviruses were produced 
by using the Phoenix amphotropic packaging system as described previously [13]. After 48 to 
96 h, culture supernatants were harvested and frozen or filtered through a 0.45 mm pore filter. 
MJS, HeLa, 293T, U373 and U937 cell lines were infected with 1 ml lentivirus-containing 
medium in tissue culture dishes coated with 12 mg/ml retronection. Transduction efficiency 
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was examined by measuring GFP or surface NGFR expression. In the case of U937 cells 
transduced with pSicoR-EF1a-zeocin-P2A-based vectors, cells were selected using zeocin 
(400 µg/ml) to obtain pure populations. 
Induction of EBV lytic cycle in AKBM cells, RNA isolation and RT-PCR
The EBV lytic phase was induced in AKBM cells by cross-linking surface IgG with 
50 mg/ml goat F(ab’)2 fragments to human IgG (Cappel; MP Biomedicals, Solon, OH). 
Discrimination between IE and late lytic phases was achieved by inhibition of viral DNA 
replication and late lytic phase gene expression using phosphonoacetic acid (PAA). PAA (pH 
7.4 in 100 mM Hepes) at a final concentration of 300 mg/ml was added 1 h prior to EBV lytic 
phase induction. Total RNA was extracted using TRIzol reagent (Invitrogen) and treated with 
DNase (TURBO DNAsefree kit; Applied Biosystems), according to manufacturer’s protocols. 
cDNA was synthesized using random hexamers and the Moloney murine leukemia virus 
reverse transcriptase (Finnzymes), and used for amplification with Taq DNA Polymerase. EBV 
BILF1 expression was measured using the primers 5’-GTATGGCGTTGGAGAAGACC-3’ 
and 5’-TAATCAGCAGGAGTACCAGACA-3’; BZLF2/gp42 expression with the primers 
5’- ATTCTACCTGTGGTAACTAGA-3’ and 5’-TTAGCTATTTGATCTTTG-3’and 
18S rRNA expression with the primers 5’-GTAACCCGTTGAACCCCATT-3’ and 
5’GATCCGAGGGCCTCACTAAAC-3’. DNA fragments of the expected length were 
visualized by 1% agarose gel electrophoresis and ethidium bromide (EtBr) staining.
Antibodies
The mouse monoclonal antibodies (mAbs) used in this study were: W6/32, which detects 
HLA class I molecules [33]; L243, which detects class II HLA-DR (American Type Culture 
Collection); anti-FLAG M2 (Sigma); and 3D12, detecting HLA-E (eBioscience). The rat mAb 
3F10 (Roche) was used for detection of HA-tags. The human mAbs used were produced locally 
[34] and included VDK1D12, detecting HLA-A1; SN230G6 detecting HLA-A2; WIM8E5 
detecting HLA-A68; VTM4D9 detecting HLA-B7; BVK 5B10 detecting HLA-B8; OUWF11 
detecting HLA-B15, FVS4G4 detecting HLA-B18 and WK4C11 detecting HLA-C (Cw*01, 
Cw*03, Cw*08, Cw*12 and Cw*14). Additional antibodies used were Allophycocyanin 
(APC)-conjugated goat anti-mouse IgG (H+L) (Leinco Technologies); APC-conjugated goat 
anti-human IgG + IgM (H+L) (Jackson Immuno Research); APC-conjugated donkey anti-rat 
IgG F(ab’)2 (H+L) (Jackson Immuno Research); R-phycoerythrin (PE)-conjugated goat anti-
mouse Ig F(ab’)2 (Dako); PE-conjugated goat anti-human IgM F(ab’)2 (Southern Biotech); 
biotinylated goat anti-mouse Ig (Dako) and APC-conjugated streptavidin (BD Pharmingen). 




Surface expression of specific molecules was determined using the indicated primary 
antibodies. Bound antibodies were detected using goat anti-mouse IgG-APC, or for staining 
of specific HLA class I alleles, goat anti-human IgG + IgM-APC. For HLA-E detection, a 
streptavidin-biotin-based three-step staining was performed. Double staining of marmoset 
fibroblasts, to examine co-expression of MHC class I and FLAG-BILF1 on single cells, was 
performed by consecutive incubation with anti-FLAG mAb, APC-conjugated anti-mouse 
Ab and PE-conjugated W6/32. Stained cells were analyzed on a FACScalibur flow cytometer 
(Becton Dickinson) and using FlowJo software (TreeStar).
Transient transfections and luciferase assays
To examine activation of NF-κB by EBV BILF1wt, EBV BILF1-K122A and EBV BILF1-
∆C19, 293-κB-luc cells were seeded in a 96-well plate at a density of 2 x 105 cells/ml, 200 
ml/well, 24 h before transfection with lipofectamine 2000 following the manufacturer’s 
instructions. Cells were transfected with 70 ng of phRL-TK (constitutively expressing 
Renilla luciferase) and 160 ng of constructs encoding EBV BILF1 wt or mutants, or vector 
alone. NFκB-induced firefly luciferase and Renilla luciferase activity were assayed using the 
Luciferase Assay Reagent (Promega, Madison, WI) and Renilla Luciferase Assay System (both 
Promega), respectively, according to the instructions of the manufacturer. Luminescence was 
measured with the LB940 Mithras Research II microplate reader (Berthold Technologies). For 
transfection of primary marmoset fibroblasts, cells were seeded in a 6-well plate at a density 
of 2.5 x 105 per ml, 2 ml/well, 24 h before transfection with lipofectamine 2000 according 
to the manufacturer’s instructions. Cells were transfected with 4 mg DNA and analyzed for 
expression of GFP and surface proteins after 48 h. 
Acknowledgements
We are grateful to Jianmin Zuo and Martin Rowe (School of Cancer Sciences, University 
of Birmingham, UK), Martine Smit and Henry Vischer (Department of Chemistry and 
Pharmaceutical Sciences, VU, Amsterdam, The Netherlands) and Patrick Beisser (Department 
of Medical Microbiology, Maastricht University, The Netherlands) for helpful discussions and 
for generously sharing reagents.
This work was financially supported by the Dutch Cancer Foundation, grant UL 2005-
3259 (BG, EW); the Netherlands Organisation of Scientific Research, Vidi grant 917.76.330 
(MR); and the National Institutes of Health, grant CA068051 (FW).  
160723 Proefschrift.indd   126 24.07.2016   21:50:29


















































Supplementary Figure 1. C-tail point 
mutations fail to abrogate EBV BILF1-
mediated downregulation of surface HLA 
class I. MJS cells were transduced with 
GFP- (control), EBV BILF1/GFP- (BILF1) 
and (A) EBV BILF1-V299A/GFP- or (B) 
EBV BILF1-Y303A/GFP-encoding lentivirus. 
After 7 days, surface expression of FLAG-
BILF1, HLA class I and HLA class II was 
determined by flow cytometry. Transduced 
and untransduced MJS cells were mixed 
before antibody staining to allow comparison 
in a single assay.
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Supplementary Figure 2. EBV BILF1 
does not affect trNGFR levels in U373-
HLA-B8 wt or U373 HLA-B8 short cells. 
U373-HLA-B8 wt and U373-HLA-B8 short 
cells were transduced with GFP-encoding 
(control) or  EBV BILF1/GFP-encoding 
(BILF1) lentivirus. After 7 days, surface 
expression of trNGFR and FLAG-BILF1 was 
measured by flow cytometry.
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Cytoplasmic exposure to foreign DNA or mislocalized self-DNA can trigger secretion of 
type I interferon (IFN). The DNA sensors interferon-inducible protein 16 (IFI16) and cyclic 
GMP-AMP (cGAMP) synthetase (cGAS) recognize intracellular DNA and induce type I IFNs 
via the STING-TBK1-IRF3 axis. DNA sensing is protective as part of an anti-viral immune 
response, but may also be pathological by promoting auto-inflammatory and auto-immune 
diseases. B cells exert multiple functions such as antibody secretion, antigen presentation, and 
pathogen sensing. B cells sense CpG-containing DNA via the endosomal Toll-like receptor 
9, thereby can contribute to anti-viral immune responses, but also to auto-immune diseases. 
We report here that human B cells fail to secrete type I IFN upon cytoplasmic DNA 
exposure, although they possess the DNA sensors cGAS and IFI16 and the signalling 
components TBK1 and IRF3. Primary B lymphocytes and most B cell lines tested appear 
to lack the central adaptor protein STING that activates TBK1 and IRF3. B cells expressing 
STING also did not secrete type I IFNs upon dsDNA or cGAMP stimulation. Our data 
suggest that the cytoplasmic DNA sensing pathway may be dysfunctional in human B cells. 
Unresponsiveness of these cells to cytoplasmic DNA may render B cells attractive targets for 
infection by DNA viruses. 
160723 Proefschrift.indd   134 24.07.2016   21:50:31




Type I interferons (IFNs) play a central role in antiviral immunity as they induce the 
expression of interferon-stimulated genes (ISG) that create an anti-viral state [1]. Most 
cell types are believed to be able to produce the type I IFNs IFN-α and IFN-β [2]. They are 
encoded by 12 IFN-α genes and the IFN-β gene in humans. Type I IFNs are potently induced 
by viral nucleic acids (reviewed in [3,4]). Different RNA and DNA species trigger several 
pattern-recognition receptors (PRRs) resulting in activation of distinct downstream signalling 
cascades, which eventually converge and induce interferon regulatory factor 3 (IRF3)-induced 
transcription of type I IFN genes. The nucleic acid-sensing PRRs are located in endosomes, the 
cytoplasm, and even in the nucleus [3]. Viral RNA triggers Toll-like receptor 3 (TLR3) and the 
retinoic acid-inducible protein 1 (RIG-I)-like receptors, RIG-I and melanoma differentiation-
associated protein 5 (MDA5), present in endosomes and the cytoplasm, respectively [5,6]. 
Foreign dsDNA is sensed by the endosomal TLR9 and several cytoplasmic and nuclear DNA 
sensors including interferon-inducible protein 16 (IFI16) and cyclic GMP-AMP (cGAMP) 
synthetase (cGAS) [7]. TLR9 senses unmethylated CpG DNA and induces the transcription of 
pro-inflammatory cytokines through NF-κB [8]. The cytoplasmic DNA sensor cGAS directly 
binds to the backbone of cytosolic dsDNA in a sequence-independent manner and produces 
the cyclic dinucleotide 2’3’-cGAMP [9,10]. cGAMP acts as a second messenger molecule and 
activates the central adaptor protein STING (stimulator of interferon genes; also known as 
MPYS, MITA, and ERIS) and in turn, TANK-binding kinase 1 (TBK1) and IRF3 are activated 
[11,12,13]. Nuclear and cytoplasmic IFI16-dependent DNA sensing has also been linked to 
type I IFN production via STING activation, but the underlying molecular details remain 
enigmatic at this point [14]. In certain cell types, such as fibroblasts and endothelial cells, 
IFI16 forms an inflammasome upon DNA sensing, which results in caspase-1-dependent IL-
1β maturation [15,16]. 
Activation of nucleic-acid sensing PRRs must be tightly regulated in order to prevent 
recognition of cellular “self ”-nucleic acids. To this end, the RNA sensor RIG-I recognizes 
5’-triphosphates that are present on viral RNA, but absent from cellular mRNA [17]. In 
contrast, cGAS and IFI16 are triggered by dsDNA irrespective of any apparent sequence or 
modification. Therefore, they may be triggered by foreign or self-DNA when present in the 
cytoplasm. The cytoplasm is typically devoid of self-DNA. However, certain genetic defects 
allow cytoplasmic accumulation of self-DNA, thereby triggering an type I IFN response. 
Autoimmune diseases like systemic lupus erythematosus (SLE) exhibit an IFN signature, 
which has been suggested to involve activation of the cytoplasmic and endosomal DNA 
sensing pathways by accumulating and mislocated self-DNA (reviewed in [18,19]). Mouse 
models with genetic defects in DNase function are used to study auto-inflammatory diseases. 
The lethality observed in both DNase II-/- and Trex1-/- (DNase III) mice is abrogated by 
STING- or cGAS-deficiency [20,21,22,23]. Moreover, DNase II-/-cGAS-/- and Trex1-/-cGAS-/- 
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did not develop polyarthritis and showed limited induction of auto-antibodies, respectively, 
suggesting that DNA-driven inflammation may cause auto-immunity [20]. B cells secreting 
anti-nuclear auto-antibodies contribute to the pathology of SLE and other auto-immune 
diseases. B cell-receptor-dependent uptake of immune complexes has been implicated in 
TLR9-dependent DNA sensing and subsequent expansion of autoreactive murine B cells 
[24,25]. DNA sensing by B cells may not only have pathological effects, but might also be 
protective in anti-viral immunity. 
Herpesviruses are enveloped viruses with a DNA genome that establish latent infection in 
their hosts. Human B cells are target for infection with the human herpesvirus Epstein-Barr 
virus (EBV) and Kaposi’s sarcoma-associated herpesvirus (KSHV). EBV establishes latent 
infection in human B cells. Human B cells sense the genome of the herpesvirus EBV by TLR9, 
which initiates immune activation [26]. Interestingly, EBV infection has been postulated to 
be a trigger for SLE [27], but it remains mechanistically unclear how EBV infection could 
contribute to development of this auto-immune disease. IFI16 can be triggered by nuclear 
EBV or KSHV genomes resulting in inflammasome-mediated IL-1β maturation in B cells 
[28,29], but whether stimulation of IFI16 could also lead to type I IFN induction was not 
tested. It is currently unknown whether the dsDNA genome of EBV triggers the cytoplasmic 
DNA sensing pathway resulting in type I IFNs secretion. Human herpesviruses including 
herpes simplex virus-1 (HSV-1) and KSHV, but also the reverse-transcribed human 
immunodeficiency virus (HIV) genome and stem-loop structures of single-stranded HIV 
DNA are known to trigger the cytoplasmic DNA sensing pathway [30,31,32,33].
Given the central role of DNA recognition in immune responses to DNA viruses and 
auto-inflammatory diseases, we investigated whether human B cells produce type I IFNs 
upon exposure to cytoplasmic DNA. 
Results
The B-LCL JY does not produce type I IFNs in response to cytoplasmic dsDNA 
To investigate whether human B cells secrete type I IFNs upon cytoplasmic DNA 
exposure, we used both primary B lymphocytes and various B cell lines, as summarized in 
Table 1 (s. Material and Methods). In all our experiments, PMA-activated THP1 cells served 
as a control, since these cells efficiently respond to cytoplasmic DNA exposure. To introduce 
DNA into the cytoplasm of cells we transfected cells with dsDNA. Fluorescein (FAM)-labeled 
dsDNA allowed monitoring of DNA-uptake efficiencies by flow cytometry (Figure 1A). The 
control cell line THP1 was efficiently transfected (>90%). Exposure to labeled DNA in the 
absence of transfection reagent also resulted in labeling of THP1 cells (26%) (Figure 1A, 
left panel). Transfection reagent-independent increase in fluorescence likely reflected cellular 
uptake or binding of labeled dsDNA to the cells. We examined the EBV-positive human 
B-lymphoblastoid cell line (B-LCL) JY, a commonly used B cell line first. In JY cells similar 
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uptake efficiencies were reached as in THP1 cells allowing assessment of type I IFNs secretion 
by cytoplasmic DNA (Figure 1A, right panel). Transfection reagent-independent uptake or 
binding of labeled dsDNA was low (8%) in JY cells.
Next, we transfected unconjugated dsDNA to trigger the cytosolic DNA sensing pathway 
in JY and THP1 cells and assessed type I IFNs secretion. In contrast to THP1 cells, JY cells did 
not secrete type I IFNs upon cytoplasmic DNA exposure (Figure 1B). As a control for type I 
IFN secretion, we transfected the RNA analogue poly(I:C). JY and THP1 cells secreted type 
I IFNs upon cytoplasmic RNA stimulation (Figure 1B). Exposure to dsDNA in the absence 
of transfection reagent did not trigger a type I IFN response in THP1 cells (data not shown) 
consistent with the DNA being unable to reach the cytoplasm, in contrast to transfected 
dsDNA. JY cells appeared able to produce and secrete type I IFNs upon cytoplasmic RNA 
exposure, but not after DNA stimulation. 
To examine transcription of the IFN-β gene in JY cells, we determined levels of IFN-β1 
transcripts at 6h and 24h after dsDNA or poly(I:C) transfection by quantitative real-time PCR 
(Figure 1C). There was no increase in IFN-β1 transcripts detected after dsDNA stimulation 
in JY cells. In response to poly(I:C), a low induction of IFN-β1 mRNA levels was detected 
in JY after 6h, but a robust increase at 24h post-transfection (Figure 1C). Upon dsDNA and 
poly(I:C) stimulation, THP1 cells exhibited very high levels of IFN-β1 mRNA at 6h and at 
lower levels at 24h. Following the pattern of IFN-β1 induction, transcription of IFN-stimulated 
gene (ISG)54 was observed to both stimuli in THP1 cells, but only in response to poly(I:C) in 
JY cells (Figure 1D). To test whether dsDNA stimulation resulted in gene expression of pro-
inflammatory cytokines in JY and THP1 cells, we examined TNFα transcripts at 6h (Figure 
1E) and 24h (data not shown). There was no increase detected in JY cells, and also THP1 
showed only a very moderate and transient induction of TNFα mRNA to both nucleic acid 
stimuli at 6h (Figure 1E), which was absent at 24h (data not shown). 
These data show that the human B-LCL JY did not produce and secrete type I IFN or 
the pro-inflammatory cytokine TNFα upon cytoplasmic DNA exposure. Poly(I:C) induced 
production of IFN-β1mRNA and secretion of type I IFNs in JY cells, which in turn stimulated 
induction of ISG54. This demonstrates that whereas the type I IFN pathway is functional in 
this B cell line, it is not activated upon cytoplasmic dsDNA stimulation.
EBV-negative B cells do not secrete type I IFN upon cytoplasmic DNA 
stimulation
To assess if EBV-negative B cells, in contrast to EBV-positive JY cells, produce type I IFNs 
in response to cytosolic dsDNA exposure, two non-EBV immortalized B cell clones were 
transfected with dsDNA. The determined transfection efficiency of about 50% may be an 
underestimation (Figure 2A, one clone depicted) due to the GFP marker present in these 
cells. The B cell clones did not respond to dsDNA or poly(I:C) by type I IFN secretion (Figure 
2B, one clone depicted) suggesting that the B cell clones were unresponsive to intracellular 
nucleic acid exposure. 












































































































































































Figure 1 The human B-LCL JY fails to produce type I IFNs in response to dsDNA stimulation. A) 
Efficiencies of dsDNA transfection in the B-LCL JY and PMA-differentiated THP1 cells were determined 
by lipofectamine2000 transfection of FAM-labeled dsDNA. As controls, cells were either treated with 
the transfection reagent or FAM-labeled dsDNA alone. After overnight incubation, cells were analysed 
by flow cytometry. B) The B-LCL JY and PMA-differentiated THP1 cells were transfected with dsDNA 
or poly(I:C) using Lipofectamine2000. Cell-free supernatants were harvested 24h post-transfection and 
analysed for IFN-α/β in duplicates using a bioassay. One representative of four independent experiments 
is shown. Data are presented as mean ± SD. C-E) The B-LCL JY and PMA-differentiated THP1 cells were 
transfected as in B). RNA was isolated 6h or 24h post-transfection and analysed for mRNA levels of C) 
IFN-β, D) ISG54, E) TNFα by quantitative real-time PCR. Data are means (± SD) of normalized ratios 
relative to control sample, using β-actin as internal reference. One representative of two independent 
experiments is shown. 
Figure 2 Human B cells do not secrete type I IFN upon exposure to cytoplasmic DNA. A) To determine 
transfection efficiencies, an immortalized B cell clone was transfected with FAM-labeled DNA or as a 
control treated with FAM-labeled dsDNA alone or left untreated. B) IFN-α/β secretion from tetanus- 
or influenza-specific immortalized B cell clones and PMA-differentiated THP1 cells transfected with 
dsDNA or poly(I:C) were determined by bioassay. Cell-free supernatants were harvested 24h post-
transfection and analysed for IFN-α/β in duplicates. One representative of two independent experiments 
is shown for the influenza-specific clone. C) PBMC-derived CD19+ or CD19- cells were treated as in 
A). Control cells were treated with lipofectamine2000 alone. D) PBMC-derived CD19+, CD19- cells, 
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and PMA-differentiated THP1 cells were treated as in B). Supernatants were harvested 15 h post-
transfection. One representative of two independent experiments is shown. E and F) An EBV-negative 
B cell clone (E) or CD19+ and CD19- PBMCs (F) were stimulated with CpG DNA or transfected with 
dsDNA or poly(I:C) (as in B) and cell surface levels of CD86 were determined by flow cytometry 24 h 
post-stimulation and compared to non-stimulated control cells, which were left untreated (CpG) or 
treated with lipofectamine alone (dsDNA and poly(I:C)). Data are depicted as histograms.
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To test whether unresponsiveness to cytoplasmic DNA was a general feature of human 
B lymphocytes, we expanded our study to primary B cells. Transfection of dsDNA was 
successful in 55% of the primary CD19+ B lymphocytes and in 30% of the CD19- PBMCs 
serving as control (Figure 2C). The CD19+ B cells did not secrete type I IFN upon triggering 
with cytoplasmic DNA or RNA (Figure 2D). CD19- mononuclear cells showed only a slight 
response to dsDNA, but not to poly(I:C) stimulation (Figure 2D). The CD19- fraction 
contained about 50% CD3+ cells, 9% CD16+ cells, 4% CD14+ cells and 35% of the cells were 
negative for these three surface markers as well as for CD19. Type I IFN secretion upon dsDNA 
stimulation was likely derived from monocytes, although the percentage of monocytes was 
low in the CD19- cell fraction. It is unclear why the cells did not secrete type I IFN after 
exposure to cytoplasmic poly(I:C). By speculation, dsDNA might induce higher levels of type 
I IFN upon cytoplasmic exposure in comparison to poly(I:C) in monocytes, as observed for 
THP1 cells. In these experiments the DNA-induced type I IFN levels were low, hence it could 
be that poly(I:C)-induced levels were not detectable. 
We tested whether the primary B lymphocytes and the B cell clones were responsive to 
another nucleic acid stimulus indicating that the cells were viable at the time point of treatment. 
To this end, we stimulated the endosomal TLR9 present in B cells with the agonist CpG DNA 
(ODN 2006). CpG-mediated TLR9 stimulation of PBMC-derived B cells is known to result 
in upregulation of the activation marker CD86 [40]. The B cell clone tested expressed high 
cell surface levels CD86 prior to stimulation. A minute increase in the CD86 surface levels 
was observed upon stimulation with CpG DNA (MFI 15282 (unstimulated) vs 19915 (CpG)), 
but not with transfected dsDNA or poly(I:C) (Figure 2E). Stimulation with CpG DNA, but 
not transfection of the other two stimuli, resulted in upregulation of the activation marker 
CD86 in PBMC-derived CD19+ cells (Figure 2F, left panel). The CD19- fraction showed no 
increase in surface levels of CD86 upon nucleic acid stimulation (Figure 2F, right panel). 
The primary CD19+ and CD19- cells displayed sensitivity towards the cytotoxic transfection 
reagent, as a lower percentage of cells (around 25% for both CD19+ and CD19-) was present 
in the “live gate” in comparison to untreated or CpG-treated cells (about 80% for CD19+ and 
50% for CD19-). This demonstrates that the primary B cells were responsive to endosomal 
DNA exposure suggesting that they were viable at the point of treatment.
In conclusion, primary human B lymphocytes and EBV-negative B cell clones did not 
secrete type I IFNs upon exposure to cytoplasmic DNA, while primary CD19- cells responded 
to transfected DNA.
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Absence of STING protein in primary B cells and B cell lines, but not in B-LCL 
lines
To determine why human B cells did not respond to dsDNA stimulation, we examined the 
B cells for the following proteins of the cytoplasmic DNA sensing pathway: the DNA sensors 
cGAS and IFI16, the adaptor protein STING, and the downstream signalling molecules TBK1 
and IRF3 (Figure 3A). PMA-differentiated THP1 cells having all these proteins served as a 
control (Figure 3B-E). 
Although the transformed B-LCL JY did not respond to dsDNA stimulation, these 
cells produced cGAS, IFI16, STING, TBK1, and IRF3 (Figure 3B, lane 1). The B cell clones 
were grown in the presence of the CD40L-expressing murine feeder cell line. To exclude 
contamination of the B cell sample with feeder cells, this cell line was tested for cross-reactivity 
of the antibodies used. In feeder cells, we detected only a clear signal for TBK1, but not for 
the other proteins tested (lane 2). Therefore, we concluded that proteins detected in the B 
cell clones were not due to contamination with murine feeder cells. Both B cell clones had 
cGAS, IFI16, TBK1, and IRF3, but lacked the adaptor protein STING (lane 3 and 4). The EBV-
negative cell line 2A8 (lane6) showed the same pattern as the B cell clones, whereas THP1 
cells produced all proteins examined (lane 5). 
To examine whether transformed B cells were representative for primary B cells, we probed 
for the proteins involved in the cytoplasmic DNA sensing pathway in primary PBMC-derived 
CD19+ B cells (Figure 3C). In addition, we examined CD19- cells and total PBMCs. THP1 
cells served as positive control. CD19+ B cells from two donors possessed the DNA sensors 
cGAS and IFI16, and the signalling molecules TBK1 and IRF3, but lacked STING (lane 2 and 
3). In the CD19- cells and total PBMCs cGAS, STING, TBK1, and IRF3 were detected, but 
IFI16 levels appeared to be low (lane 4, 5, and 6). 
As an alternative source of primary human B cells, tonsillar CD19+ B cells were examined 
for the proteins of the cytoplasmic DNA pathway and compared to tonsil-derived CD19- cells 
(Figure 3D). In CD19+ cells, the DNA sensors, and the signalling intermediates TBK1 and 
IRF3 were detected, but STING protein was not (lane 2), while CD19- tonsillar cells had all 
proteins examined (lane 3). Thus, CD19+ cells exhibited the same pattern as observed for 
blood-derived CD19+ cells, respectively. 
As JY cells were the only human B cells that appeared to have STING, we tested another 
B-LCL, MRJ, and compared it to JY and THP1 cells. MRJ displayed the same profile of proteins 
of the DNA sensing pathway as JY cells (Figure 3E, lane 3), and also these cells appeared to be 
unresponsive to dsDNA stimulation (data not shown).
In conclusion, human B lymphocytes appear to produce the cytoplasmic DNA sensors 
cGAS and IFI16 and the molecules TBK1 and IRF3. Whereas the EBV-positive B-LCLs JY 
and MRJ exhibited substantial levels of STING, this protein was undetectable in other human 
B cells tested. Absence of STING would provide an explanation why the EBV-negative blood-
derived CD19+ B cells and the B cell clones did not secrete type I IFN upon exposure to 
cytoplasmic dsDNA. 
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STING-expressing cells do not produce type I IFNs upon dsDNA or cGAMP 
stimulation
Despite presence of STING and the other proteins in the B-LCLs JY and MRJ, the 
cells were unresponsive to dsDNA stimulation. To get an indication whether the STING-
TBK1-IRF3 pathway could be activated in B-LCLs, we bypassed the DNA sensing step by 
stimulating digitonin-permeabilized JY cells with the mammalian STING-activating molecule 
2’3’-cGAMP. There was no type I IFN secreted from cGAMP-stimulated JY cells at 6h post-
stimulation, while THP1 cells produced type I IFNs in the presence, but not in the absence of 
cGAMP (Figure 4A). This indicates that the STING pathway was not activated by cGAMP in 
JY cells. Sequence analysis revealed that JY cells had the same variant of STING as THP1 cells 
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Figure 3 Most human B cells are deficient for STING protein. A) Schematic overview of proteins 
involved in the cytoplasmic DNA sensing pathway. B-E) Whole cell lysates were analysed for the 
presence of cGAS, IFI16, STING, TBK1, and IRF3 by Western blot analysis. Vinculin served as loading 
control. Dashed line indicate position of removed marker lanes. B) Tetanus (Tet)- and influenza (Flu)-
specific immortalized B cell clones as well as the cell lines JY, 2A8, and PMA-differentiated THP1 cells 
were analysed. B cell clones were grown in the presence of murine feeder cells, but the feeder cells did 
not appear to account for proteins detected in B cell clone lysates. C) CD19+ and CD19- PBMCs of two 
independent donors, total PBMCs of one donor and PMA-differentiated THP1 cells were analysed. D) 
Tonsillar CD19+ and CD19- cells of one donor as well as the cell line 2A8, and PMA-differentiated THP1 
cells were analysed for indicated proteins. E) The B-LCL cell lines JY and MRJ, and PMA-differentiated 
THP1 cells were analysed by Western blot analysis. 
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To exclude potential inhibitory effects of EBV proteins, we turned to an EBV-negative 
human B cell line. As the EBV-negative B cell line 2A8 had the DNA sensors and the signalling 
component TBK1 and IRF3, but lacked STING, we assessed if reconstitution of STING 
induces a type I IFN response upon dsDNA stimulation. We stably introduced C-terminally 
HA-tagged murine STING in the EBV-negative cell line 2A8 that endogenously produced 
the sensors cGAS and IFI16, and the signalling molecules TBK1 and IRF3 (Figure 3B, lane 
6 and Figure 3D, lane 4). Murine STING is able to reconstitute human cells lacking STING 
to respond to cyclic dinucleotides [41]. Two 2A8 cell lines were generated using different 
amounts of STING-coding lentivirus. The lentiviral vector also encoded GFP, which we used 
as a marker to FACS-sort transduced cells. Pure populations of GFP+ 2A8-mSTING cells were 
used to examine presence of STING-HA by Western blot analysis (Figure 4B). The cell lines 
JY and THP1 displayed high levels of STING detected by a STING-specific antibody, whereas 
in the untransduced 2A8 cell line no signal was detected (Figure 4B). The 2A8-mSTING cells 
showed a weak signal using the STING-specific antibody, which binds human and murine 
STING. The 2A8 cell line transduced with a higher dose of lentivirus showed increased levels 
of STING in comparison to the other transduced cell line. Using an HA-reactive antibody 
allowed clear detection of HA-tagged STING in 2A8-mSTING lines (Figure 4B, lane 2 and 
3). The bands detected with the HA-reactive antibody migrated at the same height as the weak 
STING antibody-reactive bands suggesting that these bands represented HA-tagged STING 
protein. 
In a next step, we tested the transfection efficiency of 2A8 and 2A8-mSTING cells using 
the FAM-labeled dsDNA. Upon transfection, 40% of the 2A8 cells were labeled indicating 
successful uptake of the DNA (Figure 4C), while the GFP+ 2A8-mSTING cells showed a 
transfection efficiency of around 20%, which may be an underestimation due to presence of 
GFP. 
Upon transfection of poly(I:C) or dsDNA, neither the parental 2A8 cells, nor the 2A8-
mSTING cells secreted type I IFNs, in contrast to control THP1 cells (Figure 4D). To assess 
whether 2A8 cells were responsive to another nucleic acid stimulus indicating that the cells 
were viable at the time point of treatment, we stimulated the 2A8-mSTING cells with CpG 
DNA. Prior to stimulation, the cells expressed high surface levels of CD86, but the levels 
slightly increased upon stimulation with CpG DNA suggesting that the cells were viable 
(Figure 4E). 
To examine whether the STING-TBK1-IRF3 pathway could be activated in the EBV-
negative 2A8-mSTING cell line, we stimulated these cells with cGAMP. Irrespective of STING 
expression, none of the 2A8 cell lines did secrete type I IFNs upon cGAMP stimulation, 
while THP1 cells produced type I IFNs (Figure 4F). Although direct evidence is missing 
at this point that mSTING introduced in 2A8 cells was functional and present at adequate 
levels, these data indicate that exogenous or endogenous STING expression was not sufficient 
for EBV-positive or -negative B cell lines to sense the second messenger molecule cGAMP. 
This may suggest that human B cells are unresponsive to dsDNA or cGAMP stimulation, 
irrespective of the presence or absence of EBV proteins. 
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Figure 4 STING-expressing B cells fail to respond to cytoplasmic nucleic acids and cGAMP. A) JY 
and PMA-differentiated THP1 cells were stimulated with cGAMP using a buffer containing digitonin. 
Supernatants were harvested at 6 h post-stimulation. Data are mean ± SD of one representative out of 
three independent experiments. B) The cytoplasmic fraction of 2A8, mSTING-HA/GFP-transduced 
2A8 (2A8-mSTING), JY, and PMA-differentiated THP1 cells was analysed for STING and HA-tag 
expression by Western blot analysis. C) Transfection efficiency of dsDNA into 2A8 and 2A8-mSTING 
cells was determined by lipofectamine2000 transfection of FAM-labeled dsDNA. As a control, cells were 
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Type I IFN priming prior to dsDNA stimulation does not give rise to type I IFNs 
secretion in B-LCLs
Lastly, we examined whether the B-LCL JY respond to dsDNA when in a primed state. Type 
I IFNs induce expression of many ISGs via the JAK-STAT pathway, which acts downstream 
of the type I IFN receptor [1]. Upregulation of ISGs including PRRs such as RIG-I, MDA5, 
TLR3, cGAS, IFI16 and other signalling proteins limits viral replication [42,43]. Hence, type 
I IFN primes cells to detect and/or respond to PAMPs more vigorously. For example, human 
type I IFN-primed macrophages show enhanced responses to TLR stimuli in comparison 
to unprimed cells [44]. Therefore, we hypothesized that type I IFN-stimulated B cells might 
become responsive to dsDNA. 
To this end, we pre-stimulated JY and THP1 cells with IFN-β for 24h prior to transfection 
with dsDNA or poly(I:C). Pre-stimulation of JY cells with IFN-β did not give rise to a dsDNA-
left untreated or treated with dsDNA-FAM alone. Cells were analysed by flow cytometry after overnight 
incubation. D) 2A8, 2A8-mSTING, and PMA-differentiated THP1 cells were transfected with dsDNA 
or poly(I:C) using Lipofectamine2000. Cell-free supernatants were harvested at 24 h post-transfection 
and analysed for bioactive IFN-α/β in duplicates. E) 2A8-mSTING cells were stimulated with CpG DNA 
or transfected with dsDNA or poly(I:C) (as in D) and cell surface levels of CD86 were determined 
by flow cytometry 24 h post-stimulation and compared to non-stimulated control cells, which were 
left untreated (CpG) or treated with lipofectamine alone (dsDNA and poly(I:C)). Data are depicted as 
histograms. F) 2A8, 2A8-mSTING, and PMA-differentiated THP1 cells were stimulated with cGAMP 
using a buffer containing digitonin. Cell-free supernatants were harvested at 3,5 h post-stimulation and 





















































































Figure 5 IFN-β priming does not rescue responsiveness to cytoplasmic DNA exposure of the B-LCL 
JY. A and B) JY (black bars) and PMA-activated THP1 cells (grey bars) were pre-stimulated with 1000 
U/ml IFN-β for 24 h. Cells were then transfected with dsDNA or poly(I:C) using Lipofectamine2000. A) 
Cell-free supernatants were harvested at 24 h post-transfection and analysed for IFN-α/β in duplicates. 
Data are mean ± SD of one representative out of two independent experiments. A dashed line indicates 
maximum cut-off of assay. B) Cells were harvested, RNA isolated, and mRNA levels of IFN-β determined 
at 6 h post-transfection by quantitative real time-PCR. Data are means (± SD) of normalized ratios 
relative to control sample, using β-actin as internal reference. Representative data of three independent 
experiments are shown.
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induced type I IFN response (Figure 5A, left panel). In contrast, enhanced IFN I levels were 
detected in IFN-β-primed THP1 cells upon dsDNA stimulation in comparison to unprimed 
cells (Figure 5A, right panel). Secretion of type I IFN following poly(I:C) stimulation was not 
altered by pre-stimulation with IFN-β in either of the cell lines (Figure 5B). In THP1 cells, 
IFN-β transcription appeared to be slightly increased in response to nucleic acids upon IFN 
pre-stimulation, but type I IFN treatment alone also elevated transcription (Figure 5B). 
These data suggest that type I IFN-priming of the B-LCL JY did not enhance responsiveness 
to dsDNA. Overall, our data indicate that human B cells are unable to evoke type I IFN 
production in response to foreign dsDNA, and that this this is correlated with the absence of 
the adaptor protein STING in most of these cells. Curiously, despite the presence of STING, B 
cells appear to have a dysfunctional cytosolic DNA sensing pathway. 
Discussion
In this study, we report that human B cells fail to secrete type I IFNs upon exposure 
to cytosolic dsDNA, although they produce the DNA sensors cGAS and IFI16. The EBV-
negative B cell lines and primary B cells tested lacks the central adaptor protein STING that 
is required for signal transduction downstream of the cytosolic DNA sensors. B cell lines 
expressing STING did not secrete type I IFNs upon dsDNA or cGAMP stimulation. 
Cytosolic DNA sensing plays a crucial role in host immune defense against invading DNA 
viruses as demonstrated by lethality in STING-knockout mice infected with HSV-1 [30]. 
The STING protein was originally identified in murine B cell lines as a molecule involved in 
apoptosis [45], but shortly thereafter, it was recognized as the central signalling hub for DNA 
sensing [11,12,13]. Murine B cell lines representing pre-B cells, immature, memory and plasma 
B cells were used to examine presence of STING [45]. Except for the plasma B cell line, STING 
was present in the different murine B cell lines, with the highest levels found in mature B cells. 
We examined human B lymphocytes, but only detected high levels of STING in B-LCLs, but 
not in other B cells. Thus, STING is present in murine, but not in most human B cells. This is 
interesting as murine and human STING exhibit a different activation profile in response to 
cyclic dinucleotides. Murine STING is potently triggered by bacterial 3’5’- and mammalian 
2’3’-linked cyclic dinucleotides, while human STING is mainly activated by the mammalian 
2’3’-cGAMP [41]. Hence, murine STING responds to a broader spectrum of ligands, which 
most likely dictates the role of this protein in innate immune activation. Therefore, one could 
speculate that a distinct expression profile in (immune) cells is evolutionarily favored due to 
differential sensitivity towards cyclic dinucleotide ligands. 
Signaling via STING plays a central role in type I IFN induction following the recognition 
of the DNA virus, such as HSV-1 or KSHV [30,31]. Therefore, the absence of STING from 
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human B cells may render these cells more permissive for infection with the herpesviruses 
KSHV or EBV. Yet, human B cells are not devoid of functional DNA sensing. We have 
reported earlier that EBV genome activates the DNA sensor TLR9 in endosomes [26]. 
Moreover, IFI16 senses nuclear EBV and KSHV genomes resulting in subsequent formation 
of an IFI16 inflammasome and IL-1β maturation in B cells [28,29]. Thus, human B cells are 
likely to sense invading DNA viruses and initiate innate immune responses, yet they appear 
to fail to induce a type I IFN response upon cytoplasmic DNA exposure. It seems that STING 
may be expressed in human B cells under certain conditions suggested by high levels of the 
adaptor protein in the EBV-transformed B-LCLs. Since nine EBV latency proteins are present 
in B-LCLs, it remains to be determined whether they contribute to STING expression and/or 
type I IFN production. 
Interestingly, B-LCLs or the 2A8-mSTING cell line were unable to mount a type I 
IFN response upon stimulation with dsDNA, despite presence of the proteins comprising 
the cytosolic DNA sensing pathway including STING. The B cell line JY has STING levels 
comparable to those observed in THP1 cells. JY cells carried the same STING variant as 
THP1 cells (data not shown), thus mutations interfering with its function could be excluded. 
Introduction of murine STING into the EBV-negative cell line 2A8 did not render these 
cells responsive to dsDNA or cGAMP stimulation, although murine STING can reconstitute 
human cells lacking STING [41]. Although we formally lack evidence that the construct 
coding for murine STING could functionally reconstitute STING in STING-deficient cells, 
our data imply that the cytoplasmic DNA sensing pathway is not functional in human B 
lymphocytes. A similar phenomenon has been reported for activated human T lymphocytes 
[38]. The T cells appeared to sense cytoplasmic DNA supporting formation of the STING 
signalosome including TBK1 recruitment, but still these cells failed to mount a type I IFN 
response [38]. In our study, we triggered STING-expressing B cells with the second messenger 
molecule cGAMP, which did not result in activation of the STING pathway and secretion of 
type I IFNs. This suggests that signal transduction was abrogated downstream of the STING 
protein, similar to the observations for T cells. We demonstrate that the B-LCLs responded to 
transfected poly(I:C), which is sensed by the cytosolic RNA sensors MDA5 and RIG-I. They 
signal via the adaptor protein MAVS that, in turn, recruits TBK1 and IRF3 suggesting that 
signalling involving the proteins TBK1 and IRF3 was supported, at least, in the B-LCLs. This 
implies, therefore, that STING failed to activate TBK1 and IRF3 in the B-LCLs.
It is unclear why poly(I:C) stimulation of the other B cells examined failed to induce 
production of type I IFNs. The signalling intermediates TBK1 and IRF3 are employed by the 
DNA and RNA sensing pathways. Western blot analysis (Figure 3) showed that primary B 
cells and the B cell clones had similar or even higher levels of the signalling molecules TBK1 
and IRF3 in comparison to JY or THP1 cells. The latter two were responsive to poly(I:C). 
This suggests that all B lymphocytes examined were equipped with the molecules acting 
downstream of the adaptor proteins of the cytoplasmic nucleic acid sensors, but yet did not 
160723 Proefschrift.indd   147 24.07.2016   21:50:33
Chapter 5
148
respond. It remains to be determined whether human B cells have the cytoplasmic RNA 
sensors RIG-I and MDA5, as well as the adaptor protein MAVS. 
Although B cells appear to have a dysfunctional cytosolic DNA sensing pathway, the 
DNA sensor cGAS might still contribute to induction of innate immune responses against 
B-lymphotropic viruses such as KSHV or EBV. Recently, two independent groups found that 
viral particles can transfer the second messenger molecule cGAMP to other cells [46,47]. 
cGAMP was found in virions of HIV, murine cytomegalovirus, and modified vaccinia virus 
Ankara suggesting that 1) these viruses trigger the DNA sensing pathway and 2) members of 
several viral families including herpesviruses, facilitate packaging of this cyclic dinucleotide 
into the virion. This viral particle-dependent cGAMP transfer triggered a type I IFN response 
in several cell types including the cell line THP1 and DCs derived from primary human 
monocytes [46,47]. Therefore, it would be interesting to examine whether virions of e.g. EBV 
or KSHV propagated in B lymphocytes contain cGAMP and whether this could stimulate 
other cell types infected by these viruses. Hence, triggering of cGAS in B cells could result in 
cGAMP production and packaging, and subsequent transfer to other cells by released virions. 
This may allow stimulation of STING prior to sensing of viral DNA released from the capsid. 
Identification of several KSHV proteins, including the KSHV-specific K9/vIRF1 protein, 
interfering with the cGAS-STING pathway [31] argues that this pathway is involved in 
sensing of KSHV. The KSHV protein LANA inhibits cGAS and also the tegument protein 
ORF52 prevents cGAS-mediated cGAMP production in vitro and in infected cells [48,49]. 
The EBV homologue of ORF52, BLRF2, also prevented cGAMP formation in an in vitro assay, 
but whether the EBV protein EBNA1, the functional homologue of LANA, interferes with 
cGAS remains to be determined. Identification of viral proteins inhibiting cGAS function 
indicates that cGAS plays a role in detection of these viruses. As the cytoplasmic DNA sensing 
pathway appears to be dysfunctional in human B cells, it seems that viral inhibition of cGAS 
is not necessary in B cells, but required for infection of other cell types. For instance, KSHV 
infection of endothelial cells triggers activation of the cytosolic DNA sensing pathway [31].
Type I IFN stimulation of murine B cells was shown to augment B cell-receptor-dependent 
responses [50]. In human B cells, type I IFN enhances CpG-stimulated IgM production 
[51]. Hence, exposure of B cells to type I IFN appears to promote B cell functions such as 
antibody production that contribute to pathology of auto-immune diseases. Given the 
unresponsiveness of T and B cells to cytosolic DNA stimulation, it is tempting to speculate 
that lymphocytes might possess a safeguard mechanism that prevents them from triggering 
a type I IFN response upon exposure to intracellular DNA. Such a mechanism may present 
as a lymphocyte-specific inhibitor hampering activation or as an inducible, yet-unknown, 
factor facilitating signalling. In an attempt to unleash the cGAS-STING pathway in STING-
expressing B cells, we pre-stimulated the cells with IFN-β prior to introduction of dsDNA. 
However, this did not result in induction or secretion of type I IFN in the B cells. Therefore, 
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further studies are needed to identify the underlying mechanism of frustrated type I IFN 
induction observed in T and B lymphocytes upon introduction of cytoplasmic DNA. Possibly, 
corroboration of such a mechanism may contribute to the development of autoimmunity or 
other inflammatory conditions upon DNA sensing of self-DNA. 
Material and Methods
Isolation of primary human B cells
Human peripheral blood mononuclear cells (PBMCs) were isolated by Ficoll density 
gradient centrifugation from buffy coats of healthy blood donors provided by Sanquin blood 
bank Amsterdam. Isolated PBMCs contained about 55% CD3+, 15% CD19+, 12% CD16+, 7% 
CD14+ cells and 11% of the isolated cells were negative for all these markers. The antibodies used 
for this analysis were the following: AlexaFluor700-conjugated anti-CD3 (BD Pharmingen, 
UCHT1), PE-conjugated anti-CD19 (BD Pharmingen, HIB19), FITC-conjugated anti-CD16 
(BD Pharmingen, 3G8), and PE-Cy7-conjugated anti-CD14 (BD Pharmingen, M5E2).
Anonymized tonsil material was obtained from tonsillectomies. Tonsils were cut in 
small pieces and passed through a cell strainer. B cells from PBMCs and dispersed tonsils 
were positively isolated using anti-human CD19-coupled magnetic beads according to 
manufacturer’s protocol (Invitrogen). The CD19- fraction left after B cell isolation was used as 
a control. Purity of isolated cells was determined by flow cytometry. For this, cells were stained 
using PE-conjugated anti-CD19 (BD Pharmingen, HIB19) and AlexaFluor700-conjugated 
anti-CD20 (Biolegends, 2H7) antibodies. In each experiment, purity of CD19+ B cells was 95-
99%, while CD19- cells contained less than 0,4% CD19+ cells. Freshly isolated cells were used 
for experiments. Cells were resuspended in IMDM supplemented with 10% heat-inactivated 
FCS, 2 mM glutamax, 100 U/ml penicillin and 100 mg/ml streptomycin. 
Cell lines
In this study, several transformed human B cell lines were included permitting long-term 
culture. The B cell lines were transformed either by EBV in vitro (i.e. B-lymphoblastoid cell 
lines (B-LCLs)) or in vivo (i.e. Burkitt’s lymphoma-derived lines), or, alternatively, by B cell 
lymphoma protein 6 (BcL-6) and –xL transformation [34]. EBV-negative B cells originally 
isolated from BL-derived cell lines [35], were also included. An overview of all B lymphocytes 
used in this study is given Table 1.
The EBV-negative, antigen-specific B cell clones immortalized by introduction of Bcl-
6 and Bcl-xL were cultured on murine CD40L-expressing feeder cells in the presence of 
recombinant mouse IL-21 as described elsewhere [34]. Prior to use in experiments, cells were 
carefully removed from the murine feeder cells and taken up in IMDM containing 10% heat-
inactivated FCS, 100 U/ml penicillin, and 100 µg/ml streptomycin. 
The EBV-positive B-LCLs JY and MRJ, the BL-derived EBV-negative cell line 2A8, and 
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the monocytic THP1 cells were cultured in RPMI medium supplemented with 10% heat-
inactivated FCS, 100 U/ml penicillin, and 100 µg/ml streptomycin. Prior to use in experiments, 
THP1 cells were differentiated into macrophage-like cells by treatment with 150 nM phorbol 
myristate acetate (PMA, Sigma-Aldrich) for 48h.
Table 1 B cells used in this study
Cells Source Immortalization EBV status References
Primary CD19+ B cells Tonsil no unknown
Primary CD19+ B cells PBMC no unknown
B cell clone (tet or flu) PBMC Yes, Bcl-6, Bcl-xL - [34]
B-LCL (JY or MRJ) PBMC Yes, EBV (in vitro) + [36,37]
2A8 BL Yes, EBV (in vivo) -  [35]
Replication-deficient lentivirus and transduction
Third generation SIN lentiviruses were generated in 293T cells transfected with the 
lentivirus plasmid encoding mSTING-HA-IRES-GFP driven by a PGK promoter and the 
vectors pCMV-VSV-G, pMDLg-RRE, and pRSV-REV to provide the helper functions. 2A8 
cells were exposed to with lentivirus-containing supernatant to transfer the genes encoding 
murine STING and the GFP marker. To enhance transduction efficiency, cells were spin 
inoculated (1000xg, 33° C, 2h) in the presence of 4 ug/ml polybrene. GFP+ 2A8 cells were 
FACS-sorted. A pure GFP+ population of cells was propagated and used for experiments.
Reagents
For stimulation of the cytoplasmic DNA pathway, we used dsDNA (HSV60mer is derived 
from the HSV-1 genome (nucleotides 144,107-144,166 [38]), or 2’,3’-cGAMP (Sigma-
Aldrich). Unconjugated or fluorescein (FAM)-labeled DNA oligos were mixed and annealed 
in annealing buffer (10 mM Tris (pH 7.5), 50 mM NaCl, 1 mM EDTA) by heating at 95° 
C for 5 min, followed by a slow cool-down. Annealed oligos were kept at 4° C until used. 
For stimulation of TLR9, 10 µg/ml CpG DNA (ODN 2006, Invivogen) was added to culture 
medium and incubated with cells for 24h. The cytoplasmic RNA pathway was triggered by 
polyinosinic-polycytidylic acid (poly(I:C), Invivogen). Where indicated, cells were treated 
with 1000 U/ml IFN-β (pbl assay science) added to culture medium 24h prior to transfection. 
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Transfections and transfection efficiencies
Cells were transfected with dsDNA or poly(I:C) using Lipofectamine2000 (Invitrogen). 
DNA or poly(I:C) were mixed at a ratio of 1 µg stimulant per 1ul lipofectamine2000. 
Complexes were allowed to form for 20 min before adding it to the cells. In general, 0.3x106 
cells seeded per well of a 24-well plate were transfected with 4 µg DNA or 2 µg poly(I:C) to 
introduce stimuli to the cytoplasm. Supernatants and/or cells were harvested for analysis at 
indicated time points, but typically 6h or 24h post-transfection. Transfection efficiencies were 
determined by exposing cells to cells with FAM-labeled dsDNA/lipofectamine, and assessing 
fluorescence by flow cytometry after overnight incubation. 
Flow cytometry
To determine cell surface levels of indicated markers, cells were stained with antibodies 
of indicated specificity. Cell were washed in PBS supplemented with 0,5% BSA, and 0,02% 
sodium azide. Cells were antibody-stained with the following antibodies: mouse α-HLA-DR-
PE (L243, BD Biosciences), and anti-CD86-PE (BD Pharmingen). Stained cells were washed, 
fixed, and subjected to a LSR II flow cytometer (BD Biosciences). Flow cytometry data were 
analysed using FlowJo (Treestar). 
cGAMP stimulation
Digitonin-permeabilized cells were stimulated with cGAMP. For this, cells were taken up 
in digitonin buffer (5 µg/ml digitonin, 50 mM HEPES (pH 7.0), 100 mM KCl, 85 mM sucrose, 
3 mM MgCl2, 1 mM ATP, 0,1 mM GTP, 0,1 mM DTT, 0,2% BSA) containing 1 µM cGAMP. 
Cells were incubated for 10 min at 37° C, before buffer was replaced by culture medium. 
Type I IFN Bioassay
IFN-α/β levels in cell-free culture supernatants were determined using the HEK Blue 
IFN-α/β reporter cell line (Invivogen), which in response to type I IFN stimulation produces 
the secreted embryonic alkaline phophatase (SEAP). Supernatants were plated with 5x104 
reporter cells in 100 µl in a 96 well plate. Cells were incubated for Colorimetric analyses were 
performed at 620-655 nm using a plate reader. 
Quantitative real-time PCR
RNA was isolated from stimulated cells at indicated time points by using the High Pure 
RNA Isolation Kit (Roche) according to manufacturer’s protocol. Levels of mRNA were 
assessed in duplicates by real-time PCR using the TaqMan RNA-to-CT 1-step kit (Applied 
Biosystems). The following TaqMan probes were used: hIFN-β (Hs01077958_s1), hISG54 
(IFIT2) (Hs01922738_s1), hTNF-α (Hs01113624_g1), and hβ-actin (Hs99999903_m1). 
Duplicates with CT values > 1 apart were excluded from analysis. Expression levels were 
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normalized to β-actin using the 2-ΔΔCT method, and data are presented as fold induction 
(±SD) over lipofectamine2000-treated control samples. 
Western blot analysis 
Total cell lysates were generated using RIPA lysis buffer (ThermoFisher) supplemented 
with 0,2% SDS, protease inhibitor mix (Roche), 50 U/ml Benzonase (Sigma-Aldrich), and 50 
mM sodium fluoride (phosphatase inhibitor). NP40 lysis mix (0.5% NP40 (Igepal-CA630), 
50 mM Tris HCl (pH 7.5), 150 mM NaCl) containing protease inhibitor mix (Roche) was 
used to generate post-nuclear lysates as described elsewhere [39]. Lysates were denatured 
using Laemmli sample buffer containing 20 mM DTT. Proteins were separate on Bio-Rad 
premade Criterion Tris-HCl gels (4-20% gradient) or on handcast gels (10%) and transferred 
on PVDF membranes. Membranes were blocked and probed with the following specific 
antibodies: anti-cGAS (HPA031700, Sigma-Aldrich), anti-IFI16 (C-18, sc-6050, Santa Cruz), 
anti-STING (D2P2F, Cell Signaling), anti-TBK1 (D1B4, Cell Signaling), anti-IRF3 (D6I4C, 
XP, Cell Signaling or sc9082X, Santa Cruz), anti-vinculin (hVIN-1, Sigma-Aldrich), and anti-
HA (3F10, Roche). Membranes were incubated with secondary HRP-conjugated antibodies 
and ECL substrate subsequently to visualize bands using an ImageQuant LAS 4000 mini 
Luminescent Image Analyzer (GE Healthcare Life Sciences) or films. 
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Herpesviruses establish lifelong persistent infections in immunocompetent hosts. The 
herpesvirus Epstein-Barr virus (EBV) has evolved numerous immune evasion strategies that 
reduce immune activation and recognition of latently as well as productively infected cells. 
In this thesis, we defined new cellular targets of known and newly identified EBV evasion 
molecules acting during the lytic cycle and unraveled their underlying molecular mechanisms. 
In the first part, the findings of each chapter are summarized and discussed. In the second 
part, overarching points related to the research topic are addressed. 
In Chapter 2, an shRNA-based approach was employed to reduce translation of the virus-
encoded shutoff protein BGLF5 in productively EBV-infected B cells. The list of cellular 
molecules whose level is decreased by BGLF5-mediated RNA destabilization was extended 
by the innate immune molecules CD1d and TLR2. In lytically infected B cells, CD1d surface 
expression was reduced compared to latently infected cells. This phenotype was substantially 
rescued upon knock-down of the BGLF5 transcript. Expression of the BGLF5 gene in EBV-
negative cells decreased CD1d and TLR2 surface levels, thereby confirming the involvement 
of BGLF5. In addition to CD1d, a panel of cell surface markers was tested in lytically infected 
BGLF5-silenced B cells and compared to control cells. Some of these molecules displayed a 
limited downregulation, whereas certain molecules were strongly downregulated. Overall, 
the effect of BGLF5-mediated shutoff appeared to be rather limited, although the efficient 
shutoff by BGLF5 had been demonstrated using pulse-chase analysis in an earlier study 
[1]. Our findings on the limited effect of BGLF5 are supported by a study, in which the 
contribution of BGLF5 on the downregulation of HLA I in lytically infected B cells was 
found to be marginal [2]. Similar to our study, a shRNA approach was used to investigate 
the extent of BGLF5-mediated HLA I downregulation. In both studies BGLF5 transcript 
and protein levels were reduced up to 75%. The remaining levels of BGLF5 protein could 
contribute to downregulation of the molecules tested; thereby the effect of BGLF5 might be 
underestimated. Our preliminary pulse-chase analysis of BGLF5-silenced cells suggests that 
remaining BGLF5 protein was sufficient to induce efficient shutoff. Viral proteins are known 
to combine distinct functions. Also, BGLF5 has a dual function in EBV infection. The BGLF5 
protein has RNase and DNase activity [3,4]. The RNase activity is responsible for shutoff, 
while the DNase function contributes to genome processing [1,5]. Therefore, silencing 
BGLF5 may also affect other processes of EBV replication. In BGLF5-silenced cells, the 
late phase of lytic replication was delayed. To exclude that this is due to insufficient genome 
processing, it might be interesting to selectively inhibit RNase function, without interfering 
with DNase activity. However, BGLF5 has one catalytic site for both activities making it 
challenging to generate a mutant that lacks only RNase activity. Two studies attempted to find 
such a mutant, but none of the BGLF5 mutants fulfilled these requirements entirely [6,7]. The 
best candidate obtained from these studies has a single mutation (K231M) in the so-called 




“bridge”, a structural feature of BGLF5 [4]. This mutant displayed severely impaired shutoff 
function as determined by rescued GFP reduction, HLA I cell surface expression and T cell 
recognition as well as cytosolic poly(A) binding protein relocalization compared to wild-type 
protein. Its DNase activity was reduced as well, but not absent. The maintained DNase activity 
determined differed significantly amongst the two studies, therefore, it remains unclear how 
suitable the BGLF5 mutant would be for complementation studies. Moreover, introduction of 
such a mutation into the BGLF5 gene in EBV-infected B cells is, however, laborious, if done 
in EBV-infected B cells (s. section on Genetic modifications). Still, this might be an elegant 
solution to yet another problem intrinsic to shRNA-based BGLF5 knockdown: the BGLF5-
coding transcript also encodes BGLF4. Hence, shRNAs targeting the BGLF5 transcript 
simultaneously reduce BGLF4 levels. Knockdown of the BGLF4 transcript, coding for the 
EBV protein kinase, decreases expression of 31 late viral genes [8]. Indeed, we observed 
decreased levels of late protein expression on the cell surface of BGLF5-silenced cells during 
the lytic cycle. Therefore, the strong effect of the early gene product BGLF5 on CD1d observed 
in EBV-infected B cells may also be accounted to late viral proteins. 
We describe late viral proteins to interfere with CD1d surface detection in Chapter 3. EBV 
gp150, the viral protein displaying the strongest effect on CD1d of all late viral glycoproteins, 
appeared to interfere with detection of several additional cell surface molecules including 
the antigen-presenting molecules HLA I and HLA II. Decreasing HLA I and II  reduced the 
CD8+ and CD4+ T cell response to gp150-expressing cells by about 40% and 60%, respectively.. 
This has been confirmed by the Rowe lab [9] and is the first known function of EBV gp150. 
Importantly, comparing lytically infected B cells harboring gp150-deficient EBV to wild-
type EBV revealed that in the absence of gp150 B cells displayed higher levels of antigen-
presenting molecules. This suggests that gp150 contributes to immune evasion of several 
T cell subsets during the late phase of lytic replication. It has been postulated earlier that 
besides the early inhibitors BNLF2a, BGLF5, and BILF1, additional HLA I immune evasion 
molecules act during the late lytic phase [2]. It is currently unclear whether there are more 
late proteins targeting HLA I, but none of the late EBV glycoproteins showed substantial 
downregulation. We identified two additional glycoproteins, gp350 and BMRF2, interfering 
with CD1d surface expression, but the mechanisms underlying their action remains to be 
established. We focused on the elucidation of the mechanism of EBV gp150. Microscopy 
analyses of gp150-expressing cells led to the conclusion that gp150 acts on the cell surface, as 
antibody-based detection of GFP-tagged HLA molecules was impaired. In contrast, these HLA 
molecules were still present on the cell surface as indicated by GFP fluorescence. Supporting 
the hypothesis that the heavily glycosylated protein gp150 acts at the cell surface, inhibition or 
absence of sialoglycosidases or enzymatic removal of sialic acids from surface glycoproteins 
increased the antibody-mediated detection of surface molecules. This suggested that gp150 
shields antigen-presenting molecules by means of its glycans. In sharp contrast, Quinn et al. 
claimed that EBV gp150 enhances ubiquitin-dependent internalization of HLA from the cell 
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surface, although a reduction in total HLA levels was not detected [9]. Furthermore, they 
report that proteasome inhibition completely rescued the gp150-mediated downregulation 
of HLA molecules, which is opposing to our findings. They observed only an effect of gp150 
on HLA I molecules, but not on other molecules [9]. This discrepancy may be accounted to 
lower expression levels of gp150. We find that decreasing doses of gp150-coding lentivirus 
resulted in a reduced phenotype. Future studies should address the question whether gp150 
acts in both suggested ways on antigen-presenting molecules and whether the expression 
levels of gp150 influence the mode of action. The Ebola glycoprotein is the only viral protein 
reported to act in a similar way [10]. It seems plausible that other heavily glycosylated 
(herpes)virus proteins shield cellular surface molecules.  A homologue of the BDLF3 gene is 
present in the genome of rhesus LCV, but displays the lowest degree of conservation among 
all glycoproteins [11]. As the glycans present on gp150 shield surface molecules, it may be 
assumed the exact amino acid sequence is less relevant to its function providing glycosylation 
is supported. Given that BDLF3 of rhesus LCV is predicted to be heavily glycosylated, it seems 
likely that it has immune evasive properties similar to EBV gp150. BDLF3 is absent from 
marmoset LCV [12]. This may suggest that BDLF3 appeared rather late during evolution of 
the lymphocryptoviruses. 
Another immune evasion molecule of EBV is the constitutively active orphan GPCR BILF1 
[13,14]. BILF1 had been reported to interfere with HLA I surface expression by reducing 
the exocytic trafficking of HLA I to the cell surface and enhancing endocytosis resulting in 
degradation of this antigen-presenting molecule [14,15]. Reduction of HLA I impaired CD8+ 
T cell recognition of BILF1-expressing cells [14]. BILF1 appeared to interfere predominantly 
with presentation of late viral antigens [2]. In Chapter 4, we report that EBV BILF1 
displays specificity towards certain HLA molecules as HLA-A, -B and, -E were targeted for 
downregulation, but HLA-C appeared virtually resistant to BILF1-mediated downregulation. 
To downregulate HLA I molecules, BILF1 required its C-terminal cytoplasmic tail. Yet, the 
cytoplasmic tail of EBV BILF1 appeared not to be sufficient to render marmoset LCV BILF1, 
which is unable to downregulate HLA I or LCV MHC I, capable of downregulating HLA I 
molecules. This suggests that an additional feature in BILF1 is required to allow it to act as 
immune evasion molecule.  HLA I molecules lacking their cytoplasmic tail were not targeted 
for downregulation. Therefore, the cytoplasmic part of HLA I molecules was the determinant 
of BILF1 sensitivity. We identified three amino acid residues in the cytoplasmic tail of HLA-C 
that were not present in the cytoplasmic tail of BILF1-sensitive HLA I molecules. Changing 
the three residues into those of the HLA-C molecule rendered an otherwise sensitive HLA-B 
molecule resistant to downregulation. The molecular mechanism underlying BILF1-mediated 
downregulation is largely unclear, but BILF1 is reported to co-immunoprecipitate with HLA 
I [14]. To assess how the identified amino acids render HLA-C molecules resistant to BILF1-
mediated downregulation,  it may be interesting to determine whether BILF1 can interact 
with HLA-C, despite its inability to substantially downregulate this HLA molecule. This could 




facilitate further elucidation of the mechanism of action of BILF1 and assist in identification 
of potential intracellular adaptor proteins involved in sorting or internalization of HLA I 
molecules. 
Lastly, we aimed to learn more about evasion of innate immune pathways present in B 
cells by EBV. Herpesviruses have been shown to be recognized by the cytosolic DNA sensing 
pathway resulting in type I IFN production or inflammasome formation (reviewed in [16]). 
The genome of EBV and KSHV is sensed by the DNA sensor IFI16 resulting in inflammasome 
formation in B cells [17,18]. Several viral evasion molecules, including EBV BLRF2, interfering 
with DNA sensing pathway have been identified [19,20,21] supporting the notion that this 
immune pathway plays a role in the immune response to herpesviruses. The cytosolic DNA 
sensing pathway in human B cells was analysed in Chapter 5, as B lymphocytes are target 
cells for the DNA viruses EBV and KSHV. Neither primary B lymphocytes, nor the B cell lines 
examined, produced type I IFNs upon exposure to cytoplasmic DNA. A similar phenomenon 
is reported for T lymphocytes [22]. This raises the following question: Why do lymphocytes 
have the DNA sensors cGAS and IFI16, but are unresponsive to cytoplasmic DNA? Most B 
lymphocytes lacked the STING protein, an essential adaptor protein of the cytoplasmic DNA 
sensing pathway. Interestingly, B cells producing STING also did not mount a type I IFN 
response upon stimulation with DNA or cGAMP suggesting that STING expression was not 
sufficient to reconstitute the pathway in B cells. This resembles the situation in T lymphocytes: 
The DNA sensors, STING and the downstream molecules are present, but T lymphocytes do 
not respond to cytoplasmic DNA, although they sense the DNA [22]. Presence of the sensors 
in lymphocytes suggests that these cells are responsive under certain conditions that remain 
to be determined. It is tempting to speculate that lymphocytes possess a safeguard mechanism 
that regulates responsiveness to cytoplasmic DNA. Therefore, these cell types may serve as a 
study field to unravel regulatory pathways of cytoplasmic DNA sensing. Unresponsiveness 
to cytosolic DNA may make lymphocytes attractive target cells for DNA viruses such as 
herpesviruses. It remains to be determined whether other target cells of EBV sense the viral 
genome and initiate a type I IFN response. 
Conclusions and future directions
It is well established that patients lacking functional T cells are prone to developing 
EBV-associated diseases or malignancies (Chapter 1). The EBV proteins studied in this 
thesis (Chapter 2, 3, and 4) interfere with generation and recognition of antigen-presenting 
molecules on the cell surface resulting in reduced T cell activation during the productive 
cycle of EBV infection. Investigation of EBV immune evasion molecules to understand their 
molecular mechanism of action and to assess their cellular targets significantly contributes 
to our understanding of EBV biology. Considering that EBV has even more T cell evasion 
molecules, this demonstrates that T cell activation is a major threat to EBV infection. To 
counteract efficient T cell recognition, this virus evolved several ways of interference acting at 
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different phases of the lytic cycle as well as during latency. Yet, we are far from comprehending 
how and when individual EBV proteins contribute to EBV infection and how this impacts 
pathogenesis on an organismic level. Studying the innate immune DNA sensing pathways 
of B cells (Chapter 5) expands our knowledge on immune pathways that may limit EBV 
infection. In conclusion, insights are gained on the cellular pathways that are involved in 
antiviral defense.
Animal models
Although attempts have been made to determine the contribution of individual EBV 
proteins to immune evasion during primary infection or lytic cycle in vitro [9,23,24], the role 
of distinct immune evasion strategies in vivo is largely unclear. One obstacle is the requirement 
for a permissive animal model that supports EBV infection. As EBV has a very narrow host 
range [25], the use of mice with reconstituted human immune system compartments (HIS 
mice) infected with EBV or infection of rhesus macaques with the closely related rhesus LCV 
is warranted [12,26,27]. Similar models have been informative for the investigation of the role 
of immune evasion in vivo for other human-specific viruses like HCMV. A cluster of rhesus 
CMV genes encoding immune evasion molecules (Rh182-189, which act homologous to the 
HCMV genes US2-US11) that interfere with MHC I-mediated antigen presentation to CD8+ 
T cells are essential to establish a secondary persistent infection (‘superinfection’) in CMV-
positive rhesus macaques [28]. The rhesus CMV-specific MHC I evasion molecule VIHCE 
was not required for superinfection. Depletion of CD8+ T cells allowed the RhUS2-US11-
deficient rhesus CMV to establish secondary persistent infection [28]. Interference with 
MHC I was not required for primary infection. This demonstrates that superinfection, but not 
primary infection relies on the presence of immune evasion molecules and that T cell control 
is effective, if not evaded. It is likely that the immune evasion genes are also not required for 
primary EBV infection in a naïve host when EBV-specific T cells are still absent. It remains 
to be investigated whether immune evasion plays a role during infection of uninfected cells 
in an EBV-experienced host or whether they rather contribute to prolonging the time span of 
virus production during reactivation. The EBV evasion genes BCRF1 and BNLF2a, coding for 
vIL-10 and BNLF2a, respectively, are expressed upon primary infection of B cells in vitro [23]. 
Thereby, they may contribute to immune evasion during the pre-latent phase of infection in 
B cells. 
To study infection with the EBV-related rhesus LCV, a specific pathogen-free colony of 
rhesus LCV-naïve rhesus macaques is required  This animal model supports oral transmission, 
latent and lytic rhesus LCV infection and reproduces other key aspects of human EBV infection 
[12,29]. In a first study evaluating contribution of immune evasion, naïve rhesus macaques 
were infected with rhesus LCV lacking the innate immune evasion gene BARF1 coding for the 
colony stimulating factor 1 (CSF-1) blocking protein. The viral load was reduced during lytic 
infection and frequency of latently infected cells was decreased [30]. This demonstrates that 
evasion of the innate immune system is important for efficient rhesus LCV infection.




HIS mice have hematopoietic cells of human origin and are used to study EBV infection 
in vivo. They improved our understanding of the role of NK cells early during EBV infection 
[31]. NK cells appear to control lytically, but not latently, infected B cells. In the absence of 
NK cells, CD8+ T cells expanded more dramatically and tumor incidence was higher [31]. 
However, the use of HIS mice is limited as not all steps of the EBV life cycle can be modeled, 
e.g. oral transmission, which requires infection of epithelial cells. Despite the human origin 
of the hematopoietic compartment, all non-hematopoietic cells including epithelial cells 
are of murine origin. Hence, life cycle steps involving non-hematopoietic cells cannot be 
investigated using this model.
These two examples show that the recent advances in establishing animal models to study 
EBV infection in vivo are promising. Further comprehension of the role of individual viral 
gene products, including immune evasion proteins, during infection may be expected within 
the coming decade. In addition, the contribution of specific immune pathways or cells to 
control viral infection should be studied in order to provide a complete picture of virus-host 
interaction.   
Genetic manipulations
Genetic manipulation of the viral genome is a prerequisite to study the function and role 
of individual gene products of EBV or rhesus LCV in vivo. To investigate the contribution of 
gene products in vitro, transcript knock-down approaches can be employed, although often 
there is a preference for knock-out of viral genes. Once a gene-deficient viral genome (present 
in a cell line or a virus particle) is generated, many of the following steps in research become 
easier and clearer phenotypes can be obtained in comparison to knock-down approaches. The 
necessary genetic modification of the EBV genome can be achieved by the use of bacterial 
artificial chromosomes (BAC) or classical recombination [32]. For in vitro experiments, 
the major drawback of the BAC-based system is the necessity to infect B cells. Typically, in 
vitro infected B cells show a very low efficiency of entering the lytic cycle, thereby making it 
challenging to study genes expressed during the lytic cycle. Therefore, predominantly genes 
involved in primary infection and latency can be studied with viruses derived from the BAC 
system. In contrast, this system is indispensable for in vivo studies. The EBV BAC system was 
generated in the late 1990s [33], but a rhesus LCV BAC was only established recently [34] 
making it possible now to delete individual genes from rhesus LCV to test their function in 
vitro or in vivo. 
As an alternative, and especially for lytic cycle-expressed genes, a classical recombination 
approach can be employed to delete, substitute, or introduce genes. The Akata cell line or the 
AKBM cell line, a derivative of the Akata cell line, allows efficient lytic replication, thereby 
being a suitable model to study the contribution of individual lytic phase gene products 
in vitro. As several copies of the EBV genome are present,, the classical recombination 
approaches to modify all genomes present are consequently very inefficient and laborious 
due to tedious screenings of clones, as described for the generation of the BDLF3-knock-
160723 Proefschrift.indd   163 24.07.2016   21:50:35
Chapter 6
164
out Akata cell line [35]. The recently developed CRISPR/Cas9-based genome editing systems 
promise to facilitate fast and efficient editing of any kind of genome [36,37]. However, the 
genome editing systems do not prove to be a very effective tool to interrupt or introduce genes 
into the numerous EBV genomes present in a single cell as of yet [38]. Therefore, shRNA-
based approaches as applied for BGLF5 (Chapter 2) or other gene products [2] may continue 
to be the tool of choice for studying essential, but also non-essential individual EBV proteins. 
Coinfections
Endemic Burkitt’s lymphoma occurring in equatorial Africa and Papua New Guinea is 
associated with coinfection of the malaria-causing parasite Plasmodium falciparum and EBV 
[39,40]. Although this link is known for half a century, it cannot be fully explained yet. Two 
recent studies provide important insights into the molecular mechanisms [41,42] (reviewed 
in [43]). In short, individuals chronically infected with Plasmodium falciparum had higher 
numbers of germinal center B cells that made high levels of activation-induced cytidine 
deaminase (AID), an enzyme involved in somatic hypermutation and class switching of 
immunoglobulin genes [42]. Consequently, EBV-positive germinal center B cells were more 
abundant in individuals infected with Plasmodium falciparum in comparison to uninfected 
ones [42]. In combination, the increased risk of AID-induced translocation and EBV-mediated 
survival of B cells, two factors favoring cancer cell development, may explain the higher 
incidence of BL in areas where Plasmodium falciparum –mediated malaria is holoendemic. 
The example of Plasmodium falciparum and EBV coinfection resulting in lymphoma 
formation is extreme.  There are more examples of microorganisms shaping their (micro)-
environment, which may have deleterious or beneficial consequences. Interaction of the 
‘virome’, defined as all viruses or virus-related sequences present in an individual, and the 
host influences phenotypes of health and disease (reviewed in [44]). Infection with persistent 
viruses such as herpesviruses, and especially with the highly disseminated EBV, might be 
a significant determinant. Continuous replication and shedding of EBV occurs in healthy 
carriers [45], hence there might be a low level of permanent immune stimulation by lytically 
replicating cells. Moreover, latently infected cells may release cytokines and type I IFNs as 
latent EBV gene products have been identified that activate and/or modulateinnate immune 
pathways (Chapter 1). For example, LMP1 activates the several innate pathways, including 
the NF-κB pathway [46] and also the EBERs are sensed by different innate immune pathways 
[47,48]. Moreover, there are virally-encoded miRNAs present in EBV-infected cells that 
possibly induce transcriptional changes influencing immune-related genes ([49,50,51] 
and Hooykaas et al, personal communication). These different gene products are not only 
restricted to the virus-infected cell itself, since different RNA species including miRNA and 
EBERs might also be transferred by exosomes to other cells or even non-permissive cell types 
[52,53]. Thereby, EBV infection may shape our immune responses, but not per se in a negative 
fashion. One example of beneficial herpesvirus infection is illustrated in a report on knock-
out mice lacking single immune factors such as HOIL-1, IL-6, or caspase-1, but being resistant 




to lethal doses of Listeria due to latent infection with MHV68, a murine gamma-herpesvirus 
[54]. It is, therefore, exciting to consider our herpesviruses not only as pathogens, but also as 
“commensals” that might contribute to health and disease. 
Glycosylation
Studying herpesviruses provides insights into its intriguing immune evasion mechanisms 
that enable the viruses to persistently infect their host, but also offer insights on fundamental 
molecular processes and modifications. EBV gp150 shields cell surface molecules by means of 
its abundant N and Olinked glycans (Chapter 3). A similar mechanism has been reported for 
Ebola glycoprotein [10]. Glycosylation of viral proteins also aids evasion of antibody-mediated 
neutralization (reviewed in [55]) including HCMV gN and BoHV-4 gp180 [56,57]. The 
glycosylation not only shielded epitopes within the glycosylated protein, but also prevented 
antibody-binding to other viral proteins [57]. A recent study suggests that viral glycoproteins 
can induce glycan-dependent immune responses [58]. The authors found that HSV-2 triggers a 
mucosal CXCL10 response preceding the early IFN response. The CXCL10 response appeared 
to be dependent on O-linked glycosylation of the viral glycoproteins. Cellular carbohydrate 
receptors like C-type lectins did not sense the glycosylation and activate signaling pathways. 
Instead, enzymatic or repeated flushing-induced disruption of the mucosal layer resulted 
in CXCL10 secretion. Therefore, the authors concluded that O-linked glycosylation of the 
virion was required to cross the mucus layer efficiently and to enter the underlying cells [58]. 
In summary, these studies suggest that glycosylation of viral proteins fine-tunes and adds 
functions to the glycoproteins. In addition, viral glycoproteins also interact with different 
cellular lectins (reviewed in [59]). Sialic acid–binding Ig-like lectins (Siglecs) are primarily 
present on immune cells and many of them trigger immune modulatory responses via 
intracellular signaling domains such as immunoreceptor tyrosine-based inhibitory motif 
(ITIM) Other Siglecs associate with a protein containing immunoreceptor tyrosine-based 
activating motif (ITAM). The signalling cascade initiated by sialic acid binding can dampen 
the outcome of other immune signalling pathways [60]. It is tempting to speculate that sialic 
acid-decorated glycoproteins of EBV such as gp150 may alter immune signalling events 
in cis or trans by activating Siglecs present on B cells or on cells interacting with B cells, 
respecitvely. This could be considered as immune evasion strategy. Altered glycosylation in 
cancer and auto-immunity is also increasingly recognized [61,62], but how and to what extent 
this impacts immune responses or other processes remains largely unclear. It is challenging 
to study the role of glycosylation of proteins without affecting the functionality of the protein. 
Yet, it is interesting to consider glycosylation as an additional layer of regulation similar to 
other post-translational modifications. 




Investigation of the immune evasion strategies of the oncogenic γ-herpesvirus EBV 
provides essential insights in the underlying molecular working mechanisms and targets 
of the viral molecules. The knowledge on their different strategies might aid in designing 
anti-viral drugs or therapies to counteract these in order to cure EBV-associated diseases 
and malignancies. Currently, there is no drug available to treat infectious mononucleosis, 
which can be life-threatening in patients with certain immunodeficiencies. Targeting viral 
evasion molecules that interfere with innate or adaptive immune responses could improve 
immune recognition resulting in a better or faster control of the viral infection by the host. 
Alternatively, it is interesting to speculate whether viral evasion molecules might be exploited 
as tool to prevent or dampen unwanted immune responses [63,64]. Exploitation of molecules 
interfering with antigen presentation could be used to make transplanted or own organs such 
as the pancreas “invisible” to the immune system to prevent unwanted T cell attack. Viral 
molecules targeting innate immune responses might be exploited to reduce inflammation or 
auto-immunity. Of note, there are obvious obstacles such as delivery and safety issues, but also 
problems regarding preexisting immunity. In case of interference with antigen presentation, 
it needs to be considered that viral infection of the “immune-invisible” graft might not be 
properly controlled by the immune system. To identify the best viral target molecule to limit 
viral infection or the molecules with the greatest therapeutic potential, profound knowledge 
on the contribution and role of individual viral molecules during the replicative cycle and 
pathogenesis of the virus in vivo is required. Vaccination against EBV appears to be an 
attractive option to prevent associated diseases and malignancies. However, we should also 
consider that viruses that coevolved for millions of years together with their host may provide 
benefits, although certain individuals are at risk to develop disease or malignancies. 
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Virussen hebben een gastheer nodig om zich te kunnen vermenigvuldigen (repliceren). 
Om de gastheer tegen virale en andere microbiële infecties te beschermen heeft het een 
immuunsysteem, waarmee het lichaamsvreemde moleculen kan herkennen en daarop kan 
reageren. Er wordt tussen het aangeboren en het verworven afweersysteem onderscheden. 
Een deel van de lichaamsvreemde moleculen, vooral virale nucleïnezuren, kan snel door 
gespecialiseerde sensoren van het aangeboren immuunsysteem herkend worden, bij voorbeeld 
door Toll-like receptoren. Een virus-specifieke immuunrespons wordt door het verworven 
immuunsysteem aangemaakt.  De immuunrespons kan geïnitieerd worden als geïnfecteerde 
cellen stukjes (peptiden) van lichaamsvreemde virale eiwitten in de antigeen-presenterende 
moleculen HLA klasse I (HLA I, ook MHC I) en HLA klasse II (HLA II, ook MHC II) op 
het celoppervlak presenteren. De vreemde peptiden in de antigeen-presenterende moleculen 
kunnen door specifieke CD8+ en CD4+ T-cellen worden herkend. Dit leidt tot activatie van de 
T cel, die de virus-geïnfecteerde cel direct kan doden of andere cellen kan activeren, die bij de 
immuunrespons betrokken zijn. Deze immuunrespons verwijderd de meeste virusinfecties 
en geeft langdurige immuniteit tegen dit virus. 
Herpesvirussen zijn DNA-virussen, die de  bijzondere eigenschap hebben dat zij een latente 
infectie in een gastheer kunnen bewerkstelligen, ook al worden ze door het immuunsysteem 
herkend en wordt er immuniteit ontwikkeld. Dit is mogelijk doordat herpesvirussen 
verschillende indrukwekkende manieren hebben ontwikkeld om aan herkenning door 
het immuunsysteem te ontsnappen. De levenscyclus van herpesvirussen bestaat uit twee 
verschillende fases, de latente en de lytische infectie. Tijdens de latente infectie van cellen 
worden er geen nieuwe virusdeeltjes geproduceerd. In een latent geïnfecteerde cel worden 
er geen of nauwelijks nieuwe virale eiwitten gemaakt en ook het genoom wordt  slechts op 
een laag niveau geamplificeerd, enkel om ervoor te zorgen dat de delende cellen het virale 
genoom behouden. Verder hebben sommige latente virale eiwitten immuun-modificerende 
eigenschappen. Zo zorgen deze mechanismen ervoor dat de latente infectie niet goed 
“zichtbaar” is voor het immuunsysteem. In tegenstelling tot de latente fase, worden tijdens de 
lytische fase veel virale eiwitten geproduceerd, het genoom wordt vermenigvuldigd en nieuwe 
virusdeeltjes worden gemaakt. Om te voorkomen dat de virus-producerende cellen snel door 
het immuunsysteem herkend en opgeruimd worden, hebben herpesvirussen verschillende 
manieren gevonden om herkenning van de geïnfecteerde cellen te beïnvloeden (immuun-
evasie). 
In dit proefschrift staan de resultaten beschreven van ons onderzoek naar hoe het 
herpesvirus Epstein-Barr virus (EBV) de antigeen-presentatie op het celoppervlak van EBV-
geïnfecteerde cellen kan verhinderen. In hoofdstuk 1 is de achtergrond van dit onderzoek 
gedetailleerd beschreven. EBV hordt bij de herpesvirussen, specifieker de lymfocryptovirussen. 
Voorbeelden van andere herpesvirussen, die mensen als gastheer hebben, zijn herpes simplex 
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virus, de veroorzaker van koortslip, of het waterpokkenvirus. EBV kan de ziekte van Pfeiffer 
veroorzaken als de gastheer voor het eerst tijdens adolescentie in aanraking met EBV komt. 
EBV infectie is ook geassocieerd met verschillende vormen van kanker, zoals het Burkitt’s 
lymfoom en Hodgkin’s lymfoom. In de gastheer infecteert EBV B-cellen en epitheelcellen. In 
B-cellen kan EBV een latente infectie veroorzaken, maar ook lytisch repliceren. Tijdens de 
lytische fase zorgen verschillende EBV eiwitten ervoor dat er minder antigeen-presenterende 
moleculen op het celoppervlak terechtkomen, zodat minder EBV-afkomstige peptiden 
gepresenteerd kunnen worden. Drie verschillende EBV eiwitten met deze eigenschap zijn in 
de hoofdstukken 2, 3, en 4 behandeld. 
In hoofdstuk 2 wordt beschreven hoe de aanmaak van het EBV ‘shutoff ’ eiwit BGLF5 
middels een shRNA approach verminderd wordt in B-cellen, waarin EBV lytisch in repliceert, 
en welke invloed dit heeft op diverse celoppervlakte-eiwitten. Op deze manier zijn twee 
tot dusver onbekende doelwitten van BGLF5 geïdentificeerd, namelijk de transcripten die 
coderen voor CD1d en Toll-like receptor 2. Doordat BGLF5 deze transcripten afbreekt wordt 
de expressie van deze eiwitten op het celoppervlak verlaagd. De twee eiwitten zijn onderdeel 
van het aangeboren immuun system. TLR2 draagt bij aan de herkenning van pathogenen en 
CD1d is een antigeen-presenterend molecuul, dat lipiden in plaats van peptiden aan T-cellen 
presenteert. 
In hoofdstuk 3 wordt immuun-evasie van HLA I, II, en CD1d door EBV tijdens de late 
lytische fase beschreven. Een EBV-eiwit, gp150, draagt eraan bij dat de detectie van alle 
drie de antigeen-presenterende moleculen op het celoppervlak van EBV-negatieve cellen 
verlaagd wordt. De functie van het EBV-eiwit gp150 was niet eerder bekend. Verder hebben 
we het moleculaire werkingsmechanisme van gp150 opgehelderd. EBV gp150 draagt niet 
bij aan een versnelde afbraak van de bestudeerde eiwitten, maar de moleculen blijven op 
het celoppervlak aanwezig. Het zwaar geglycosyleerde eiwit gp150 dekt middels zijn suikers 
(glycanen)  moleculen op het celoppervlak af, wat de herkenning door CD8+ en CD4+ T-cellen 
vermindert. Voor herpesvirussen is dit een unieke manier van evasie, en er is een soortgelijke 
mechanisme slechts voor een ander viraal eiwit beschreven, namelijk het Ebola glycoeiwit. In 
afwezigheid van gp150 in lytisch replicerende EBV-geïnfecteerde B-cellen komt een groter 
aantal HLA en CD1d moleculen op het celoppervlak terecht dan wanneer gp150 ook tot 
expressie komt. Dit geeft aan dat tijdens de productieve EBV-infectie van B-cellen gp150 ook 
een bijdrage levert aan de verminderde herkenning van antigeen-presenterende moleculen 
op het celoppervlak en dus ontsnapping aan T-celherkenning. 
In hoofdstuk 4 zijn de moleculaire details beschreven van BILF1-afhankelijke 
verlaging van HLA I moleculen op het celoppervlak. Voor interferentie met HLA I zijn de 
cytoplasmatische staart van zowel BILF1 als het HLA I molecuul noodzakelijk. Verder wordt 
aangetoond dat niet alle HLA allelen gevoelig zijn voor BILF1. De celoppervlakte-niveaus 
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van HLA-C moleculen worden namelijk niet of nauwelijks door BILF1 verlaagd. We hebben 
de verantwoordelijke aminozuren in de cytoplasmatische staart van HLA-C moleculen 
geïdentificeerd en introductie van deze aminozuren in een BILF1-gevoelig HLA molecuul 
maakt het resistent. BILF1 wordt door meerdere relateerde lymfocryptovirussen (LCV), 
waaronder EBV, rhesus LCV, en marmoset LCV gecodeerd. Of de BILF1 eiwitten van deze 
drie LCVs allemaal de immuunevasie-eigenschap hebben was onbekend. BILF1 van EBV 
en van rhesus LCV kunnen de celoppervlakte-expressie van humaan MHC I verlagen, maar 
marmoset BILF1 kan dit niet. Ook kan marmoset BILF1 niet de oppervlakte expressie van 
marmoset MHC I beïnvloeden. Dit zou kunnen betekenen dat BILF1 evolutionair gezien pas 
recent zijn evasie-eigenschap heeft ontwikkeld. 
Over de herkenning van EBV door het aangeboren immuunsysteem is minder bekend. 
B-cellen hebben verschillende sensoren zoals Toll-like receptoren, maar over de aanwezigheid 
van cytosolische en nucleaire DNA-sensoren in B-cellen was vrijwel weinig bekend. Het 
DNA-genoom van EBV zou door dit soort sensoren herkend kunnen worden. In hoofdstuk 5 
is beschreven dat hoewel B-cellen wel cytoplasmatische DNA-sensoren tot expressie brengen, 
het essentiële adaptereiwit STING afwezig was in de meerderheid van de bestudeerde primaire 
B-cellen en cellijnen. B-cellen, die wel de eiwitten van de volledige signaleringscascade leken 
te hebben, reageerden ook niet op geïntroduceerd DNA , waaruit we concluderen dat de 
cascade in B-cellen niet functioneel is. Het is interessant om te speculeren of dit B-cellen tot 
attractieve gastheercellen voor EBV en andere DNA-virussen maakt. 
Het laatste hoofdstuk, hoofdstuk 6, geeft een samenvatting van de bevindingen uit 
alle eerdere hoofdstukken van dit proefschrift alsmede een discussie in de context van de 
gerelateerde vak  literatuur. Verder worden de ontwikkelingen en mogelijkheden van het 
EBV- en herpesvirusonderzoek en implicaties daarvan voor de kliniek besproken. Uit de 
eerste drie hoofdstukken blijkt dat evasie van HLA II, CD1d, en vooral HLA I een belangrijke 
rol in de levenscyclus van EBV moet spelen, omdat EBV hier zoveel verschillende manieren 
voor ontwikkeld heeft, die in verschillende fasen van de lytische replicatie actief zijn. De hier 
besproken eiwitten BGLF5, gp150, en BILF1 kunnen samen met andere EBV-eiwitten, zoals 
BNLF2a en gp42, de herkenning door CD8+ en CD4+ T-cellen verstoren. Het is belangrijk 
om de werkwijze van deze evasieeiwitten te begrijpen, want dit zou de grondlaag voor de 
ontwikkeling van anti-virale therapien, bij voorbeeld van de ziekte van Pfeiffer, kunnen zijn. 
Verder is het interessant om er over na te denken, of (gemodificeerde) virale evasieeitwitten, 
die de antigen-presentatie verminderen, kunnen gebruikt worden om getransplanteerde of 
eigen organen (bi voorbeeld de pancreas, het insuline producerend orgaan) tegen ongewilde 
aanval door T cellen te voorkomen zo als in een orgaanafstoting-reactie of type I diabetes. 




Viren sind kleine infektiöse Partikel, die aus einem viralen Genom, das die Erbinformation 
beinhaltet, und Eiweißen (Proteinen) bestehen. Im Gegensatz zu Bakterien können Viren 
nicht eigenständig replizieren (sich vermehren). Viren benötigen eine Wirtszelle, die sie 
infizieren, „kapern“ und dazu benutzen können, um zu replizieren. Das Immunsystem des 
Menschen sorgt dafür, dass virale und andere Infektionen erkannt und beseitigt werden. 
Man unterscheidet zwischen dem angeborenen und dem erworbenen Immunsystem. Das 
angeborene Immunsystem erkennt körperfremde Moleküle (z.B. das virale Genom) durch 
zelluläre Sensoren in und auf Körper- und Immunzellen. Ein Beispiel für solche Sensoren 
sind die Toll-like-Rezeptoren. Die Erkennung von körperfremden Molekülen führt zur 
Aktivierung der Sensoren, die andere zelluläre Eiweiße hinzuziehen und damit eine 
Signalkaskade auslösen, um so eine schnelle, aber unspezifische Immunantwort auszulösen. 
Diese angeborene Immunantwort stimuliert die Entwicklung der Erreger-spezifischen 
(erworbenen) Immunantwort. Die erworbene Immunantwort besteht einerseits aus der 
Antikörper-basierten humoralen Immunität, und andererseits aus der zellulären Immunität. 
Hauptbestandteil der zellulären Immunität sind bestimmte Blutzellen, die sogenannten 
T-Zellen, die kleine Stückchen (Peptide) von körperfremden Eiweißen (Antigenen) erkennen 
können. Die Peptide werden auf der Zelloberfläche durch antigen-präsentierende Moleküle, 
die sogenannten MHC-Moleküle (die im Menschen auch HLA-Moleküle genannt werden) 
präsentiert. Es gibt HLA-Moleküle der Klasse I und II. T-Zellen erkennen diese HLA-Moleküle 
zusammen mit den präsentierten Peptiden und werden dadurch aktiviert. Aktivierte T-Zellen 
können entweder (Virus-infizierte) Zellen, die die fremden Peptide auf der Zelloberfläche 
präsentieren, direkt töten oder anderen Zellen, die an einer Immunantwort beteiligt sind, 
helfen, aktiv zu werden. Die erworbene Immunantwort sorgt normalerweise dafür, dass 
Infektionsherde entfernt werden und eine langanhaltende Immunität gegen den spezifischen 
Erreger etabliert wird. 
Die Familie der Herpesviren umfasst behüllte Viren mit einem DNA-Genom. Es gibt 
mehrere humane Herpesviren, die Erkrankungen wie Lippenherpes (Herpes simplex Virus 
1), Genitalherpes (Herpes simplex 2), Windpocken (und bei Reaktivierung Gürtelrose) 
(Varicella-Zoster Virus) oder Pfeiffersches Drüsenfieber (Epstein-Barr-Virus) verursachen 
können. Herpesviren haben die Besonderheit, dass sie eine latente Infektion verursachen, 
d.h. das Virengenom  verbleibt nach einer Infektion im Körper, obwohl das Immunsystem 
die Viren erkannt und Immunität entwickelt hat. Herpesviren haben verschiedene 
beeindruckende Strategien entwickelt, um die Immunantwort zu umgehen oder ins Leere 
laufen zu lassen. Der Lebenszyklus von Herpesviren besteht aus zwei Phasen, der latenten 
und der lytischen Infektion. Während der latenten Phase werden keine neuen Viruspartikel 
produziert. Auch werden keine oder kaum virale Proteine generiert, und das virale Genom 
wird nur auf einem niedrigen Niveau vervielfältigt, was nur dazu dient, dass das virale 
Genom auch in den Tochterzellen der sich teilenden und infizierten Zelle vorhanden bleibt. 
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Durch die wenigen viralen Proteine (und somit präsentierten Peptide) und die niedrige 
Genomvervielfältigungsrate sind die latent infizierten Zellen für das Immunsystem fast 
gänzlich „unsichtbar“. Zusätzlich haben einige der viralen Proteine, die in der latenten 
Phase produziert werden, immunmodifizierende Eigenschaften, die dafür sorgen, dass die 
Immunerkennung und –aktivierung reduziert wird. Im Gegensatz zur latenten Phase werden 
in der lytischen Phase neue virale Eiweiße produziert, das virale Genom stark vervielfältigt 
und neue Viruspartikel generiert. Um zu verhindern, dass infizierte Zellen, die sich in der 
lytischen Phase befinden, vom Immunsystem - aus viraler Sicht - zu schnell entdeckt und 
zerstört werden, haben Herpesviren eine Reihe von Strategien entwickelt, um die Erkennung 
der infizierten Zelle zu verspäten und somit mehr Zeit zur Produktion von noch mehr 
Viruspartikeln zu haben. 
In dieser Arbeit werden die Ergebnisse unserer Forschung zu der Frage, wie das Epstein-
Barr-Virus (EBV) die Antigenpräsentation auf der Zelloberfläche von EBV-infizierten Zellen 
verhindern kann, vorgestellt. In Kapitel 1 sind die Hintergründe unserer Forschungsarbeit 
detailliert beschrieben. EBV gehört zur Familie der Herpesviren und zur Unterfamilie 
der Lymphocryptoviren. Mehr als 90% der erwachsenen Weltbevölkerung sind mit EBV 
infiziert. EBV kann das Pfeiffersche Drüsenfieber verursachen, welches bei erstmaliger EBV-
Infektion vor allem, aber nicht ausschließlich, im Jugend- oder Erwachsenenalter auftritt. 
Die Infektion mit EBV spielt auch bei verschiedenen Formen von Krebs, zum Beispiel 
dem Burkittslymphom oder dem Hodgekinslymphom, eine Rolle. EBV infiziert B-Zellen 
(die Antikörper-produzierenden Zellen des Immunsystems) und Epithelzellen. EBV kann 
B-Zellen latent infizieren, aber auch in ihnen lytisch replizieren. Während der lytischen Phase 
sorgen verschiedene EBV-Proteine dafür, dass weniger Antigen-präsentierende Moleküle 
auf die Zelloberfläche kommen und somit weniger Peptide von EBV-Eiweißen präsentiert 
werden. Drei verschiedene EBV-Eiweiße mit dieser Eigenschaft sind Gegenstand der Kapitel 
2, 3 und 4. 
Das EBV-Protein BGLF5 ist Gegenstand von Kapitel 2. BGLF5 sorgt während der 
lytischen Phase von EBV dafür, dass die Produktion von Wirtsproteinen, unter anderem 
HLA-Moleküle, zu Gunsten von viralen Eiweißen massiv abnimmt. In Kapitel 2 ist 
beschrieben wie die Menge an BGLF5 in lytisch infizierten B-Zellen unter Zuhilfenahme von 
shRNAs reduziert werden kann. In den Zellen mit verringerter Anzahl BGLF5-Molekülen 
wurde die Menge von verschiedenen Zelloberflächenmolekülen bestimmt und mit Zellen, 
die die normale BGLF5 Menge haben, verglichen. Auf diese Art und Weise konnten wir das 
Eiweiß CD1d als Ziele identifizieren, dessen kodierende mRNA von BGLF5 abgebaut wird. 
Dies resultiert in einer geringeren Produktion von CD1d und einer reduzierten Menge dieser 
Eiweiße auf der Zelloberfläche. In Zellen, in denen das BGLF5-Gen zur Expression gebracht 
wurde, konnte auch TLR2 als Ziel festgestellt werden. Die zwei Proteine CD1d und TLR2 sind 
Teil des angeborenen Immunsystems. TLR2 trägt zur Erkennung von Erregern bei. CD1d ist 
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ein nicht-klassisches Antigen-präsentierendes Molekül, das Lipide statt Peptide an T-Zellen 
präsentiert. Die beschriebene Methode erlaubt somit, neue Zieleiweiße zu identifizieren. 
In Kapitel 3 wird dargestellt, wie EBV die Antigenpräsentation durch HLA I, II und CD1d 
während der späten lytischen Phase verringert. Das EBV-Eiweiß gp150, das die Zelloberfläche 
erreicht, trägt dazu bei, dass die Erkennung aller drei Antigen-präsentierender Moleküle 
durch T- Zellen abnimmt. Die Funktion von EBV gp150 war zuvor unbekannt. Des Weiteren 
haben wir den molekularen Wirkmechanismus studiert. EBV gp150 sorgt nicht dafür, dass 
die Zieleiweiße schneller als gewöhnlich abgebaut werden, sondern kann die Eiweiße auf der 
Zelloberfläche maskieren, sodass sie nicht mehr für T-Zellen erkennbar sind. Dies wird dem 
relativ kleinen EBV-Protein gp150 durch seine ungewöhnlich vielen Zuckermodifikationen 
ermöglicht. Diese Vermeidungsstrategie ist bisher einzigartig für Herpesviren, und ein 
vergleichbarer Mechanismus ist nur für ein anderes virales zucker-modifiziertes Eiweiß, das 
des Ebolaviruses, bekannt. In der Abwesenheit von gp150 in der lytischen Infektionsphase 
sind mehr Zelloberflächen-HLA und –CD1d-Moleküle in B-Zellen detektierbar als in 
Abwesenheit von gp150.  Das heißt, es ist denkbar, dass auch in EBV-infizierten und lytisch-
replizierenden B-Zellen das Eiweiß gp150 zur Abnahme von T -Zellerkennung beiträgt. 
In Kapitel 4 werden die Ergebnisse unserer weiterführenden Studie über EBV BILF1 
dargelegt. BILF1 ist ein EBV-Protein, das während der frühen lytischen Phase produziert 
wird und dafür sorgt, dass weniger HLA I-Moleküle auf der Zelloberfläche anwesend sind. 
Wir beschreiben die Erkenntnisse über die molekularen Details der BILF1-abhängige 
Abnahme von HLA I-Eiweißen auf der Zelloberfläche. Dazu wurden verschiedene BILF1 und 
HLA I-Mutanten von uns generiert und studiert. BILF1 benötigt seinen cytoplasmatischen 
Teil um die Menge an Zelloberflächen-HLA I zu verringern. Des Weiteren kann BILF1 
das Erreichen der Zelloberfläche des HLA I-Eiweißes nur verhindern, wenn HLA I seinen 
cytoplasmatischen Teil besitzt. Überdies können wir zeigen, dass nicht alle HLA I-Proteine, 
die durch die verschiedenen HLA-Allele kodiert werden, durch BILF1 beeinflusst werden. Die 
Menge der HLA-C-Zelloberflächenmoleküle wird nämlich kaum oder gar nicht verringert. 
Die dafür verantwortlichen Aminosäuren konnten im cytoplasmatischen Teil von HLA-C 
ausfindig gemacht werden. Wenn diese Aminosäuren an den entsprechenden Positionen in 
einem BILF1-sensitiven HLA I-Protein eingefügt werden, wird das HLA I-Eiweiß resistent 
gegen BILF1. Mehrere verwandte Lymphocryptoviren (LCV), unter anderem EBV, Rhesus-
LCV und Marmosetten-LCV kodieren BILF1. Es war unbekannt, ob BILF1 von diesen drei 
LCVs über die Eigenschaft verfügt MHC-Moleküle am Erreichen der Zelloberfläche zu 
hindern. BILF1 von EBV und Rhesus-LCV können humanes MHC I auf der Zelloberfläche 
verringern, während Marmosetten-LCV BILF1 dies nicht kann. Auch Marmosetten-MHC 
I-Eiweiße kann Marmosetten-LCV BILF1 nicht vermindern, d.h. es verfügt nicht über die 
Eigenschaft, die Menge an Zelloberflächen-MHC I zu verringern. Dies könnte bedeuten, dass 
evolutionär gesehen BILF1 über die Eigenschaft der Verminderungsstrategie erst relativ kurz 




Im Gegensatz zum erworbenen Immunsystem ist über die Erkennung von EBV durch das 
angeborene Immunsystem weniger bekannt. B-Zellen verfügen über verschiedene Sensoren 
wie Toll-like-Rezeptoren, aber ob B-Zellen cytoplasmatische und Zellkern-ständige DNA-
Sensoren haben, war weitestgehend unbekannt. Das DNA-Genom von EBV könnte von dieser 
Sorte Sensoren erkannt werden. In Kapitel 5 ist beschrieben, dass B-Zellen cytoplasmatische 
DNA-Sensoren haben, aber das Adaptereiweiß STING in den meisten primären B-Zellen 
und B-Zelllinien abwesend ist. Das Protein STING ist für den cytoplasmatischen DNA-
Erkennungssignalweg essentiell und ohne dieses Eiweiß kann das Erkennungssignal nicht 
weitergegen werden. Somit verfügen die meisten der getesteten B-Zellen nicht über einen 
vollständigen Signalkaskadenweg für die Erkennung von DNA. Interessanterweise reagieren 
B-Zellen, die anscheinend alle Eiweiße der DNA-Erkennungs- und Signalkaskade haben, nicht 
auf cytoplasmatische DNA. Daraus ziehen wir die Schlussfolgerung, dass die Signalkaskade in 
B-Zellen nicht funktionstüchtig ist. Es ist interessant zu spekulieren, ob die Abwesenheit von 
dem DNA-Erkennungsweg B-Zellen zu attraktiven Wirtszellen für EBV und andere DNA-
Viren macht. 
Das letzte Kapitel, Kapitel 6, fasst die Ergebnisse aus den anderen Kapiteln dieser Arbeit 
zusammen und beinhaltet eine Diskussion dieser im Kontext relevanten Fachliteratur. 
Des Weiteren werden die möglichen zukünftigen Entwicklungen in der EBV- und 
Herpesvirenforschung und deren klinische Anwendbarkeit diskutiert. Die in den ersten 
vier Kapiteln dargestellten Ergebnisse zeigen, dass die Umgehung der Antigenpräsentation 
der HLA II-, CD1d- und vor allem HLA I-Eiweiße eine wichtige Rolle spielen muss, weil 
EBV so viele verschiedene Strategien dafür entwickelt hat, die in verschiedenen Phasen der 
lytischen Replikationsphase aktiv sind. Die hier besprochenen EBV-Proteine BGLF5, BILF1 
und gp150 können gemeinsam mit anderen EBV-Eiweißen, wie zum Beispiel BNLF2a und 
gp42, die Erkennung durch T-Zellen stören. Es ist wichtig, die molekularen Arbeitsweisen 
dieser Eiweiße zu verstehen, weil dies die Grundlage für die Entwicklung von anti-viralen 
Therapien, zum Beispiel gegen das Pfeiffersche Drüsenfieber, bilden kann. Außerdem 
ist es interessant darüber nachzudenken, inwiefern (modifizierte) virale Eiweiße, die die 
Antigenpräsentation verringern, therapeutisch genutzt werden können, um zum Beispiel 
transplantierte oder eigene Organe vor ungewollten T-Zell-Attacken zu bewahren, wie dies 
der Fall in Organabstoßungsreaktionen nach Transplantationen oder Diabetes Typ I der Fall 
ist. 




Gram AM, Oosenbrug T, Marthe F.S. Lindenbergh, Christian Büll, Anouskha Comvalius, 
Kathryn J.I. Dickson, Joop Wiegant, Hans Vrolijk, Robert Jan Lebbink, Gosse J. Adema, 
Marieke Griffioen, Mirjam H.M. Heemskerk, David C. Tscharke, Lindsey M. Hutt-Fletcher, 
Emmanuel J.H.J. Wiertz, Rob C. Hoeben, Maaike E. Ressing; The Epstein-Barr Virus 
Glycoprotein gp150 Forms an Immune-evasive Glycan Shield at the Surface of Infected Cells; 
PLoS Pathog. 2016 Apr 14;12(4):e1005550. 
Ressing ME, van Gent M, Gram AM, Hooykaas MJ, Piersma SJ, Wiertz EJ; Immune Evasion 
by Epstein-Barr Virus. Curr Top Microbiol Immunol. 2015;391:355-81. 
van Gent M, Gram AM, Boer IG, Geerdink RJ, Lindenbergh MF, Lebbink RJ, Wiertz EJ, 
Ressing ME. Silencing the shutoff protein of Epstein-Barr virus in productively infected B cells 
points to (innate) targets for immune evasion; J Gen Virol. 2015 Apr;96(Pt 4):858-65.
Griffin BD*, Gram AM*, Mulder A, Van Leeuwen D, Claas FH, Wang F, Ressing ME, Wiertz 
E; EBV BILF1 evolved to downregulate cell surface display of a wide range of HLA class I 
molecules through their cytoplasmic tail; J Immunol. 2013 Feb 15;190(4):1672-84. * Equal 
first authorships
Horst D, Geerdink RJ, Gram AM, Stoppelenburg AJ, Ressing ME; Hiding lipid presentation: 
viral interference with CD1d-restricted invariant natural killer T (iNKT) cell activation; 
Viruses. 2012 Oct 23;4(10):2379-99. 
Gram AM, Frenkel J, Ressing ME.; Inflammasomes and viruses: cellular defence versus viral 
offence; J Gen Virol. 2012 Oct;93(Pt 10):2063-75. 




Anna Gram was born on May 30, 1987 in Basel, Switzerland. She grew up in Germany 
and finished her school education in 2006. The same year, she started her Biology study at 
the Ruprecht-Karls-Universität in Heidelberg, Germany and obtained her Bachelor diploma 
in 2009. Thereafter, she moved to Utrecht, The Netherlands to study ‘Biomedical Sciences’ 
with a focus on ‘Infection & Immunity’. Anna spent her research internships at the UMC 
Utrecht in the groups of Prof. Leo Koenderman (supervised by Dr. Laurien Ulfman) and 
Prof. Emmanuel Wiertz/Dr. Maaike Ressing (supervised by Dr. Sytse Piersma) working on 
cell adhesion mechanisms (9 month) and evasion of the complement system by Epstein-
Barr virus (6 month), respectively. She wrote her Master thesis about inflammasomes under 
supervision of Dr. Joost Frenkel. 
After obtaining her Master diploma in 2011, Anna started her PhD training at the UMC 
Utrecht in the group of Prof. Emmanuel Wiertz under supervision of Dr. Maaike Ressing. In 
2013, she moved with Dr. Maaike Ressing to the LUMC in Leiden to join the group of Prof. 
Rob Hoeben, where she continued her PhD studies. In 2015, Anna spent three month as 
visiting scientist in the group of Prof. Søren Paludan at Aarhus University, Denmark. The stay 
was supported by two fellowships. The results of her PhD studies are described in this thesis. 
Currently, Anna is working as a postdoc on a multi-disciplinary joint project between the 
department of Molecular Cell Biology and Hematology (both LUMC) in close collaboration 
with Genmab. 
160723 Proefschrift.indd   180 24.07.2016   21:50:36
